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List of Abbreviations 
  
AC  Ameroid constrictor 
BA  Bile acids 
BBB  Blood-brain barrier 
CatDx  Catalyst Dxe chemistry analyzer 
CB      Cellophane band 
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
CTA  Computed tomographic angiography 
EHPSS Extrahepatic portosystemic shunts 
HE   Hepatic encephalopathy 
IHPSS  Intrahepatic portosystemic shunts 
IV   Intravenous 
MRA  Magnetic resonance imaging with angiography 
MRI  Magnetic resonance imaging 
NH3  Ammonia 
NH4+  Ammonium 
PockBA PocketChem BA 
PRPS  Per-rectal portal scintigraphy 
PSS  Portosystemic shunt 
SBA  Serum bile acids 
SF   Shunt fraction 
Tc   Technetium 
TFB  Thin film band 
TSPS  Transsplenic portal scintigraphy 
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1. Introduction 
 
A portosystemic shunt (PSS) is an anomalous vascular communication connecting the portal 
circulation to the venous part of the systemic circulation. As a consequence blood drained 
from the gastrointestinal tract bypasses the liver. Portosystemic shunting may occur within 
the hepatic parenchyma (intrahepatic, IHPSS) or outside the liver (extrahepatic, EHPSS) 
(Figure 1). Portosystemic shunts result from developmental embryogenesis anomalies 
(congenital) or form secondary to portal hypertension (acquired). 
The origin, site of insertion, and diameter of the shunting vessel may impact the fraction of 
the liver that is hypoperfused and consequently the severity and progression of the clinical 
signs and the severity of the histopathologic changes. 
 
 
This PhD thesis will be introduced by an overview of the scientific literature that was 
available before the onset of the PhD research, in order to better understand the rationale and 
the scientific aims of this thesis. This literature review will be confined to congenital EHPSSs 
in dogs, the topic of all studies presented in this work.  
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Figure 1. Portal blood flow in the dog; A, Normal blood flow through 
hepatic sinusoids; B, Intrahepatic portosystemic shunt (IHPSS), anomalous 
vascular communication, connecting portal vein to systemic circulation 
inside the liver; C, Extrahepatic portosystemic shunt (EHPSS), anomalous 
vascular communication, connecting portal to systemic circulation outside 
the liver. Caudal vena cava (CVC), hepatic veins (HV), portal vein (PV), 
splenic vein (SV) (based on http://dx.doi.org/10.1136/vetreccr-2014-
000105) 
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2. Anatomy of the Normal Liver and Hepatic Vasculature in Dogs 
 
The liver of dogs comprises five lobes (left lobe, quadrate lobe, right medial lobe, right 
lateral lobe and caudate lobe), two processes and a galbladder (Figure 2). The left lobe is the 
largest and is subdivided into the left lateral and left medial lobes. The quadrate lobe lies 
almost on the midline, and its lateral aspect forms the medial side of the fossa containing the 
gallbladder. The right medial lobe lies laterally to the quadrate lobe; its medial aspect forms 
the lateral side of the gallbladder fossa. The right lateral lobe lies laterally to the medial lobe, 
and is usually fused with the caudate lobe, which is subdivided into the caudate and papillary 
processes.1  
The liver has the most complicated vasculature of any organ. The blood supply to the liver 
comes from two distinct sources, the hepatic artery and the portal vein. The nutrient-rich 
blood coming from the gastrointestinal tract flows in from the portal vein. The portal vein 
provides nearly 80 % of the total blood volume to the liver, and 50% of the oxygen supply. 
The remaining part, 20% and 50%, respectively, is supplied via the hepatic artery.2 Within 
the liver parenchyma, drainage occurs into the hepatic veins that drain into the abdominal 
portion of the caudal vena cava. 
 
 
Figure 2. Anatomy of the liver lobes in the dog: A, Diaphragmatic view of the liver; B, Visceral 
view of the liver  (From Evans HE: The digestive apparatus and abdomen. In Evans HE, 
deLahunta A: Miller’s Anatomy of the Dog, ed 4, St Louis, 2013, Saunders/Elsevier.) 
 
 
A B
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2.1 Portal Vein 
 
The portal vein is created by the confluence of the cranial mesenteric vein, which mainly 
drains the small intestines, and the caudal mesenteric vein, which drains the colon and 
proximal rectum. Additional tributaries joining the portal vein cranially include the splenic 
vein, which drains blood from the spleen and part of the stomach, and, the gastroduodenal 
vein, which drains the pancreas, duodenum, and stomach (Figure 3).1,3  
 
 
 
Figure 3. The portal vein with its tributaries in a canine cadaver: Ventral left obliqe view after 
removal of the parietal leave of the omental bursa and transection of the left lobe of the pancreas (left 
is cranial). 1, Portal vein; 2, Cranial mesenteric vein; 3, Caudal mesenteric vein; 4, Splenic vein;  
5, Left gastric vein; 6, Gastroduodenal vein; 7, Right portal vein branch; 8, Left portal vein branch; L, 
Liver; St, Stomach; P, Pancreas.   
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Figure 4. Vascular corrosion cast (Baston’s #17) of the portal vein (red) and caudal vena cava (blue) 
of a normal dog: Ventral caudo-cranial view (top is cranial).  
1, Portal vein; 2, Right portal vein branch; 3, Right lateral lobe branches; 4, Caudate process of 
caudate lobe branches; 5, Left portal vein branch; 6, Quadrate lobe, left lateral lobe and left medial 
lobe branches; 7, Right middle lobe and papillary process of the caudate lobe branches; 8, Caudal 
vena cava; 9, Right hepatic vein branches; 10, Left hepatic vein branches. 
 
 
The cranial mesenteric vein is the largest tributary to the portal vein. Just cranial to the 
insertion point of its gastroduodenal tributary, the portal vein divides into 2 branches, the 
right and left portal vein (Figure 3; Figure 4). The right portal vein is shorter and smaller than 
its left counterpart and supplies the caudate process of the caudate lobe and the right lateral 
lobe of the liver. The left portal vein further divides into a central branch supplying the right 
medial lobe and the papillary process of the caudate lobe, and a left branch supplying the 
quadrate, left medial, and left lateral liver lobes.4,5 In 60% of dogs, the left portal vein also 
gives rise to a branch that supplies the dorsal part of the right lateral liver lobe.5 
 
General Introduction 
 10
2.2 Hepatic Artery 
 
The hepatic artery is a branch of the celiac artery, the first visceral branch of the abdominal 
aorta at the level of the first lumbar vertebra. The hepatic artery divides mainly into 3 
branches (right lateral, right medial, and left branch), although additional branches can be 
present.5 The right lateral branch supplies the caudate and right lateral hepatic lobe.6 The 
right medial branch supplies the right medial lobe, the dorsal part of the quadrate lobe, and a 
portion of the left medial lobe. The left hepatic branch gives rise to the cystic artery and 
branches to the left lateral, the quadrate and part of the left medial lobe.5 The hepatic arteries 
are usually located on the ventral surface of the eponymous portal vein branches, although 
some arterial branches, such as the left hepatic branch are found dorsally.7 
 
2.3 Hepatic Veins 
 
Blood from the portal vein and from the hepatic arteries mixes within the hepatic sinusoids 
before collecting in central veins. These central veins merge and form the hepatic veins that 
drain into the abdominal part of the caudal vena cava. Dogs usually have 5 to 8 hepatic veins, 
but the amount of branches and topography varies.2,3,7-10 
 
 
 
3. Embryology of the Liver Vasculature in Dogs 
 
3.1 Normal Dog 
 
The venous system of the abdominal cavity originates from 3 main embryonic veins; the 
umbilical, vitelline, and cardinal veins.9 In dogs, the portal vein and its tributaries are formed 
from the embryonic vitelline veins.11,12 Vitelline veins also form the hepatic sinusoids. The 
caudal vena cava and the azygos vein are formed through several transformations of the 
cardinal venous system.9,11,12 It is suggested, but never demonstrated, that in normal dogs, 
numerous preexisting nonfunctional portosystemic anastomoses may open in case of 
sustained elevated pressures in the portal system.9,13 
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3.2 Congenital Extrahepatic Portosystemisch Shunts  
 
The development of abdominal vasculature in utero explains the anatomical variations 
observed in dogs with congenital PSS.  
Congenital EHPSSs represent inappropriate functional connections between the 
embryonic cardinal and vitelline systems that persist postnatally.9 Those shunt types are thus 
developmental anomalies; they are not derived from pre-existing embryonic connections. 
Nevertheless, it has been suggested that some congenital EHPSSs result from concurrent 
portal microvascular underdevelopment that increases intrahepatic portal resistance, forcing 
residual anomalous vessels to remain open.14 
A congenital EHPSS most commonly occurs as a single extrahepatic vessel that provides 
vascular communication between the portal venous and the systemic venous circulation, 
bypassing the liver. However, some animals have two or more congenital 
communications.9,14 Connections of these anomalous vessels have been found between the 
portal vein or its tributaries and the caudal vena cava (portocaval shunts), the azygos vein 
(porto-azygos shunts), the renal vein, the phrenic vein (portophrenic shunts), the internal 
thoracic vein, and the umbilical vein (Figure 5).15,16 The majority of congenital EHPSSs are 
portocaval.14,17-19 The relative incidence of the different anatomical types of congenital 
EHPSS, based on origin and termination of the shunting vessel, seems subjected to regional 
differences in dog populations.16 
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Figure 5. Types of extrahepatic portosystemic shunts in the dog: 
A, Portal vein to caudal vena cava; B, Portal vein to azygos vein; 
C, Left gastric vein to caudal vena cava; D, Splenic vein to 
caudal vena cava; E, Left gastric, cranial mesenteric, caudal 
mesenteric, or gastroduodenal vein to caudal vena cava; F 
Combinations of two of the above communications. (Adapted 
from Fossum TW, Editor: Small Animal Aurgery, ed 3,St Louis, 
2007, Mosby/Elsevier) 
 
 
4. Incidence and Demographic Data in Dogs with Congenital Extrahepatic 
Portosystemic Shunts 
 
Congenital PSSs are reported in 0.18% of all dogs, and in only 0.05% of mixed-breed 
dogs.20,22 Approximately 66% to 75% of all congenital PSS are extrahepatic.20,22 
Three-quarter of the congenital EHPSSs are identified in young dogs, but congenital 
shunts, especially shunts with porto-azygos or portophrenic communication, are also 
diagnosed in dogs older than 2 years of age.16,22-25 There is no clear gender predisposition.25,26 
Extrahepatic PSSs are most commonly seen in small- or toy breed dogs.12,18,20,27 In several 
breeds a hereditary base is suspected.14,20 However, a genetic background for EHPSS has so 
far only been demonstrated in the Maltese28, the Cairn terrier18,29, and the Yorkshire terrier.21 
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5. Clinical Signs in Dogs with Congenital Extrahepatic Portosystemic 
Shunts 
 
In few cases of dogs with a congenital EHPSS, a history of anesthetic intolerance or 
prolonged recovery is the only sign to suspect the presence of a PSS.19,27,30,31 The majority of 
dogs with EHPSS have intermittent episodes of dullness, lethargy, or “abnormal” behavior 
whereas also the gastrointestinal and urinary systems are commonly affected.  
Clinical signs are considered milder in dogs with a porto-azygos shunt than in patients 
with a portocaval shunt; the same applies to portophrenic versus other portocaval 
communications. The diaphragm likely compresses porto-azygos and portophrenic shunt 
types during respiration or with gastric distention after meals, resulting in temporary 
improvement of the portal perfusion.14 
Hepatic encephalopathy (HE) occurs in up to 95% of dogs with a congenital EHPSS, but 
the clinical signs of HE can vary between very obvious to subtle and, in the last situation, 
may go unnoticed by the owner or even by the attending veterinarian. Typical signs of 
“abnormal” behavior include stargazing, head pressing, staring into walls or corners, random 
barking, pacing, aggression, ataxia, unresponsiveness, circling, trembling or shaking.27,30,32,33 
The neurological abnormalities are often episodic and may be more pronounced after eating 
high protein meals.27,33 
Dogs with a congenital EHPSS typically are undersized or reported to be the runt of the 
litter. Many have a history of weight loss or failure to gain weight.34 They can present with 
gastrointestinal signs including vomiting, diarrhea, anorexia, pica, and/or signs of 
gastrointestinal bleeding.18,19,27 As a consequence of hepatic dysfunction, bile production is 
diminished, hindering digestion and causing maldigestion and malabsorption symptoms.35 
Nausea, inappetence and vomiting are also suggested to be caused by toxic substances 
affecting the chemoreceptor trigger zone in the brain.35,36 
Often lower urinary tract signs such as hematuria, stranguria, pollakiuria, or urinary tract 
obstruction are observed due to the presence of ammonium (bi)urate calculi formation and 
secondary urinary tract infection.18,19,33 Polydipsia with secondary polyuria is common in 
dogs with a congenital EHPSS. Both may be triggered by an altered renal medullary gradient 
due to low blood urea nitrogen (BUN), by changes in portal vein osmoreceptors, and by 
urinary tract disease but they may also be attributed to HE.14,24,37 
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6. Pathophysiology of Hepatic Encephalopathy in Dogs with a 
Portosystemic Shunt 
 
A healthy liver filters, neutralizes and detoxifies neurotoxic substances that are absorbed 
across the gastrointestinal barrier and drain into the portal system.12,18 In the presence of a 
PSS, however, a vast proportion of the portal blood bypasses the liver and those toxic 
byproducts of metabolism thus accumulate in the blood.38 In addition, the liver lacks the 
nutrient supply from the blood.12,18 Therefore, the blood that is not shunted cannot be 
efficiently detoxified due to too little functional parenchyma.36 
Hepatic encephalopathy is a metabolic syndrome that may result from a variety of liver 
diseases and that is characterized by diffuse cerebral and neuropsychiatric dysfunction.36,39,40 
Some degree of HE is likely present in nearly every dog with a PSS, but the symptoms as 
well as their severity may be episodic and vary considerably. Although the syndrome is well 
recognized and contributing factors have been determined, the pathogenesis of HE 
particularly in dogs with PSS remains largely unknown. In humans, HE is mainly associated 
with acute or chronic liver diseases and advanced cirrhotic disease and far less with 
congenital portal venous bypasses, because the latter are extremely rare congenital 
malformations in humans.41 It also frequently develops in human patients who underwent 
transjugular intrahepatic portosystemic stent-shunt insertion.42,43 
In patients with HE, various neurotransmitter systems are affected.36,44 More than 20 
different compounds have been found in excess in the cerebrospinal fluid (CSF) circulation 
of patients with HE, including ammonia, aromatic amino acids, endogenous benzodiazepines, 
gamma-aminobutyric acid (GABA), glutamine, short-chain fatty acids, tryptophan, and 
others. However, none of those substances have unambiguously been shown to be the single 
cause of the neurological impairment; therefore, HE can be considered a multifactorial 
metabolic disease.36,40 The mentioned substances may affect neuronal and astrocyte function, 
resulting in cell swelling, inhibition of membrane pumps or ion channels, an elevation in 
intracellular calcium concentrations, depression of electrical activity, and interference with 
oxidative metabolism.45-47 These effects, in addition to an altered permeability of the blood-
brain barrier (BBB) in HE, impair cerebral function.13,45,46 
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Ammoniaa is considered the most important neurotoxic substance. Increased ammonia 
concentrations in the brain trigger a sequence of metabolic events. These have been 
extensively studied in HE in rats, humans, and dogs.13,33,45,46,48 Dogs with PSS do have 
excessive accumulation of ammonia in the body since the atrophied liver is incapable of 
efficiently converting the blood ammonia whereas most of the blood bypasses the liver via de 
the shunting vessel.36,49 
At physiological pH, most ammonia in the blood is in the form of the positively charged 
ammonium ions (NH4+) and little as gas form (NH3).27,50-52 Intra- and extracellular pH has an 
important influence on the distribution and the form of ammonia.36,51 Whereas NH3 readily 
diffuses across membranes, NH4+ does not.36 NH3 passively diffuses into the brain and is 
captured in the brain parenchyma as NH4+ due to a lower pH in the brain compared to the 
systemic system.53-55 
Ammonia has both direct and indirect neurotoxic effects. It is involved in the injury to the 
astrocytes, which comprise about one third of the entire brain volume.39,56-60 The astrocytes 
have the key function to protect the brain from excessive neuroexcitation. They contribute to 
the ability of brain endothelial cells to form the BBB, a physiologic barrier that impedes 
passive diffusion of solutes from the blood into the central nervous system (CNS). In 
addition, the astrocytes are responsible for the ammonia conversion in the CNS, where 
glutamine is formed out of glutamate and ammonia by the glutamine synthetase reaction.36 
As there is no urea cycle in the brain that changes ammonia into urea, ammonia removal 
relies almost exclusively on glutamine synthetase, primarily localized in astrocytes.61 In case 
of excess ammonia in and around the brain parenchyma, there is an increase in tryptophan 
and glutamine, decreased ATP availability, increased glycolysis, and decreased microsomal 
Na+ K+-ATPase.62,63 
 
Two main hypotheses have been proposed to better explain the role of ammonia in the 
pathogenesis for HE: the osmotic gliopathy theory and the Trojan horse theory. Both models 
challenge the traditional thought that glutamine, produced during the glutamine synthesis in 
astrocytes to protect the brain from blood-derived ammonia, is harmless. 
 
  
                                                
a Except when specified, ammonia refers to the sum of ammonium ions (NH4+) and ammonia free base 
(NH3) 
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The ammonia-glutamine-brain swelling osmotic gliopathy hypothesis 
In response to hyperammonemia, the glutamine synthesis within the astrocytes is stimulated 
to deal with the excess ammonia. Unfortunately, glutamine is osmotically active and 
therefore it is also harmful. The osmotic gliopathy theory postulates that the accumulation of 
glutamine within the astrocytes leads to subsequent swelling of the astrocytes (Figure 6).47 
Small increases in the water content within the altered astrocytes may lead to considerable 
functional neurological consequences.44 
Despite the general acceptance of this hypothesis, it is currently considered an 
oversimplification to assume that ammonia-related problems in the brain only include 
glutamine-induced astrocyte swelling.44 Ammonia concurrently evokes mitochondrial 
abnormalities and triggers the generation of oxidative stress.59,60 
 
The Trojan horse theory 
According to the Trojan horse theory, glutamine acts as a carrier of ammonia (Trojan horse) 
when excessive amounts of glutamine are transported from the cytoplasm across the 
mitochondrial membranes via a glutamine carrier.59 In the mitochondria, glutamine is 
hydrolyzed by glutamine synthetase, resulting in the generation of ammonia and glutamate. 
The glutamine-derived ammonia within the mitochondria leads to excessive production of 
free radicals and induction of mitochondrial permeability transition (Figure 7).59 
Under normal circumstances, astrocytes efficiently protect neuronal CNS cells from the 
blood. However, in case of excess blood ammonia, the astrocytic glutamine synthetase 
process becomes overwhelmed and free ammonia reaches the neurons instead of being 
detoxified by the astrocytes. The resulting increase in neuronal ammonia hampers the 
neuronal glutaminase process, resulting in decreased production of neuronal glutamate 
causing neural dysfunction.36 
 
 
At the start of this PhD, little was known about the amount and distribution of ammonia in 
the CSF and/or CNS in dogs with EHPSS and about its association with clinical signs of HE. 
However, when dogs served as experimental model to mimic chronic HE in human patients 
by creation of a portocaval shunt in addition to a partial hepatectomy, ammonia levels in the 
CSF were elevated.64 Those dogs all developed HE signs. 
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Figure 6. Schematic representation of the ammonia-glutamine-brain swelling osmotic gliopathy 
hypothesis. Astrocytes eliminate excess ammonia by amidation of glutamate to glutamine by 
glutamine synthetase (GS). The resulting glutamine is retained within the astrocytes, and its osmotic 
effect within the astrocyte causes it to take up water, causing it to swell. 
 
 
 
 
Figure 7. Schematic representation illustrating the Trojan horse hypothesis in ammonia neurotoxicity. 
Glutamine travels into the mitochondria via a glutamine carrier (GC). Mitochondrial glutaminase 
(Gase) hydrolyses glutamine and ammonia is generated. This glutamine-derived ammonia generates 
reactive oxygen species (ROS).  
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7. Diagnosis of Congenital Extrahepatic Portosystemic Shunt in Dogs 
 
7.1 Physical Examination 
 
Physical examination may reveal mild abnormalities, poor body condition, small body stature 
and ptyalisim in animals with congenital EHPSS.14 
Even when the owner reports neurologic signs, the neurologic examination may fail to reveal 
any abnormalities. In some animals, clinical signs manifest at a later age and may be 
associated with other progressive or acquired conditions such as gastrointestinal or urinary 
pathology.   
Animals with EHPSS may have other concurrent congenital defects. Cryptorchidism is 
reported in nearly half of the male dogs that are presented with congenital EHPSS.26,34 
 
 
7.2 Clinicopathologic Findings  
 
Laboratory testing is among the first steps recommended in the diagnostic workup of dogs 
suspected to have an EHPSS. A complete blood count (CBC), serum biochemistry profile, 
fasting ammonia measurements, ammonia tolerance test, pre- and postprandial serum bile 
acids (SBA), coagulation tests, and urinalysis are recommended.  
Abnormalities detected on blood analyses performed for other reasons unrelated to PSS 
diagnosis might sometimes raise the suspicion of the presence of a PSS.19,27,30,31 
 
7.2.1 Haematology, Biochemistry, and Coagulation Profiles 
Changes in the CBC are observed in 60 to 70% of the dogs with congenital EHPSS and may 
include leukocytosis, microcytosis, and normocytic, normochromic, non-regenerative anemia 
and mild thrombocytopenia. Leukocytosis may be explained by the decreased bacterial 
clearance of the portal blood, resulting in increased antigenic stimulation.17,18,34,65-67 The 
cause of the microcytosis, and normocytic, normochromic, non-regenerative anemia is not 
fully understood, but has been associated with abnormalities in iron metabolism.66,67 Platelet 
counts in dogs with PSS are also lower than in normal dogs.68 
Changes in the biochemistry profile are common in dogs with congenital EHPSS.17 Due to 
decreased hepatic synthesis of the respective substances; hypoalbuminemia (50%), reduced 
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BUN (70%), hypocholesterolemia, and/or hypoglycemia are observed. As with any hepatic 
vascular anomaly, mild to moderate increases in serum liver enzyme activities are often 
present. In immature patients, alkaline phosphatase is typically higher than alanine 
aminotransferase.69 Severely elevated liver enzyme activities33 or hyperbilirubinemia70 most 
likely indicate other concurrent underlying liver disease; they are not typical for the presence 
of a congenital EHPSS. 
Since liver dysfunction will lead to impaired synthesis of clotting factors on the one hand 
and decreased clearance of activated clotting factors on the other hand, it is self-evident to 
encounter coagulation abnormalities in dogs with congenital EHPSS. The activated partial 
thromboplastin time (aPTT) becomes prolonged, often without prolongation in prothrombin 
time (PT). Spontaneous bleedings do not regularly occur but hemostatic problems may be 
encountered during surgical intervention.71,72 
 
7.2.2 Urinalysis 
Urinalysis is recommended in all dogs suspected of congenital EHPSS. More than half of the 
patients are hyposthenuric or isosthenuric.27,30,73 As stated earlier, many factors may 
contribute to the low urine specific gravity; psychogenic polydipsia associated with HE, a 
decreased renal medullary concentration gradient and portal vein osmoreceptor 
alterations.13,14,24,38 
Another common abnormality is the presence of urinary crystals; ammonium biurate 
crystalluria is reported in 26% to 57% of dogs with a congenital EHPSS.18,23,74 This can be 
explained by deficiencies in both the urea and the uric acid cycle due to impaired liver 
function, resulting in excessive ammonia and urate excretion by the kidneys.14 
Mild proteinuria can be seen in dogs with EHPSS and is suspected to be secondary to 
glomerular lesions.75 In cases of more severe proteinuria, urinary tract heamorrhage 
secondery to urolithiasis or a concurrent urinary tract infection should be suspected.14 
 
7.2.3 Liver Function Tests 
In an animal with normal hepatic vascularity, portal blood delivers nutrients and specific 
hepatotrophic factors to the liver.12,18 Therefore, the perfusion rate of the liver has a great 
impact on its function and on its volume. Liver volumes in dogs with congenital EHPSS are 
smaller than those in normal dogs.76 
Abnormalities in liver function tests are suggestive of liver dysfunction. The tests reflect 
accumulation of substances normally cleared by the liver. However, they cannot differentiate 
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the types of liver disease. The most commonly used screening tests in the diagnostic work-up 
of dogs suspected of EHPSS are based on either the concentration of serum bile acids (SBA) 
or on the concentration of ammonia in venous blood samples. The idea behind combining 
several liver tests is to reveal diagnostic patterns that better differentiate PSS from other liver 
diseases. 
 
Pre- and Postprandial Serum Bile Acid Concentrations 
The liver is the only organ where the complete bile acid (BA) biosynthesis can occur. Bile 
acids are synthesized and conjugated in the liver and stored in the gallbladder. After 
stimulation by food uptake, the gallbladder contracts and the BAs are released into the 
duodenum. They are then reabsorbed from the distal ileum and, in normal dogs, recirculate to 
the liver via the portal venous circulation by first-pass extraction.13,36,77,78 However, in 
animals with EHPSS, the BA enterohepatic cycle is disturbed because the liver is bypassed 
and there is little hepatic mass, resulting in accumulation of SBAs.8,36,69 
To perform a (paired) SBA concentration measurement test, the first venous blood sample 
needs to be preprandial, taken after the animal has been fasted for at least 12 hours; the 
second blood sample is postprandial, taken 2 hours after feeding (at least two teaspoons of 
commercial or homemade diets). The sensitivity and specificity of a single preprandial SBA 
are 78-98% and 58-87%, respectively.77,79,80 whereas sensitivity and even specificity rise to 
100% and 89%, respectively when paired samples are evaluated in the diagnosis of PSS.767 
Obviously, hepatobiliary diseases other than PSS may also lead to elevated SBA 
concentrations.69,77 
 
Baseline Ammonia Concentration 
The vast majority of the ammonia is produced by bacterial metabolism of nitrogenous 
compounds in the gastrointestinal tract, mainly in the large intestine by anaerobic and 
coliform bacteria.13,30 Ammonia is also liberated from glutamine from the mesenteric arterial 
circulation by the enterocytes of the small and large intestines.36 Ammonia is transported 
towards the liver by the portal blood flow. The portal blood ammonia is converted in the 
normal liver to urea in the periportal hepatocytes or to glutamine by the perivenous 
hepatocytes.44,49 With normal liver function, up to 85% of the ammonia from the 
gastrointestinal tract is deaminated via the urea cycle. In animals with PSS the conversion of 
ammonia to urea is inefficient, resulting in increased serum ammonia levels.36 
When testing blood ammonia, blood sample handling is important to avoid preanalytical 
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errors. The sample needs to be collected in a closed EDTA-coated tube and should either be 
processed immediately or be put in a cooled centrifuge with further cooling of the plasma 
until analysis to avoid falsely elevated ammonia levels.81 
Baseline venous ammonia levels are generally not considered to be as sensitive as SBA 
measurements in the diagnosis of PSS in clinically affected dogs,18,83 although using optimal 
cut-off values can increase the accuracy for selective diagnosis of PSS.80 Dogs with EHPSS 
in which signs of HE are successfully controlled by medical management can have normal 
blood ammonia values. Likewise, baseline ammonia may be within normal limits if the dog 
did not eat for a prolonged period.18,83 When liver function tests are used for population 
screening for the presence of congenital shunts in apparently healthy pups, ammonia 
measurement is preferred over SBA due to its higher sensitivity.79 
 
Before the onset of the PhD research, there was only one study on the comparison of 
arterial and venous blood ammonia levels in dogs with HE due to a variety of liver diseases, 
including EHPSS.38 In that study, significantly higher ammonia levels were found in arterial 
blood compared to venous blood. However, the study did not discern between disease entities 
and differences in ammonia levels in EHPSS dogs were not presented separately. We know 
from research in human patients with HE that significantly higher arterial than venous blood 
ammonia levels are observed.51 In men, it is the arterial ammonia level that is used as a 
measure to predict intracranial hypertension and cerebral edema in case of HE.84,85 
 
Ammonia Tolerance Tests 
If normal baseline venous ammonia is observed in dogs suspected of PSS, an ammonia 
challenge can be considered to assess the patient’s ability to clear ammonia. Two ammonia 
tolerance tests have been described in the literature. 
The first test is the postprandial ammonia tolerance test in which chicken and rice is used 
as a source of ammonia.86 Six hours after the feeding, the concentration of venous ammonia 
peaks in dogs with hepatocellular disease. The test reaches a sensitivity of 91% in the 
diagnosis of congenital portosystemic vascular anomalies.86 
The second test is the oral or rectal ammonia tolerance test in which ammonium chloride 
is administered via an oral or rectal route, respectively. Rectal administration is often 
tolerated better and is easier than the oral route.83 Venous blood samples are taken 20 and 40 
minutes after rectal administration.87 
Although the sensitivity of these ammonia tolerance tests is 95% to 100%,73,83,87 it is not 
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safe to administer ammonia in dogs that indeed have a PSS because HE signs may be 
exacerbated.8 
 
 
7.3 Diagnostic Imaging  
 
Even in dogs with a high suspicion of the presence of a congenital EHPSS based on history, 
signalment, and laboratory results, achieving the definitive diagnosis of EHPSS can represent 
a real challenge. Fortunately, several imaging modalities are nowadays available to either 
document the presence or absence of a PSS or to additionally map the anatomy of the 
abnormal portosystemic communication. 
 
7.3.1 Abdominal Radiographs  
Plain abdominal radiographs will not help to reach the definitive diagnosis of portosystemic 
shunting since they do not allow visualization of the PSS itself. They may, at most, reveal 
secondary changes that are supportive of the presence of a PSS. The most observed 
abnormality registered on plain abdominal radiographs is microhepatica. Also bilateral 
renomegaly is often present.17,27 Animals with shunts may also have uroliths in the bladder, 
kidneys or ureters, although they might not be noticed on radiographs since ammonium urate 
or biurate calculi are usually radiolucent unless they also contain struvite or calcium salts.74 
 
7.3.2 Mesenteric portovenography 
Historically, mesenteric portography was performed frequently to confirm the tentative 
diagnosis of PSSs. In the time, it was the “gold standard” for diagnosing portosystemic 
shunting.88 It provides excellent imaging and localization of shunting vessels (Figure 8) but it 
is a highly invasive technique.33 This procedure requires a laparotomy, portable fluoroscopy 
(C-arm or temporary closing of the abdomen after jejunal or splenic vein catheterization to 
transport the patient to a standing fluoroscopy unit), and intravenous contrast medium. 
Sensitivity of mesenteric portography to diagnose a PSS has been reported to be between 
85% and 100%, the main influencing factor being patient positioning.17,27,33 Classically, 
differentiation of IHPSS from EHPSS on portography is based on the point where the shunt 
diverges from the portal vein.88 
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Figure 8. Mesenteric portovenogram in a dog with a porto-
azygos shunt (SH), depicting the dorsal intra-abdominal course 
of the shunting vessel; the azygos vein (AZ) is also filled with 
contrast. Based on the lateral view only, the insertion of the 
shunt cannot be visualized. (Courtesy of Department of 
Veterinary Medical Imaging and Small Animal Orthopedics) 
 
Some surgeons still prefer using mesenteric portovenography to pre-operatively diagnose 
PSS, despite the fact that less invasive alternatives (ultrasound, scintigraphy, CT, MRI) are 
available. Direct and indirect risks associated with laparotomy are not in the benefit of the 
dog or not acceptable to the owners when less invasive options for diagnosing PSS are 
available.14 Other surgeons perform mesenteric portovenography at the time of surgery, after 
the presence of a PSS has already been confirmed by other imaging techniques. Although this 
allows “real time” intraoperative imaging of the shunting vessel, the images may be difficult 
to interpret by the patient positioning. Furthermore, the surgeon and staff are exposed to 
radiation and the surgical time is prolonged, increasing the risk of infection and 
hypothermia.14 
Alternatives to the mesenteric injection have been described; the contrast can be injected 
in the spleen (ultrasound-guided splenic venography), via the jugular vein (retrograde 
transjugular venography), or via the femoral artery (cranial mesenteric arteriography).14 
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7.3.3 Abdominal Ultrasonography 
In contrast to radiography, ultrasonography is a valuable means to accurately diagnose 
congenital EHPSS in dogs. In cooperative patients, most EHPSS will be detected already by 
two-dimensional, grey-scale ultrasonography without the need for general anesthesia.89 The 
technique is noninvasive and the equipment is available in most practices. It is currently 
considered the gold standard to assess the portal vascular supply without anesthetizing the 
patient.90 
The ultrasound examination in dogs suspected of EHPSS will not only reveal the shunting 
vessel. It allows evaluation of the entire abdomen, including the entire urinary tract. 
Whenever the combination of microhepatica, renomegaly and uroliths is present, the tentative 
diagnosis of the presence of a PSS becomes definitive even if the PSS cannot be seen 
ultrasonographically.91 Ultrasonography has a high sensitivity for detection of calculi, even 
when they are small and radiolucent.89,92 
In dogs with an EHPSS terminating in the vena cava, turbulence within the caudal vena 
cava can be evident; yet it can occasionally be seen in dogs without portocaval shunting. In 
dogs with a porto-azygos communication, the shunt often courses along the aorta in the 
craniodorsal abdomen but its termination in the azygos vein cannot be defined. In the 
majority of dogs with a congenital EHPSS, the portal vein to aorta ratio is reduced, in most 
cases below smaller than 0.65 (Figure 9).91 
In the ultrasonographic diagnosis of congenital EHPSS, many factors may impede proper 
screening of the abdominal vasculature.89,91,92 Since congenital EHPSS is predominately seen 
in toy breeds, the patients are often small and also the vessel diameters may be small. 
Multiple ultrasonographic examinations may be needed before a confident diagnosis can be 
established. Portophrenic shunts are sometimes overlooked because they are situated cranial 
to the liver and lungs may lead to artifacts. Gas in the gastrointestinal tract may obscure the 
anomalous vessel connecting to the portal vein and/or the caudal vena cava.15  
Because ultrasonographic detection of shunts in dog is operator- and experience-
dependent, the reported sensitivity varies from 74% to 95% and the specificity from 67% to 
100%.89,92,93 Although experienced operators will consistently detect congenital EHPSS by 
grey-scale ultrasound, the sensitivity of ultrasound improves by additional use of color-flow 
and pulse-wave Doppler, revealing changes in blood flow.89,92 Portal flow velocity in dogs 
with a congenital EHPSS is either faster than 15 cm/sec or a variable velocity is observed and 
the flow is not unidirectionally.27 
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Figure 9. The diameter of the portal vein at the porta hepatis 
was much smaller than before a wide branch splitted off (this 
branch is not visible on the image). The portal vein to aorta 
ratio (0.41) is significantly smaller than in normal dogs (range 
0.71–1.20)91 and is characteristic for animals with an EHPSS 
(but also in dogs with idiopathic noncirrhotic portal 
hypertension). ? (Courtesy of Department of Veterinary 
Medical Imaging and Small Animal Orthopedics) 
 
More recently, the use of transsplenic injection of microbubbles (agitated saline in 
heparinized blood) has been evaluated to aid in the ultrasonographic diagnosis of PSS in dogs 
during grey-scale ultrasound.94 The different shunting patterns could be easily and 
objectively identified. The microbubbles helped to identify the shunting vessel as well as its 
terminus in all cases of congenital EHPSS. However, for this technique dogs need to be under 
mild to moderate sedation. 
 
7.3.4 Scintigraphy 
Nuclear imaging is a useful, noninvasive method used in the diagnosis of PSS. In contrast to 
most other imaging techniques, which are anatomical, scintigraphy is a functional imaging 
technique that is primarily used to confirm or refute the presence of a PSS. It involves the 
acquisition of dynamic images with a gamma camera to evaluate the temporal uptake of a 
radioisotope on a nuclear portogram.  
Technetium pertechnetate (99mTc pertechnetate) is the most commonly used radioisotope 
for this purpose.92 It can be administered by two different routes; via the rectum95,96 or within 
the spleen.97,98 For both techniques, the dogs are usually shortly anesthetized to facilitate 
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administration of the radioisotope and to restraint the dogs during the imaging process.  
Per-rectal (transcolonic) portal scintigraphy (PRPS) involves infusion of the radioisotope 
via a catheter per rectum into the colon.95,96 The radioisotope is absorbed across the colonic 
mucosa and drained via the colonic veins into the caudal mesenteric vein and ultimately into 
the portal vein. For the transsplenic portal scintigraphy (TSPS), the radioisotope is injected 
under ultrasound-guidance into the splenic parenchyma. The isotope drains to the splenic 
vein and then into the portal circulation.97,98 
A nuclear portal venogram is obtained and the shunt fraction (SF) can be calculated, 
which represents the amount of blood that bypasses the liver.97 In dogs without a PSS, the 
radioisotope first travels to the liver via the normal portal circulation before reaching the 
heart. Radioactivity in the liver will arrive sooner and in greater concentration than in the 
heart (Figure 10). On PRPS, a SF below 15% is considered normal; the normal SF in TSPS is 
much lower, 2-4% maximally.98 In dogs with a PSS, the radioisotope leaves the portal vein 
system through the shunting vessel to travel to the heart, bypassing the liver. In these cases, 
the nuclear portogram will reveal the opposite situation with radioactivity that arrives first 
and with a higher count density in the heart and not in the liver (Figure 11). Thereafter, the 
radioisotope will reach the liver through the hepatic arterial circulation. In general, most dogs 
with congenital PSS have shunt fractions on PRPS or TSPS above 60% to 80%.95 Based on a 
nuclear portogram, it is not possible to make a distinction between intra- versus extrahepatic 
portocaval shunts.98 
There are several arguments to favor TSPS above PRPS. A sensitivity and specificity of 
88% and 67%, respectively is reached for PRPS,96 whereas both approximate 100% for 
TSPS.99 Theoretically, a caudally located EHPSS may not be visible if the portal tributary 
comprising the shunt is located upstream from the splenic vein, but those shunts are 
extremely rare.100 The low count density images obtained by PRPS do not always allow 
anatomical description of the PSS based on the nuclear portogram. On the other hand, TSPS 
enables differentiation between portocaval and porto-azygos shunts and between single and 
multiple shunts.98,101 Falsely increased SFs are obtained in PRPS if the radioisotope is 
administered too aborally in the rectum; it will be absorbed directly into the caudal vena cava 
instead of being absorbed into the portal system. Far less radionuclide is required for TSPS 
compared to PRPS, thus leading to a decreased and shortened radiation exposure to patient, 
staff and owner.98,101 
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Figure 10. Transsplenic nuclear portal venogram in a dog without portosystemic shunting (top 
image- static images after injection of the radioactive tracer) and calculation of shunt fraction 
(bottom image). The regions of interest are marked in yellow (liver) and red (heart); 
radioactivity is first demonstrated in the liver. (Courtesy of Department of Veterinary Medical 
Imaging and Small Animal Orthopedics) 
 
 
 
Figure 11. Transsplenic nuclear portal venogram in a dog with an extrahepatic portocaval shunt 
(top image- static images after injection of the radioactive tracer) and calculation of shunt 
fraction (bottom image). The majority of the radioactivity first arrives to the heart and only later 
reaches the liver. (Courtesy of Department of Veterinary Medical Imaging and Small Animal 
Orthopedics)   
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7.3.5 Computed Tomography Angiography 
Computed tomography angiography (CTA) is a rather recent imaging modality that now 
supplants traditional mesenteric portography as the gold standard for the evaluation of the 
portal venous system anatomy in dogs.15,102 It involves an intravenous (IV) injection of an 
iodinated contrast medium, using single and multi-slice CT scanners and providing three-
dimensional images.103-105 Dual-phase, arterial and portal CTA provides a complete 
evaluation of portal and hepatic vasculature, reducing the chance of missing small tributaries 
vessels, and is therefore considered superior to single-phase computed tomography.104 
However, dual-phase CTA demands bolus tracking with meticulous timing of the injected 
contrast to get a clear arterial and a portal phase images. 
Computed tomographic angiography is noninvasive, fast, and provides excellent anatomic 
detail of portal tributaries and branches allowing the identification of the origin and insertion 
of the PSS (Figure 12). In contrast to ultrasonography, CTA is less operator-dependent,104-107 
it can be performed in dogs of any size108 and allows further manipulation of the images after 
the scan is completed.15 A sensitivity of 96% and a specificity of 89% have been reported.107 
The main disadvantage of the use of CT is the need for general anesthesia and the higher 
radiation burden to the patient compared to ultrasonography, MRI and even scintigraphy. The 
former was addressed in a recent study with a 16-slice system in which a novel CTA protocol 
only involved sedation without the need for test injections, delay times or timing 
determinations.109 Specificity and sensitivity were reported to be 100%. 
Anatomic details obtained by CTA reconstructions are valuable for presurgical planning.15 
Thanks to CTA, the portal anatomy in a large number of dogs with EHPSS has been 
accurately described and nomenclature for the different type of shunts was provided.15 Yet, 
before this PhD research was started, there was no study in dogs on porto-azygos shunt 
anatomy and different types were not described.  
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Figure 12. Computed tomographic angiography images obtained in a dog with an extrahepatic 
portocaval shunt, dorsal vental views, head is pointed up. Images are taken at different levels showing 
the origin (A) and insertion (B) of the shunting vessel. A, The shunt (SH) leaves the portal vein (PV) 
caudal to the porta hepatis; the splenic vein (SV) drains into the shunt. B, The shunt (SH) enters the 
caudal vena cava (CVC) from the left, at the level of the cranial pole of the right kidney. (Courtesy of 
Department of Veterinary Medical Imaging and Small Animal Orthopedics) 
 
 
7.3.6 Magnetic Resonance Angiography 
Magnetic resonance imaging (MRI) with angiography (MRA) is sporadically utilized as a 
diagnostic technique for PSS in dogs. It involves intravenous injection of a paramagnetic 
contrast medium, and provides three-dimensional images.110-113 Similar to most CTA 
protocols, MRI requires general anesthesia. With MRA, there is no need for bolus tracking of 
the contrast; consequently, MRA does not require the exact timing necessary with traditional 
CTA. However, MRA takes longer than CTA. By utilizing positive-pressure ventilation and 
breath-hold techniques, MRA sequences can be obtained quickly and free from motion 
artifacts.112,113 The accurate characterization of PSSs, including the origin and insertion, can 
be identified with nearly 79% sensitivity and 100% specificity (Figure 13).110 
Excellent anatomic details on shunt morphology can be obtained by MRA, which is useful 
for presurgical planning.110,112,113 Although MRA is a promising new diagnostic modality in 
the diagnosis of PSS, CTA provides similar detail, is performed more quickly, and is less 
expensive than MRA.  
Although brain MRI is not routinely performed in PSS dogs with clinical HE, it has been 
used occasionally to assess potential brain lesions in those patients.114-117 Widened sulci with 
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a variable degree of grey matter atrophy was observed in all dogs and hyperintensity of the 
lentiform nuclei on the T1W images in 90%.114 
 
 
 
Figure 13. Magnetic resonance angiography images obtained in 
a dog with a portocaval shunt, dorsal maximum-intensity 
projection. The shunt (SH) leaves the portal vein (PV) caudal to 
the porta hepatis; the cranial continuation of the portal vein is 
not visible on this image. CVC: caudal vena cava; AO: aorta. 
(Courtesy of Clinic for Small Animal Surgery and 
Reproduction, Ludwig-Maximilians-University Munich) 
 
Before this PhD research was started, there were no publications on other diagnostic 
imaging techniques that specifically focused on the brain in dogs with EHPSS. Quite 
recently, proton magnetic resonance spectroscopy (1H MRS) was performed in 4 dogs with a 
congenital EHPSS, allowing in vivo assessment of metabolic derangements.117 High 
concentrations relative to water of the glutamine-glutamate complex were observed as well as 
lower myo-inositol peak areas, the latter most likely in an attempt to buffer the ammonia-
induced glutamine excess.118  
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8. Treatment of Congenital Extrahepatic Portosystemic Shunts 
 
The treatment of dogs with congenital EHPSS includes first management of clinical signs by 
means of medical support, and secondly surgical correction of the portosystemic shunting, if 
possible. Medical management will control clinical signs caused by the liver bypass but will 
not resolve the underlying diminished hepatic perfusion; therefore, surgery is recommended. 
Medical management has its role for long-term therapy when surgery is not possible or 
declined. 
 
8.1 Medical Management 
 
Medical treatment strategies in EHPSS patients aim to decrease the concentration of 
circulating ammonia. They can be divided into three categories; those that decrease 
absorption of ammonia from the gastrointestinal tract, those that improve ammonia 
conversion through the urea cycle, and those that increase removal of ammonia from the 
systemic circulation.119 Medical treatment generally consists of a dietary, antimicrobial, and 
synthetic disaccharide regimen.  
Diets can be commercially available products for dogs with hepatic or gastrointestinal 
disease or homemade diets that contain low level high-quality, easily digestible 
protein,14,18,33,34,52,120 that are fed in small portions and at frequent intervals.52 
Antimicrobial treatment consists of antibiotics such as metronidazole, ampicillin, or 
neomycin, aiming to decrease urease-producing bacteria.33 
Disaccharides consist of oral administration lactulose (0.5–1 mL/kg/day divided into 2 to 3 
doses) but, if severe HE signs are present, lactulose can also be administered transrectally.33 
Lactulose is not absorbed in the small intestines and is degraded into volatile free fatty acids 
by colonic bacteria. The resulting acidification gives a shift to nonabsorbable ionized 
ammonium, increased colon motility, and an altered and less ammonia-genic flora. The 
ammonia formation from glutamine metabolism in the intestinal mucosa may also be reduced 
by lactulose.14 
Nutraceuticals such as S-adenosyl-L-methionine (SAMe), ursodeoxycholic acid, vitamin E, 
and milk thistle (silymarin) have been recommended as hepatic supportive therapy for a 
variety of liver diseases.121 However, no controlled studies have evaluated their effectiveness 
for treatment of animals with EHPSS. 
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When a patient presents with signs of HE, aggressive efforts should be instituted to 
stabilize the patient and decrease the ammonia concentrations. In conditions of acute, severe 
HE, therapy includes administration of lukewarm water enemas, oral and rectal lactulose, 
antibiotics, IV fluid therapy and anticonvulsant therapy, if indicated.19,33 Conditions that 
aggravate HE such as hypovolemia, hypokalemia, alkalosis, and metabolic acidosis, should 
be corrected and drugs like benzodiazepines, barbiturates, and methionine should be avoided. 
Glucocorticoids, which induce catabolism, should be also avoided if possible.14,119 
Seizures not caused by hypoglycemia or hyperammonemia are initially treated with a 
benzodiazepine.33 Some clinicians prefer midazolam to intravenous diazepam, which 
contains a propylene glycol carrying agent that requires liver metabolism.14,119 Others feel 
that diazepam is the anticonvulsant of choice for immediate effect in an animal having 
seizures from hepatic encephalopathy associated with PSS.14,119 After seizures are controlled, 
loading doses of and continued treatment with phenobarbital, potassium bromide, sodium 
bromide, or levetiracetam may be considered, particularly if continued seizure activity is 
anticipated. Although many neurologists prefer levetiracetam, to date, there is little evidence 
to support the use of levetiracetam in dogs with PSS to control hepatic encephalopathy–
associated seizures.14 
 
A minimum of 2-3 weeks of medical treatment is recommended before planning any 
anesthetic event, implying that the definitive diagnosis of PSS might be postponed as well as 
the surgical intervention.14,119 Patients that are cachectic, that show signs of HE, or are 
unstable should be managed medically until they can tolerate the stress of anesthesia and 
surgery. Underweight patients may benefit from longer medical management to improve their 
body condition score before surgery. It may be tempting to owners to renounce the surgical 
intervention, keeping their dog on medical management indefinitely, since extremely good 
results are obtained after initial stabilization in the majority of the congenital EHPSS patients. 
However, medical treatment does not influence the fact that the liver is bypassed by nutrients 
and hepatotrophines;12,18 thus, the liver will continue to slowly deteriorate.  
 
 
8.2 Surgical Attenuation 
 
As discussed above, it is best to first install a medical treatment aimed at reducing the 
circulating ammonia concentration before presenting an EHPSS patient for surgery. Because 
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the liver is a key organ in the coagulation cascade, and liver function is impaired due to the 
inadequate perfusion, most surgeons will routinely administer vitamin K prior to surgery in 
order to avoid bleeding-related issues at the time of surgery.71,72 
The classical pre-operative 12-hour fast is not recommended in toy breeds and especially 
not in immature animals. To them, small amounts of easily digestible food can be offered 
until 4 to 6 hours pre-operatively.65 
The main goal of a surgical intervention in patients with PSS is to redirect portal blood 
flow towards the liver parenchyma. Most animals will not tolerate acute complete occlusion 
of shunts.32,82,122 Intra-operative evaluation of the portal vein may reveal portal atresia or 
even agenesis.65 Some surgeons rely on the degree of opacification of the portal branches 
during intra-operative portovenography to assess the portal vein capacity.123 Dogs with little 
or no demonstrable portal vasculature might not be good surgical candidates, irrespective the 
intended surgical modality.65,123 In most cases, however, gradual attenuation should be 
attempted to reduce the risk of postoperative complications.32 
The traditional approach was (partial) suture ligation of the shunting vessel. The degree of 
attenuation was based on visual inspection for evidence of portal hypertension, such as pallor 
or cyanosis of the intestines, increased intestinal peristalsis, cyanosis or edema of the 
pancreas, and increased mesenteric vascular pulsations. To be more objective, the surgeon 
can measure portal and central venous pressures.17 Partially attenuated shunts can be 
completely ligated during a subsequent surgery in 75% of animals.82 
Nowadays, most surgeons rely on devices other than sutures to obtain gradual and 
ultimately total attenuation of the shunting vessel, thus avoiding multiple surgical and 
anesthetic episodes. 
 
Because PSS are considered hereditary in many breeds, neutering of affected animals is 
recommended if the animal is cardiovascularly stable during the anesthesia.20,22,29,124 In male 
dogs presented with cystoliths of any size or in female dogs with large bladder stones, a 
cystotomy is also performed during the same anaesthetic procedure.23 
 
8.2.1 Surgical Attenuation Devices 
Options for surgical attenuation of congenital EHPSS include partial occlusion with ligatures 
or a more gradual attenuation of the shunting vessel with ameroid constrictor, thin film band, 
or hydraulic occluder.14,17,23,82,125,126 Most commonly used surgical options for attenuation of 
EHPSS include placement of an ameroid constrictor or a cellophane or other type of thin film 
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band.15,65,102,107,125,127,128 
 
Ameroid Constrictors 
An ameroid constrictor (AC) is a ring shape commercial device, which has an inner ring of 
compressed casein that is surrounded by a stainless steel collar.129 Both the casein and the 
steel ring have a slot to allow slippage of the device over the flattened shunting vessel after 
which a key is inserted to prevent dislodgment from the vessel (Figure 14). The ACs are 
available in different sizes; intra-operatively, an AC should be chosen that produces minimal 
reduction in vessel diameter after placement.14,129,130 
 
 
 
Figure 14. Placement of an ameroid constrictor on a portocaval 
shunt in a dog. The key (white arrowhead) has been partially 
inserted and will to be pushed deeper to fill the slot in the casein 
ring. 
 
Casein is a hygroscopic substance; it swells by slowly absorbing body fluid, resulting in a 
partial reduction of the internal luminal diameter, physically compressing the shunting 
vessel.131 It is suggested that additional gradual shunt occlusion is obtained by implant-
associated inflammation and stimulation of a fibrous tissue reaction that obliterates the 
vessel.129,131,132 Closure will occur over two or more weeks.133 In some animals, thrombus 
formation could result in more rapid obstruction of partially attenuated shunts.14 Early 
attenuation of the shunt may also occur due to the sheer size and heft of the AC, due to the 
weight of the device when the patient is in a standing position or if the AC kinks the 
shunt.129,130  
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Cellophane and other Thin Film Bands 
Cellophane band (CB) is a malleable thin film band composed out of plant-derived cellulose. 
Only recently, it has been realized that several so-called CBs should be named thin film 
bands since many bands alleged to be CBs are not cellophane-based.127,128 
During surgery, a strip of thin film is folded lengthwise into three layers to make a thick, 
flexible band, which is placed around the shunt (Figure 15).14 The band is held in place by 
securing the ends together with surgical clips in an alternating configuration.134 Most 
surgeons will place a band around the vessel to produce little immediate reduction in 
diameter; large shunts should not be attenuated to less than 3 mm to achieve a successful 
clinical outcome.126 
 
 
 
Figure 15. A strip of cellophane band is folded lengthwise into 
three layers; this flexible band will then be applied around the 
PSS. 
 
Cellophane bands induce a chronic low-grade foreign body reaction resulting in gradual 
occlusion of the encircled vessel.133 The attenuation process is slower than after AC 
placement.133 Thin film bands cause fibrous tissue reaction and slow progressive shunt 
occlusion comparable to CB, but they have different structural and mechanical 
properties.127,128 
The main advantages of CB over AC are that the material is cheaper, not heavy nor bulky 
and placement requires less dissection.130 More, Miller and Fowler introduced a less invasive 
approach than open surgery, consisting of laparoscopic placement of a CB around a 
congenital EHPSS in 2 dogs.135 
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Hydraulic occluders 
A hydraulic occluder is composed of a silicone cuff connected to a vascular access port by 
tubing to allow percutaneous control (Figure 16).136,137 The devices are designed specifically 
as an aid in the treatment of intrahepatic PSS but can be used on congenital EHPSS to obtain 
controlled attenuation. The cuff is positioned around the shunt, the opposing ends are secured 
with a non-absorbable suture and the port is implanted subcutaneously. To gradually occlude 
the shunt after surgery, a small amount of sterile fluid is injected transcutaneously into the 
port every 2 weeks. Complete shunt closure is not dependent on fibrous tissue formation and 
the device remains life long in place.137 
The potential advantage of a hydraulic occluder over other devices available to gradually 
attenuate PSSs is that complete occlusion of the vessel encircled by the cuff can be obtained. 
Furthermore, it is currently the only device in which attenuation can be reversed if clinically 
deemed necessary. 
 
 
 
Figure 16. Canine hepatic shunt occluder with subcutaneous 
access port. (Image https://www.docxs.net/vet_supplies.php) 
 
Thrombogenic coils 
A thrombogenic coil is a polyester fiber-covered flexible metallic strip that stimulates 
thrombosis on and around the device (Figure 17). Coils were first used in the treatment of 
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intrahepatic PSS138 but they can also be used in case of congenital EHPSS.90,139 A coil, 
slightly larger than the shunt diameter, is placed into the midportion of the shunt via a guide 
wire via a jugular or femoral vein approach. Additional coils are added until more than three-
fourth of the vessel is no longer patent, as judged by venography. 
The advantages of thrombogenic coils are the avoidance of invasive surgery, the relatively 
short anesthetic period, the faster recovery and the shorter hospital stay.90,139 However, in an 
experimental study in dogs, recanalization at the site of thrombosis was observed after 
complete early occlusion.133 Furthermore, coil migration to the heart or lungs will be fatal to 
the patient.138,139 Other reported disadvantages are the requirement of specialized 
instrumentation and training and the frequent need for multiple embolization procedures.138  
 
 
 
Figure 17. Coil intended to be used in dogs with a 
portosystemic shunt. The synthetic fibres enhance thrombus 
formation. (Image http://infinitimedical.com/products/embo-
coil) 
 
8.2.2 Intra-operative Identification of the Shunt 
 
Portocaval Shunts  
In normal dogs, there are no large vessels entering the caudal vena cava between the level of 
the right renal vein and the hepatic veins. This anatomical knowledge may help the surgeon 
to correctly identify a portocaval shunt.6 The portocaval communication is always reported to 
be at the left side of the vena cava.15 The place of insertion into the vena cava is caudal to the 
porta hepatis at the level of the omental foramen in the classical portocaval shunts, but 
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portophrenic shunts terminate cranial to the liver and caudal to the diaphragm .16 In extremely 
rare cases, a shunt inserts in the caudal end of the caudal vena cava in the so-called 
colonocaval shunts.16,17 
Often, identification of the insertion of portocaval shunts is possible by retracting the 
mesoduodenum towards the midline, disclosing the caudal vena cava. At the site of shunt 
insertion, the caudal vena cava may be dilated and contain turbulent blood flow.6 It may be 
necessary to gently retract the celiac artery caudally, the caudate lobe of the liver cranially, 
and/or the pancreas medially to see the portocaval shunt termination.6 If the insertion site of 
the shunt is difficult to reach for dissection through this approach, it may be necessary to 
enter the omental bursa by tearing through the superficial leaf of the major omentum.6 The 
stomach is then retracted cranially and the intestines caudally and laterally to view the left 
border of the caudal vena cava. The omental foramen is hereby visualized from the opposite 
site and shunt dissection might be easier.6 
Portophrenic shunts are more likely to be overlooked by inexperienced surgeons. This 
might explain the fact that they are nowadays much more reported than in older 
publications.14 The distal part of the shunt is often covered by the fascia transversalis, which 
lines the abdominal surface of the diaphragm. 
Colonocaval shunts may require a caudal extension of the abdominal incision before they 
can be visualized.16,17 
 
Porto-Azygos Shunts 
To identify porto-azygos shunts, the omental bursa can be opened to allow examination of the 
dorsal bursal recesses for abnormal vessels that penetrate the diaphragmatic crura.132 
Alternatively, porto-azygos shunts may also be found by retracting the liver and stomach to 
the right so the cardia and esophagus and left diaphragmatic crus are visible.14 
 
8.2.3 Positioning of the Attenuation Device 
Portosystemic shunts may have several contributing venous tributaries before they enter the 
systemic circulation. Therefore, although it is important to identify the shunt throughout its 
length, dissection should be directed to the point where the shunt connects with the systemic 
circulation. If the shunt is attenuated too far from its insertion and a tributary is still feeding 
the shunt distal to the attenuation site, continued shunting is expected.15,128 Hence, congenital 
EHPSS should be attenuated as close to their insertion sites as possible so that blood flow 
from all tributaries of the shunt is redirected.  
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Portocaval Shunts 
There is widespread support to attenuate portocaval shunts at their terminus on the caudal 
vena cava.14,15,125 Dissection of the insertion site of portophrenic shunts cranial to the liver 
can be difficult. After the phrenic vein receives the distal gastric tributaries, a fascial layer of 
the diaphragm covers it. In some animals, prudent dissection is required before the shunt 
insertion site can be approached distal to those branches.14 
 
Porto-Azygos Shunts 
The current guidelines for attenuation of porto-azygos shunts describe dissection of the shunt 
at the abdominal side of the diaphragm.14 Particularly in case of porto-azygos shunts, it is 
important to search carefully for small branches from gastric veins that may enter the PSS 
just before the shunting vessel traverses the diaphragm.14,128 The diaphragm may be opened if 
more exposure is desired.14 
 
 
At the start of this PhD research, publications on EHPSS only contained information on 
porto-azygos shunts mentioned in the same breath as portocaval shunt data. It was also 
striking that nowhere surgical details dedicated to porto-azygos shunts were provided. 
However, sticking to the general principles of successful PSS attenuation, it seems logical to 
also attenuate porto-azygos shunts as close to their insertion site as possible, but it was 
nowhere recommended. 
 
8.2.4 Peri-operative Complications Related to Surgical Attenuation 
Survival rate from the surgery is over 95% but monitoring of dogs in the immediate 
postoperative period remains crucial. Complications after placement of gradual attenuation 
devices to treat congenital EHPSS are fewer compared to (partial) ligation. 
There is no need for intra-operative portal pressure measurements but although 
postoperative portal hypertension is uncommon, it can be fatal.14,65 Acute severe portal 
hypertension can occur in the immediate postoperative period when complete occlusion of 
the shunting vessel by kinking of the shunt within an AC or by thrombus formation occurs. 
Increased abdominal pain or diarrhea and/or vomitus that may contain fresh or digested blood 
can be the first signals observed before clear evidence of hypovolemic shock and abdominal 
distention become more obvious.14,65 Mild portal hypertension will induce ascites that is self-
limiting in days to weeks in the majority of the cases.33 
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Many dogs experience a prolonged anesthetic recovery. With adequate pre-operative 
imaging, pre-surgical planning can significantly shorten the surgical procedure. Nonetheless, 
many patients become very hypothermic because the majority are small breed dogs, often 
immature and/or skinny. For the same reasons, those dogs are particularly sensitive to 
postoperative hypoglycemia; although some researchers suggest that the main mechanism for 
the hypoglycemia in dogs with congenital EHPSS is an increased baseline postoperative 
cortisol concentration.140 Blood glucose levels should be monitored regularly as long as the 
dog does not eat spontaneously after anesthesia and whenever the patient displays lethargy or 
dullness.65 
Blood pressure also needs to be assessed regularly in the immediate postoperative period 
to check for hypotension.65 
Anemia may be present postoperatively, even in the absence of intra-operative 
hemorrhage. The red blood cells sequestrate in the spleen or are diluted by perioperatieve 
fluid therapy.33 
Post-attenuation neurological dysfunction, unrelated to hypoglycemia or 
hyperammonemia, may occur in the first 3 to 6 days after surgery, likely due to changes in 
the concentration of certain neurotransmitters or other metabolic alterations.50 An incidence 
as high as 12% has been described.141 The severity of the neurological signs may vary from 
facial twitching, muscle fasciculation, abnormal vocalization, and ataxia up to status 
epilepticus.23,50,141-143 A high mortality rate is associated with the development of 
postoperative status epilepticus. Pretreatment with levetiracetam is reported to potentially 
decrease the incidence of postoperative seizures.144 
 
 
8.3 Postoperative Care 
 
Dogs are discharged on a protein-restricted diet for at least a month; also lactulose is 
generally continued after surgery. There are no published guidelines concerning the length of 
the supportive treatment. It has been studied that liver volumes in dogs with congenital 
EHPSS normalize within a month after successful surgery.76 It is therefore conceivable that 
medical management after surgery is continued until then. 
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9. Prognosis in dogs with a Congenital Extrahepatic Portosystemic Shunt 
 
9.1 Long-term Prognosis with Medical Management Alone 
 
Prospective studies on the medical management of dogs with EHPSS have not been reported. 
However, there are retrospective studies that looked at this issue.34,52,145,146 However, none of 
those studies evaluated EHPSS and IHPSS separately, potentially biasing the results. In the 
oldest study, the owners of two-thirds of the dogs requested euthanasia after a mean treatment 
period of less than 10 months.34 In the most recent retrospective study on 27 dogs with CPSS 
(21 EHPSS and 6 IHPSS) evaluated after long-term (median 1936 days) medical 
management alone, 89% were euthanized or died due to conditions related to PSS at a 
median of 836 days after diagnosis.146 Dogs with EHPSS controlled by medical management 
alone presented with neurologic signs that were similar or less persistent than before 
treatment. In those retrospective studies, no correlation could be demonstrated between levels 
of serum bile acids, serum proteins, albumin, ALP, ALT, or MCV and survival times.52,146 
Likewise, most of the blood parameters did not change significantly after medical 
management was installed.34 
 
 
9.2 Long-term Prognosis after Surgical Attenuation 
 
Retrospective studies on surgical treatment of EHPSS by different attenuation devices 
demonstrated that surgical treatment of EHPSS resulted in significantly improved survival 
rate and lower frequency of persistent clinical signs compared to medical management 
only.52,145,146 
Surgical treatment aims at resolution of all clinical symptoms by gradual but complete 
closure of the original congenital EHPSS without concurrent development of acquired PSS. 
However, that is not the only possible long-term outcome observed in congenital EHPSS 
after surgical attenuation. Improved portal blood flow and subsequent improvement or even 
normalization of the clinical status can be observed after incomplete closure. Poor clinical 
response may also result from the presence of a second shunt, incorrect placement of the 
attenuation device or due to concomitant primary portal vein hypoplasia.19,125,128,147. At last, 
there are also dogs that develop multiple acquired portosystemic shunts due to portal 
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hypertension. In such cases, persistence or recurrence of clinical signs will be 
observed.14,32,65,119 It has been suggested that actively inducing too much reduction in shunt 
diameter at the time of placement of the device is associated with a poorer long-term outcome 
due to an increased risk of acquired shunting.126 
Many of the older studies are retrospective and categorize postoperative outcomes solely 
based on the evolution of the clinical signs or based on clinical signs and laboratory 
parameters. In more recent studies, most of the dogs are subjected to postoperative diagnostic 
imaging to objectively assess successful shunt closure. It became obvious that surgical 
outcome based on complete absence of portosystemic shunting is less favourable than 
outcome based on clinical improvement. Also comparison between pre- and postsurgical 
laboratory parameters is often inconclusive to assess absence of postoperative 
shunting.125,128,148 
The sensitivity and specificity of postoperative paired SBA measurements has not been 
reported. But it is obvious that accuracy is far less than when used in the diagnosis of PSS 
and that they are not adequate for postoperative monitoring.18 Normal postprandial SBAs 
have been reported despite the presence of persistent shunting or multiple acquired PSS.125,128 
Furthermore, it is not uncommon to observe persistent abnormalities in SBA concentrations 
in asymptomatic dogs after successful surgical attenuation.18,125,128,148,149 
Similar to paired SBAs, ammonia is a popular test in the diagnosis of PSS. When the PhD 
research was initiated, there was no study investigating the evolution of ammonia post-
attenuation. 
 
 
 
10. Conclusion  
Extrahepatic portosystemic shunts in dogs are most commonly seen as congenital 
communications in young small breed dogs. Neurological manifestations are most common, 
but yet not understood. Medical management before surgical attenuation is always 
recommended. Surgical attenuation should be considered in an attempt to improve perfusion 
of the liver and ultimately liver function. Outcome is difficult to predict since many 
observations before and after surgery are still poorly understood.   
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Literature on extrahepatic portosystemic shunts (EHPSS) in dogs is far from sparse, yet 
shortcomings and gaps on a number of aspects of this fascinating disease inspired us for 
further research. Until the start of this research, there was no single study concentrating on 
porto-azygos shunts. The existing gap in knowledge concerning the particular morphology 
and the surgical approach could not rest aside our curiosity. Furthermore, many assumptions 
on the pathophysiology of hepatic encephalopathy (HE) in EHPSS dogs were extrapolated 
from what is known in human patients with liver disease exhibiting (sub)clinical HE signs. 
This lapse in species-specific knowledge evokes controversy and discussion about specific 
implementation of treatment of neurological signs observed in EHPSS dogs. Therefore, we 
aimed to gain more information about ammonia concentration in different body fluids 
including the CSF and, consequently, to demonstrate changes in the central nervous system in 
dogs affected by HE due to a congenital EHPSS.  
 
 
The specific aims of this doctoral thesis were three-fold: 
 
1. The first aim of this thesis was to provide a detailed description of various anatomical 
types of porto-azygos shunts and to describe and document a transdiaphragmatic 
surgical approach to attenuate porto-azygos shunts in dogs (Chapter 1 and 2). For this 
purpose, a large number of dogs with porto-azygos shunts were evaluated using Computed 
Tomographic Angiography (CTA) with special attention to the site of insertion of these 
vascular anomalies (Chapter 1). In addition, a cadaveric and clinical study was established to 
document a transdiaphragmatic surgical approach to attenuate porto-azygos shunts inserting 
in the thoracic part of the azygos vein (Chapter 2). We hypothesized that porto-azygos shunts 
insert into the thoracic part of the azygos vein and that a transdiaphragmatic surgical 
approach is suitable to attenuate these shunts and eliminates the risk of missing late 
tributaries to the shunting vessel. 
 
2. The second aim of this work was to evaluate the ammonia concentrations in the blood 
and cerebrospinal fluid (CSF) of dogs with an EHPSS (Chapter 3 and 4), in an attempt to 
shed more light on the etiopathogenesis of HE in dogs with EHPSS. For this purpose, the 
ammonia concentrations in arterial blood, venous blood and CSF in control dogs and in dogs 
with a congenital EHPSS were compared on the day of diagnosis. At preset time points 
before and after surgery the ammonia concentrations were measured and related to the 
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surgical and clinical outcome. We hypothesized that in dogs with HE and 
hyperammonaemia due to the presence of an EHPSS the arterial ammonia concentration 
would exceed the venous level, and that the ammonia levels in the blood and the CSF would 
be positively correlated. 
 
3. The third aim of this PhD was to document the alterations in the regional cerebral blood 
flow (rCBF) in EHPSS dogs with overt HE signs, and to determine which areas of the brain 
have an altered perfusion based on brain perfusion imaging scans (Chapter 5). For this 
purpose, SPECT scans analyses were compared between control dogs and dogs with an 
EHPSS with clinical signs of HE. We hypothesized that the rCBF in PSS dogs with clinical 
signs of HE might be altered, with the changes being observed in dogs with clinically 
apparent signs of neurological dysfunction and hyperammonimia.  
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1. Abstract  
 
Objective: To describe the morphology of porto-azygos shunts in a large series of dogs using 
computed tomography (CT) angiography.  
 
Study Design: Retrospective study. 
 
Animals: Dogs (n=36) with porto-azygos shunts.  
 
Methods: CT angiography was performed in dogs subsequently proven to have a porto-
azygos shunt. The origin and insertion of the shunts were assessed on native images. The 
diameter of the porto-azygos shunt and the portal vein, cranial and caudal to the shunt origin, 
were measured. The porto-azygos shunt anatomy was studied on three-dimensional images.  
 
Results: All porto-azygos shunts originated either in the left gastric vein (33 left gastro-
azygos shunts) or the right gastric vein (3 right gastro-azygos shunts). Two left gastro-azygos 
shunts had concurrent caval-azygos continuation and 2 right gastro-azygos shunts had a 
caudal splenic loop. All shunts crossed the diaphragm through the esophageal hiatus. The 
majority of porto-azygos shunts (32) followed a straight pathway after traversing the 
diaphragm, although 4 shunts followed a tortuous route. All shunts terminated in the thoracic 
part of the azygos vein, perpendicular to the aorta. The shunt diameter at insertion was only 3 
mm on average. The insertion site was consistently the narrowest part of the shunt.  
 
Conclusion: CT angiography was well suited to provide anatomic details of porto-azygos 
shunts and comprehensively documented that all porto-azygos shunts had a thoracic terminus, 
after crossing the diaphragm through the esophageal hiatus. Different shunt types existed with 
minor variations.   
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2. Introduction 
 
A portosystemic shunt is an anomalous vessel that bypasses the liver, diverting blood 
drainage from the venous gastrointestinal tract directly into the systemic circulation.1 Porto-
azygos shunts account for 25% of all congenital extrahepatic portosystemic shunts in dogs.2,3 
Computed tomography (CT) angiography provides accurate details on the shunting vessels 
and their tributaries.4-6 In general, descriptions of porto-azygos shunt anatomy in dogs are 
vague and often it is not mentioned whether the point of insertion of the shunt into the azygos 
vein is situated in the abdomen or in the thorax. A preoperative description of the porto-
azygos shunt insertion site facilitates the surgical approach and reduces the duration of the 
surgery, as well as the risk for continued shunting because of improper selection of the site of 
attenuation.4,7,8 Porto-azygos shunts that traverse the diaphragm before entering the azygos 
vein may have tributaries from gastric veins near the diaphragm.4,9-11  
Identification of such tributary vessels is often a surgical4,9,10 and imaging challenge11 and 
it may be difficult to place an occluding device cranial to all gastric branches. If the device is 
placed too caudally, complete shunt closure will not be obtained.11 To avoid incomplete 
closure, an option is to place the occlusive device on the thoracic portion of the shunt. To our 
knowledge, there has not been a study reporting porto-azygos shunt anatomy in dogs with 
special focus on the point of insertion of the portosystemic shunt into the azygos vein. There 
is therefore insufficient information to allow thoracic attenuation of such shunts. The goal of 
this study was to provide a detailed description of various types of porto-azygos shunts in a 
large number of dogs using CT angiography with special attention to the site of insertion of 
these vascular anomalies. 
 
 
3. Materials and Methods 
 
Dogs presenting to the Animal Medical Center of Nihon University between April 2007 and 
May 2015 with a porto-azygos shunt identified by CT angiography that were treated 
surgically were included in the study. In all dogs, surgical attenuation was performed at the 
abdominal part of the shunt at the level of the diaphragm (31 by ameroid ring constrictors and 
5 by complete ligation). 
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All dogs were fasted for at least 12 hours before performing the CT scan (16 slice multi-
detector CT scanner, Aquilion 16, Toshiba Medical Systems Co, Otawara, Japan). Dogs were 
induced at the anesthetist’s discretion and anesthesia was maintained by isoflurane in oxygen. 
Dynamic CT angiography was performed with dogs in sternal recumbency according to the 
protocol described by Kutara.12 Images were acquired using a 1-2 mm slice collimation, 120 
kVp, and 150 mAs, and reconstructed using a soft tissue pass algorithm. Images were viewed 
using a window and level optimized for soft tissue (window 300 Hounsfield unit (HU), level 
100 HU). The entire circumference of the abdomen and thorax were included in the display 
field of view. Before contrast medium administration, a survey CT scan was performed from 
the level of the thoracic inlet to the pelvic inlet. At the onset of initiating a dynamic CT scan, 
iodinated contrast medium (750 mg I/kg body weight; Ioverin 300, Teva Pharma Japan Inc, 
Nagoya, Japan) was administered at 0.3-3.0 mL/s through a peripheral catheter in the cephalic 
vein by an angiographic injector (Auto Enhance A-60, Nemoto-Kyorindo, Tokyo, Japan). A 
complete abdominal CT angiography examination was performed. To target the flow, the 
region of interest was placed into the aorta at the level of the 13th thoracic vertebra. When 
150 HU was reached, the arterial phase was started. Images for the arterial phase were 
acquired every 10 seconds for a total of 700 images. The interval to maximal aortic 
enhancement and portal venous enhancement was calculated. During the portal vein phase 
images were acquired from the pelvic inlet to the thoracic inlet, 15 and 30 seconds after the 
arterial phase. A delayed phase was acquired 120 seconds after the beginning of the arterial 
phase. Images of the portal vein phase were imported into a CT image analysis program (AZE 
Virtual Place Plus, AZE, Tokyo, Japan) that allowed automatic selection of vessels based on 
HU differences. Gross anatomy of porto-azygos shunts, including the vessel of origin of the 
shunting vessel and its anatomic location, abdominal and thoracic pathway, and insertion 
point in the azygos vein (thoracic or abdominal part; level of vertebral body) was 
documented. If the shunt crossed the diaphragm, it was recorded through which hiatus it 
crossed. The diameters of the shunt vessel, portal vein, and aorta were measured on transverse 
images at set locations. Cranially, the portal vein diameter was measured at the hilus of the 
liver, caudal to the bifurcation of the vein in the right and left portal branch. On the same 
transverse image, the aortic diameter was measured. In addition, the diameter of the portal 
vein was measured immediately caudal to the origin of the shunting vessel. The shunting 
vessel was measured at its largest diameter, as well as at its terminus. If the shunt crossed the 
diaphragm, its diameter at the level of the diaphragm was defined. All measurements were 
performed by three independent observers (KI, KK, and KA) and mean values for each 
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parameter were calculated. The statistical software package SPSS Statistics (IBM, Brussels, 
Belgium) was used. Pearson correlation tests were performed to assess the correlation 
between the shunt size at insertion and the age at presentation. Significance levels were set at 
P<.05. 
 
 
4. Results 
 
A porto-azygos shunt was identified in 36 dogs on pre-operative CT images. Breeds 
represented were Yorkshire Terrier (7 dogs), Toy Poodle (5), Chihuahua (4), Pug (3), 
Papillon, Miniature Pinscher, Jack Russell Terrier, and mixed breed (2 each), Miniature 
Schnauzer, American Cocker Spaniel, Shih Tzu, Welsh Corgi, Bolognese, Cavalier King 
Charles Spaniel, Shiba Inu, Miniature Dachshund, and Norfolk Terrier (1 each). Ages at the 
time of CT imaging ranged from 3 months to 9.8 years (mean, 3.0 years). Bodyweight ranged 
from 1.5 to 8.7 kg (mean, 4.3 kg). Of the 36 dogs, 23 were female (15, intact; 8, spayed) and 
13 were male (5, intact; 8, castrated). 
 
Shunt Anatomy 
All porto-azygos shunt conformations inserted into the azygos vein in the thorax. Different 
porto-azygos shunt conformations were identified by the CT angiography (Table 1).  
 
Left Gastro-Azygos Shunts 
Left gastro-azygos shunts (33 dogs) originated from the left gastric vein. The shunting vessels 
extended cranially and dorsally, crossing the diaphragm through the esophageal hiatus (Figs 1 
and 2AB). The vast majority of the left gastro-azygos shunts (30) displayed a rather straight 
pathway, whereas 3 left gastro-azygos shunts extended craniodorsally along a curved, 
tortuous route after crossing the diaphragm. Two of the straight left gastro-azygos shunts had 
a concurrent caval-azygos continuation (Fig 3AB). In 29 dogs (85%) with a left gastro-azygos 
shunt the shunting vessel continued parallel and to the right of the aorta, inserting 
perpendicular to the azygos vein (Fig 1). However, in the remaining 4 dogs, the vessel 
coursed parallel to the left of the aorta until the level of the inserting point into the azygos 
vein. At that level, the shunt curved abruptly to the right at a 90° angle and crossed dorsal to 
the aorta to insert into the azygos vein (Fig 2). The left gastro-azygos shunts terminated in the 
thoracic part of the azygos vein at the level of T12 (13 dogs), T11 (12), T13 (6), T8 (1), and 
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T10 (1). The diameter of the portosystemic shunts at the point of insertion ranged from 1.6 to 
5.2 mm (mean, 2.9 mm). 
 
 
 
Figure 1 Left gastro-azygos shunt conformation, with a straight-lined right intra-thoracic course. (A) 
Transverse native image showing the shunting vessel coursing through the esophageal hiatus dorsal to 
the esophagus. (B) Sagittal native image showing the insertion site of the shunting vessel, situated 
cranial to the diaphragm. (C) Dorsoventral 3D reconstruction image showing the shunting vessel 
coursing to the right of the thoracic part of the aorta. (D) Sagittal 3D reconstruction image, viewed 
from the right side of the dog, showing the shunt coursing to the right of the thoracic part of the aorta 
with a characteristic L shape at insertion clearly visible. AO=aorta, AZ=azygos vein, CVC=caudal 
vena cava, DI=diaphragma, PV=portal vein, SH=shunting vessel,   
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Figure 2 Left gastro-azygos shunt conformation, with a straight-lined left intra-thoracic course. (A) 
Transverse native image showing the shunting vessel coursing to the left of the thoracic part of the 
aorta. (B) Sagittal native image showing the insertion site of the shunting vessel, situated cranial to the 
diaphragm. (C) Dorsoventral 3D reconstruction image, showing the shunting vessel coursing to the 
left of the thoracic part of the aorta, passing dorsal to the aorta to inset in the azygos vein. (D) Sagittal 
3D reconstruction image viewed from the left side of the dog, showing the shunt coursing to the left of 
the thoracic part of the aorta, passing dorsal to the aorta to insert in the azygos vein with a 
characteristic L shape clearly visible. AO=aorta, AZ=azygos vein, CVC=caudal vena cava, LGV=left 
gastric vein, SH=shunting vessel, DI=diaphragma 
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Figure 3 (A, B) Left gastro-azygos shunt conformation with a concurrent caval–azygos continuation. 
The pre-hepatic caudal vena cava was absent. The post-hepatic caudal vena cava, which was formed 
by confluence of hepatic veins, was clearly noticed. (A) Dorsoventral 3D reconstruction image. (B) 
Sagittal 3D reconstruction image viewed from the right side of the dog. (C, D) Left gastro-azygos 
shunt conformation with a tortuous intra-thoracic course. (C) Dorsoventral 3D reconstruction image. 
(D) Sagittal 3D reconstruction image viewed from the right side of the dog. AO=aorta, AZ=azygos 
vein, CVC=caudal vena cava, LGV=left gastric vein, PV=portal vein, SH=shunting vessel 
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Right Gastro-Azygos Shunts 
The right gastro-azygos shunts (3 dogs) involved the right gastric vein and extended cranially 
and dorsally, similar to the left gastro-azygos shunts, and also crossed the diaphragm through 
the esophageal hiatus. In 2 dogs, the shunts had a fairly straight course but the splenic vein 
was feeding a second and larger shunting branch, which united with the right gastric vein 
branch before crossing the diaphragm (Fig 4AB). The shunting vessel terminated in the 
thoracic part of the azygos vein at the level of T12 in both dogs and the diameters at insertion 
were 2.0 and 3.4 mm.  
 
 
 
Figure 4 (A, B) Right gastro-azygos shunt conformation with a caudal splenic loop. (A) Ventrodorsal 
3D reconstruction image. (B) Sagittal 3D reconstruction image viewed from the right side of the dog. 
(C, D) Right gastro-azygos shunt with a tortuous intra-thoracic course. (C) Dorsoventral 3D 
reconstruction image. (D) Sagittal 3D reconstruction image viewed from the left side of the dog. PV: 
Portal Vein, SH: Shunting vessel  AO=aorta, AZ=azygos vein, CVC=caudal vena cava, ,RGV=right 
gastric vein, PV=portal vein 
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The remaining shunting vessel displayed a tortuous pathway, describing an S shape after 
crossing the diaphragm. The shunting vessel was situated to the right of the aorta (Fig 4CD) and 
terminated as a 2.3 mm vessel in the thoracic azygos vein at the level of T12.  
The diameter of the portosystemic shunt at the point of insertion into the azygos vein 
ranged from 1.6 to 5.2 mm (mean, 3.0 ± 0.9 mm), which was consistently smaller than the 
diameter at the esophageal hiatus (mean, 5.0 ± 1.6 mm). In all but 5 dogs, the maximal 
diameter of the shunt exceeded the diameter of the portal vein immediately caudal to the 
origin of the shunting vessel (Table 1). Shunt size at insertion and age of the dog at 
presentation were not correlated (P=.605). 
 
 
5. Discussion 
 
To our knowledge, this is the largest study using CT angiography to determine porto-azygos 
shunt morphology. The study revealed 2 conformations of porto-azygos shunts in dogs, those 
involving the left gastric vein and those involving the right gastric vein. All porto-azygos 
shunts crossed the diaphragm through the esophageal hiatus and terminated in the thoracic 
part of the azygos vein. The maximal shunt diameter was situated in the abdominal part of the 
shunting vessel. At its point of insertion, the shunt was only 3 mm on average. 
CT angiography supplants traditional mesenteric portography as the gold standard for the 
evaluation of the portal venous system anatomy in dogs4,10,13,14 and is far less invasive. 
Additionally, CT angiography provides a comprehensive overview of the entire portal 
vasculature, including all tributary vessels that drain into the shunt. Portography only provides 
visualization of the vessels through which the injected contrast agent flows.15 When 
performed correctly and with adequate spatial resolution, CT angiography can be performed 
in dogs of any size.7 Furthermore, the technique allows for the manipulation of the images 
after acquisition and for the creation of comprehensive three-dimensional models.4 The CT 
scans of the dogs with porto-azygos shunts provided the means for identifying the shunt type 
and detailed the size and course of the anomalous vessel.  
In normal dogs, the azygos vein begins on the median plane, ventral to the body of the 
third lumbar vertebra.16 It runs cranially through the aortic hiatus, to the right of the aorta, 
terminating in the cranial vena cava. In rare cases, and considered an incidental finding, an 
azygos continuation of the caudal vena cava is observed. In this instance, the caudal vena 
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cava anastomoses with the azygos vein at the lumbar region.16-23 
In 25% of dogs with an extrahepatic portosystemic shunt, an abnormal communication 
between the portal system and the azygos vein is present.2,3 Based on CT angiography images 
of 25 dogs, Nelson and Nelson identified 4 porto-caval and 2 porto-azygos shunt types.4 In 
our study of porto-azygos communications, we also encountered right gastro-azygos shunts 
with a caudal splenic loop and left gastro-azygos shunts. Left gastro-azygos shunts were 
formerly called spleno-azygos shunts.4,14 Additionally, we identified a singular right gastro-
azygos shunt. The assumption that a right gastro-azygos shunt without double looping might 
exist in dogs was briefly raised,4 but not previously documented. 
Given the large number of dogs assessed in our study, the observed types and their 
variants likely represent the most common porto-azygos shunt conformations in dogs. The 
terminology used for naming the shunts was based on the veins that dominantly contributed to 
the shunt origin.4,14,15,24 Previous studies consistently implied that the shunting vessel in 
porto-azygos shunts joined the azygos vein at the level of the aortic hiatus.9,15 However, our 
study demonstrated that all shunting vessels crossed the diaphragm through the esophageal 
hiatus and only joined the azygos vein in its thoracic part. Despite the identification of 
different porto-azygos shunt types, our study identified little variation in the terminus of 
porto-azygos shunts on the azygos vein. The shunt diameter was consistently the smallest at 
the insertion site. 
In 12% of dogs with left gastro-azygos shunts, the shunting vessel continued in the thorax 
to the left of the aorta until the level of the inserting point into the azygos vein. This could 
have clinical significance if a thoracic approach is used to place an occlusive device. Pre-
operative CT angiography will prevent mistaking the shunting vessel for another vessel or for 
a hemi-azygos vein on the left side of the aorta. The curved, tortuous pathway of the shunt in 
the thorax, observed in the single right gastro-azygos shunt and in some of the left gastro-
azygos shunts, has not been described previously and can be relevant during surgery. As 
previously described in portosystemic shunts, preoperative imaging can decrease the surgical 
time and the degree of dissection needed for shunt evaluation.4,8,14 
Shunts with a double looping morphology were noticed in 2 dogs with a right gastro-
azygos conformation. This shunt type was previously described in a single dog.4 The naming 
convention suggests that the right gastric vein is the dominant contributor to the shunting 
vessel; however, we noticed that the caudal loop that communicated with the splenic vein had 
a larger diameter than the right gastric branch. 
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Dogs with an azygos continuation of the caudal vena cava in combination with a 
portosystemic shunt have previously been described.18,23,25 These dogs had a portal 
communication with the azygos vein in all cases18,25 except 1, which had a post hepatic porto-
caval communication.23 In our study, 2 left gastro-azygos shunts with concurrent caval-
azygos continuations were observed. To our knowledge, this is the first documentation of this 
shunt conformation with CT angiography. Azygos vein distension was easily recognized on 
the CT images at the cranial extent of the abdomen because, in those cases, the diameter of 
the azygos vein exceeded the adjacent aorta diameter. The prevalence of caudal vena cava 
anomalies in dogs is reported to be 1-3%.17,23 In most cases of azygos continuation, a 
portosystemic shunt is not simultaneously present.17,23 Yet recognition of an associated shunt 
dictates surgical intervention, whereas an isolated vena cava anomaly does not. 
Ultrasonographic measurements of the ratios between the major vessels (portal vein, 
shunting vessel and aorta) in normal dogs and dogs with portosystemic shunting have been 
reported.26 Obviously, vessel diameters are easily measured on images acquired by CT 
angiography. Within the group of dogs with the same porto-azygos shunt type, the relative 
vessel diameter differences did vary. The portal vein diameter caudal to the shunt origine was 
smaller or similar to the shunt diameter. Likewise, the portal vein diameter at the hilus of the 
liver was smaller than the portal vein caudal to the origin of the shunt, which was also 
observed in a previous CT angiography study on different types of portosystemic shunt.4 The 
diameter of the porto-azygos shunts at the site of insertion was consistently the minimal 
diameter of the shunting vessel. 
It was reported that porto-azygos shunts are often associated with less severe clinical signs 
than porto-caval shunts and are therefore mostly diagnosed in older dogs.7,27,28 In our study, 
dogs were diagnosed at a mean age of 3 years. One suggestion is that the severity of clinical 
signs is positively correlated with the amount of blood diverted from the portal circulation to 
the systemic circulation.7,29 Based on Poiseuille’s law, there might be more resistance to 
blood flow in porto-azygos shunts than in porto-caval shunts, since the diameter of the azygos 
vein is smaller than that of the caudal vena cava.16 Moreover, porto-azygos shunts can be 
partially compressed by the diaphragm during respiration and by gastric distension after 
eating, which can result in temporary improved hepatic perfusion through the normal portal 
vasculature.7,30 Furthermore, the blood that flows through a porto-azygos shunt that inserts in 
the thorax, could be assumed to travel a greater distance than through most porto-caval 
shunts, adding to the resistance of the flow.7 In addition, porto-azygos shunts were found to 
be relatively narrow at their thoracic terminus. Statistically, however, the diameter at insertion 
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could not be correlated to the age at presentation. 
 
 
6. Conclusion 
 
Computed tomography angiography is well suited to provide details on porto-azygos shunt 
anatomy in dogs. Anatomic variations in shunt types exist, but are minor. Based on our data, 
the vast majority of dogs with a congenital porto-azygos shunt have a left gastro-azygos 
shunt, whereas other shunts involve the right gastric vein. All porto-azygos shunts included in 
our case series crossed the diaphragm through the esophageal hiatus and had a thoracic 
terminus. 
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1. Abstract 
 
Objective: To describe the surgical technique and to document the feasibility of a 
transdiaphragmatic approach to attenuate porto-azygos shunts inserting in the thoracic part of 
the azygos vein. 
 
Study Design: Cadaveric study and prospective case series. 
 
Animals: Canine cadavers (n=6) and client-owned dogs with porto-azygos shunts inserting in 
the thoracic part of the azygos vein (n=9). 
 
Methods: In the cadavers, the azygos vein was filled with aqueous latex solution. Landmarks 
were established for creating a safe transdiaphragmatic approach to the caudal intra-thoracic 
portion of the azygos vein. In the clinical cases, porto-azygos communication was diagnosed 
by transsplenic portal scintigraphy. All shunts were attenuated close to their insertion site via 
celiotomy using a transdiaphragmatic approach. Peri-operative complications were recorded. 
 
Results: A 3-5 cm incision, 0.5-1 cm ventral and lateral to the level of the aortic hiatus, was 
made in the pars lumbalis part of the diaphragm. Stay sutures at both sides of the 
diaphragmatic incision were placed to open up the incision and a retractor was used to push 
the esophagus away from the aorta. Intra-thoracic insertion of the shunt was confirmed 
intraoperatively. Exposure of the shunt insertion site to the azygos vein was excellent in all 
clinical cases. No intra- or postoperative complications were encountered.  
 
Discussion/Conclusion: If thoracic attenuation of a porto-azygos shunt is considered, a 
transdiaphragmatic approach exposes the insertion site for shunt attenuation. This approach is 
a straightforward surgical procedure, without unnecessary abdominal organ manipulation, 
while the risk of missing additional contributing branches is eliminated. 
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2. Introduction 
 
Surgical attenuation is the preferred method of treatment for congenital portosystemic shunts 
(PSS) in dogs without signs of portal hypertension.1 It is recommended to attenuate shunting 
vessels as close to their insertion site as possible, so that blood flow from all tributaries of the 
shunt is redirected through the portal system.2  
Nearly one fourth of all extrahepatic PSSs in dogs are porto-azygos shunts.3,4 Although 
the majority of those shunts traverse the diaphragm to insert in the thoracic part of the azygos 
vein,2,5 it appears that most surgeons occlude porto-azygos shunts intra-abdominally rather 
than intrathoracically.2 Continued postoperative shunting is of concern if the occluding device 
is placed further away from the insertion,6 since porto-azygos shunts may have tributaries 
from gastric veins just before traversing the diaphragm.2,4,7,8 Identification of those tributary 
vessels can be a challenge as they can spasm with surgical manipulation.2,7,8 A recent report 
on CT-angiographic findings in 36 dogs with porto-azygos shunts identified 2 shunt types, 
either involving  the left or the right gastric vein all of which had a thoracic terminus after 
crossing the diaphragm through the esophageal hiatus.5 The shunts all ran parallel to the 
thoracic aorta making a near 90° bend before inserting into the azygos vein, creating a 
characteristic “L” shape adjacent to their insertion site.5 Sticking to the principles of PSS 
attenuation,2 it seems logical to only attenuate also porto-azygos shunts as close to their 
insertion site as possible, necessitating access to the thoracic cavity in cases were the shunting 
vessel terminates in the thorax. 
 
The objective of this study was to describe and document a transdiaphragmatic surgical 
approach to attenuate porto-azygos shunts inserting in the thoracic part of the azygos vein. 
 
 
3. Materials and Methods 
 
A cadaveric study and a prospective case series were designed. The transdiaphragmatic 
approach for attenuation of intrathoracic porto-azygos shunts was evaluated in canine 
cadavers (n=6) and subsequently applied in clinical cases (n=9).  
Six, small breed (< 10 kg) canine cadavers of different, sex, age and breed were used. 
Dogs were euthanized for reasons unrelated to the study. The dogs were first positioned in left 
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lateral recumbency. Ribs 2-6 were removed to create a thoracic window, exposing the 
insertion site of the azygos vein into the cranial vena cava. The azygos vein was ligated at its 
insertion site into the cranial vena cava using a 3-0 polyglactin 910. A 20 gauge peripheral 
venous catheter was placed into the azygos vein caudal to the ligature and the vein was filled 
by injection of 40 mL of aqueous latex (Polyester Demaere©, Belgium). The dogs were 
stored at 4°C for 24h to allow the latex to cure. A standard median celiotomy was then 
performed with the dogs in dorsal recumbency. Landmarks were established to create a safe 
corridor for a transdiaphragmatic approach to the caudal part of the thoracic azygos vein. 
These landmarks included the aorta dorsally and medially and the phrenic vein ventrally and 
laterally. A stab incision was made in the left side of the diaphragm 0.5-1 cm ventral and 
lateral to the aortic hiatus in the intermediate part of the pars lumbalis; the incision was 
lengthened over 3-5 cm, parallel with the direction of the muscle fibers. Stay sutures were 
placed through the diaphragm on both sides of the incision and the thoracic cavity was 
explored. All visible intrathoracic anatomical structures were recorded. Next, the ventral part 
of the ribs cranial to the attachment of the diaphragm on both sides of the thorax, including 
the associated sternum, were resected, leaving the diaphragm intact. The thoracic side of the 
transdiaphragmatic incision was evaluated with relation to its proximity to local thoracic 
structures.  
The clinical case series included 9 dogs (presented from August 2013 to January 2016) 
with porto-azygos shunts diagnosed by transsplenic portal scintigraphy using technetium 
pertechnetate 99mTcO4.8 All dogs underwent a transdiaphragmatic approach for shunt 
attenuation. All dogs received standard medical stabilization, consisting of a dietary, 
antimicrobial, synthetic disaccharide regimen for an initial 4-week period before surgery and 
vitamin K for 5 days before surgery. The intrathoracic course of the shunt was confirmed at 
the time of surgery. Based on the findings of the cadaveric study, a stab incision was made in 
the left part of the diaphragm 0.5-1 cm ventral and lateral to the aortic hiatus in the 
intermediate part of the pars lumbalis; the incision was lengthened over 3-5 cm, parallel to the 
direction of the muscle fibers. The left phrenic vein dictated the most ventral and lateral 
borders of the diaphragmatic window (Fig 1). All shunts were bluntly dissected from the aorta 
with a curved baby-Mixter forceps (Medlane®, France) close to their insertion site into the 
thoracic part of the azygos vein at the level of the characteristic “L” shape5. A cellophane 
band (CB; Marlboro cigarette wrap, Belgium) was used in the first 5 cases whereas in all 
consecutive cases (4 first surgeries and 3 revisions), an ameroid ring constrictor (AC; 
Research Instruments NW, Lebanon, OR) was placed as previously described.2,9 The 
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diaphragmatic incision was closed using a 3-0 poliglecaprone 25 in a simple continuous 
suture pattern and negative intrathoracic pressure was restored using a 3Fr feeding tube 
(Teleflex, Rusch® sterile, Germany).10 The tube was inserted through the diaphragmatic 
incision, and, after the suture was tightened, air was removed using a 50 mL syringe 
connected to the tube by a three-way stopcock. As soon as negative intra-thoracic pressure 
was established, the tube was removed. All dogs recovered from anesthesia under direct 
supervision. Fluid and pain management were continued as needed. All patients were 
hospitalized for at least 3 days after surgery. Oral medication and diet were initiated as soon 
as the dogs were willing to eat. Postoperative seizures and signs of portal hypertension were 
evaluated daily. The dogs were discharged from the hospital on the same medicinal regimen 
as pre-operatively. A postoperative transsplenic portal scintigraphy was advised 12 weeks 
after surgery to assess shunt closure. 
 
 
4. Results 
 
The dogs included in the cadaveric study had a mean body weight of 6.0 kg (range 4.3-10.2 
kg). After median celiotomy, retraction of the left liver lobes and the stomach to the right 
facilitated visualization of the left phrenic vein and the esophageal and aortic hiati. The 
position of the intrathoracic part of the aorta was identified by digital palpation through the 
diaphragm. The left phrenic vein dictated the most ventral and the most lateral border of the 
approach. Traction at the stay sutures facilitated exposure of the intrathoracic structures and 
allowed excellent visualization of the caudal part of the thoracic aorta in all cadavers. The 
sympathetic trunk was identified lateral and dorsal to the thoracic aorta at a safe distance from 
the incision line. The phrenic and the vagal nerves could not be visualized through the 
diaphragmatic window, yet both nerves were not at risk for iatrogenic damage since they 
coursed far ventral or medial to the diaphragmatic incision, respectively. The latex-filled 
azygos vein was also not visible through the diaphragmatic window. Only after extensive 
dissection between the psoas minor and quadratus lumborum muscles it was exposed dorsal to 
the thoracic aorta.  
In the clinical cases, a total of 12 transdiaphragmatic approaches were performed in 9 
dogs, 3 dogs underwent a second surgery due to failure of shunt closure. Data are summarized 
in Table 1.  
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The approach was performed exactly as defined in the cadavers, but in addition a 
moistened abdominal sponge was used to cover the parietal aspect of the liver and the 
remaining abdominal content during the transdiaphragmatic approach and the intrathoracic 
dissection of the PSS (Fig 1). On the abdominal side, the left phrenic vein and the aorta were 
clearly visible, and the aortic pulsation permitted easy identification of the thoracic aorta by 
digital palpation. The left phrenic vein dictated the most ventral and the most lateral border of 
the approach. Traction at the stay sutures facilitated access to the thorax, but additionally a 
small self-retaining retractor was used to visualize the shunting vessel by pushing the 
esophagus ventrally (up) and to the right (medial) from the aorta (Fig 2). All the shunting 
vessels crossed the diaphragm through the esophageal hiatus, dorsal to the esophagus. 
Visualization and exposure of the characteristic “L” shape was excellent in all clinical cases. 
All shunting vessels terminated at the level of T10-T12. The azygos vein itself could not be 
visualized at any occasion. The sympathetic trunk was at a safe distance from that “L” shape 
and was never at risk for iatrogenic damage. The caudal left lung lobe neither obscured the 
shunt visibility nor interfered with placement of the CB or AC. Dissection around the 
shunting vessel was minimal and placement of a CB or an AC was straightforward. 
The systemic arterial pressure, gastro-intestinal tract and pancreas were evaluated for 
signs of portal hypertension before closure of the diaphragm. There were neither technical 
issues nor intra-operative complications. All dogs recovered rapidly and uneventfully. All 
dogs were discharged 3 days after the surgery. Postoperative medical treatment was continued 
for 4 weeks and consisted of a liver diet, metronidazole (Stomorgyl; 7.5 mg/kg for the 
metronidazole fraction every 12 hours, Merial, France) and synthetic disaccharide regimen 
(Lactulose EG; 0.5 mL/kg every 8 hours, Eurogenerics, Belgium).  
Two dogs were lost for follow-up after the one-month check-up and the most recent case 
did not yet reach the 3-months follow-up. All other cases (n=6) were re-evaluated at 12 weeks 
after surgery. All owners reported their dogs to be normal, with no clinical signs related to 
portosystemic shunting. Nevertheless, scintigraphy indicated peristent shunting in 3 dogs in 
which a CB was used. In those dogs, the pre- and or postprandial serum bile acid 
concentrations were above normal values and were even elevated compared to pre-surgery 
values. A revision surgery, including a second transdiaphragmatic approach, was proposed in 
order to attenuate the shunt. Two dogs were re-operated immediately whereas in the third, the 
surgery was delayed for another 3 months in the hope that the shunt would attenuate. In the 
latter, repeated serum bile acid concentrations were consistently elevated. In all 3 cases 
surgery was repeated due to incomplete closure of the porto-azygos shunt and the CB 
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replaced by an AC. No complications were experienced with the repeated transdiaphragmatic 
approach. There were no macroscopically visible diaphragmatic scars; no adhesions on the 
abdominal or thoracic side. Follow up scintigraphy 12 weeks after the second surgical 
intervention confirmed closure of the shunt in all dogs. Serum bile acid concentrations were 
reduced compared to previous measurements, almost reaching normal values.  
 
 
 
Figure 1 Transdiaphragmatic approach to expose porto-azygos 
shunts in the thorax of dogs, caudocranial view. The dog is 
positioned in dorsal recumbency with the head pointed up. The 
parietal aspect of the liver is covered with a moistened sponge. 
The left side of the diaphragm with the left phrenic vein 
(asterisk) is visible, dictating the most ventral and most lateral 
borders of the diaphragmatic window. An incision (dotted line) 
is started 0.5-1 cm ventral to the aorta in the intermediate part of 
the pars lumbalis. The incision is lengthened over 3-5 cm, along 
the muscle fiber alignment.  
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Figure 2 Anatomic variations. (A) Typical intra-operative 
appearance of a porto-azygos shunt through a transdiapragmatic 
approach (dog 9). (A’) Identical image to A, but the 
surroundings are discolored to better accentuate the intra-
thoracic structures of interest. The shunting vessel (sh) lies 
adjacent and ventral to the aorta (a) and dorsal to the esophagus 
(e). The diaphragmatic window borders (d) are indicated. (B) 
Intra-operative image through the transdiaphragmatic approach 
in dog 3 reveals an unusual de duplication of the shunting 
vessel. (B’) Identical image to B, but the surroundings are 
discolored to better accentuate the intra-thoracic structures of 
interest. The shunting vessel (sh), indicated by the white dotted 
lines, lies adjacent and ventral to the aorta (a) and dorsal to the 
esophagus (e). The characteristic “L” shape can be appreciated 
just before its insertion into the azygos vein (*). The 
diaphragmatic window borders (d) are indicated. 
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5. Discussion 
 
The transdiaphragmatic approach to the thoracic part of a porto-azygos shunt is a 
straightforward surgical procedure, providing a safe corridor to the thorax with excellent 
exposure of the region of interest. Initial development of the approach in cadavers and 
subsequent validation in clinical cases have proven its feasibility to reach the insertion site in 
the thoracic part of the azygos vein. To the authors’ knowledge, this is the first report to 
document a transdiaphragmatic approach to the thoracic part of porto-azygos shunts in dogs. 
Transsplenic portal scintigraphy is a commonly used method for pre-operative quantitative 
measurement of portal bypass of the liver, allowing the diagnosis and differentiation of 
various shunt types (portocaval, porto-azygos or acquired).9,11 This imaging modality 
correctly distinguishes between porto-azygos and portocaval shunts in 100% of the cases, as 
the former shunt type displays a more dorsal pathway of the radionuclide and bolus activity 
that enters craniodorsally into the heart instead of caudally.9 In the current study, transsplenic 
portal scintigraphy was used to diagnose the porto-azygos shunt in all cases. Admittedly, this 
imaging modality cannot identify the precise insertion site of the shunt into the azygos vein. A 
recent study on CT evaluation of porto-azygos shunt anatomy in 36 dogs confirmed that all 
shunts had a thoracic terminus after crossing the diaphragm through the esophageal hiatus, 
dorsal to the esophagus.5 Therefore, a pre-operative CT-angiogram to unambiguously 
document the point of insertion5,7,12 was not considered a prerequisite by the authors. 
The point of insertion of the shunting vessel is of utmost importance to the surgeon, as it is 
recommended to attenuate a shunt as close to its insertion site as possible, to eliminate the risk 
of persistent shunting by unidentified tributaries.2,6 Surprisingly, a leading surgical textbook2 
differentiates between portocaval shunts, in which that recommendation is respected, and 
porto-azygos shunts, in which attenuation at the abdominal side of the diaphragm is advised, 
even though those authors acknowledged that the shunting vessel traverses the diaphragm in 
the majority of cases. The authors acknowledge the lack of historical studies that are clearly 
suggesting that intra-abdominal occlusion of porto-azygos shunts leads to a high rate of 
failure to attenuate all shunting branches. Nevertheless, support for this assertion can be found 
in the existing literature. A recent report evaluating in vivo behavior of AC using 
postoperative CT angiography in dogs with extrahepatic PSS showed that 2 of the 5 dogs with 
porto-azygos shunts (attenuated at the abdominal side) had persistent shunting due to the 
presence of a patent tributary cranial to the AC.6 We hypothesized that attenuating porto-
azygos shunts inserting in the thoracic part of the azygos vein at the thoracic side of the 
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diaphragm would have several advantages such as elimination of the risk to miss small 
tributaries and reduction of abdominal organ manipulation and potential morbidity during 
exploration of the portal vasculature, indirectly reducing surgical time.  
In order to place a device on the thoracic portion of the porto-azygos shunts inserting in 
the thorax, a surgical approach to the thorax is needed. There is a single case report describing 
a right lateral thoracic approach to attenuate a porto-azygos shunt.12 We hypothesized that a 
transdiaphragmatic approach would be preferable since it simultaneously allows evaluation of 
the gastro-intestinal tract and the pancreas before and after a CB or AC placement and it does 
not exclude abdominal exploration and/or concomitant intra-abdominal procedures. In 
addition, a lateral thoracotomy necessitates a pre-operative CT angiography to determine the 
side and the most ideal intercostal space. Furthermore, we argue that a thoracotomy is more 
invasive, more painful and more time-consuming compared to a transdiaphragmatic approach. 
Therefore the authors put the transdiaphragmatic approach forward as the surgical approach to 
a porto-azygos shunt inserting in the thorax if attenuation close to the shunt insertion is 
considered. The thoracic part of a porto-azygos shunt inserts perpendicular to the azygos vein, 
forming a characteristic “ L” shape.5 This landmark was chosen as the target site for shunt 
attenuation. The proximity between the shunting vessel and the aorta guided the authors to 
approach the region through the left side of the diaphragm. Based on data of pre-operative CT 
angiography in a large number of dogs,5 one can presume that most (if not all) porto-azygos 
shunts traverse the diaphragm at the level of the esophageal hiatus. Those observations 
dictated the guidelines for establishing the level of the diaphragmatic incision. During the 
cadaveric study and subsequently in all clinical cases, the phrenic vein was found to be a 
reliable, easy and accurate landmark to guide the diaphragmatic incision. At any stage, the 
lungs did not obscure the view nor interfere with placement of an attenuation device; 
however, the esophagus partially covered the shunting vessel. It was necessary to retract the 
esophagus ventrally and to the right to provide an excellent exposure of the characteristic “L” 
shape of the porto-azygos shunt.  
Attenuation of a porto-azygos shunt with a thoracic extension at the abdominal side of the 
diaphragm potentially allows small branches from gastric veins to enter the shunt just before 
it traverses the diaphragm.4,8 Such small tributaries might be missed on CT-images  as well as 
during abdominal exploration.2,6  Furthermore, porto-azygos shunts are sometimes difficult to 
follow intra-operatively in the abdomen, because they may become nearly undetectable with 
vigorous retraction or dissection.2,7 Manipulations to identify and to follow the course of the 
shunt in the abdomen could lead to increased morbidity. The transdiaphragmatic approach 
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overcomes all the issues raised above; the approach represents a relatively easy surgical 
procedure, without unnecessary abdominal organ manipulation, while the risk of missing 
additional contributing branches is eliminated. If the insertion site of the shunting vessel lies 
within the thorax, it seems reasonable not to follow the course of the shunting vessel 
throughout the abdomen, even if no pre-operative CT is performed. After the first 3 cases, we 
felt comfortable to outgrow exploration of the portal system, and we immediately proceed 
with performing a transdiaphragmatic approach. This subjectively reduced the procedural 
time and reduced abdominal organ manipulation.  
Three months postoperatively, persistent shunting was confirmed by scintigraphy in 3 
dogs attenuated by a CB (the 2 remaining CB dogs were lost for follow-up). In all 3 cases, the 
radionuclide followed a pathway similar to that observed before surgery, suggesting persistent 
shunting rather than the formation of acquired shunts.11 Although the owners of those dogs 
did not report clinical signs associated with portosystemic shunting, all dogs were represented 
for revision surgery. Repeated surgery was advised to eliminate the risk of recurrence of 
clinical signs since liver function (judged by serum bile acids) did not improve after the first 
intervention. At the time of the second surgery, failure of the CB to promote complete 
occlusion of the shunting vessel was confirmed. The fact that there were no adhesions at all at 
the CB site in all 3 cases is worth noting. This is in contrast with what is experienced by the 
authors at repeat celiotomy in cases with portocaval shunts attenuated by CB. The observed 
difference might be explained by the more limited amount of soft tissues in the thoracic cavity 
compared to the abdomen, causing less inflammatory and fibroblastic reaction that are 
typically associated with a chronic foreign body.13 This finding might also indicate that 
production of fibrosis induced by the CB is far less pronounced in the thorax. Because of 
these finding at re-operation, the 3 persistent cases and the more recent cases (n=6) were 
attenuated using an AC. All these shunts, except the most recent case, which has not yet reach 
the 3-months follow-up, were successfully closed after 3 months. To the authors’ knowledge, 
there is no literature to endorse the latter suggestion, but in their experience it may be prudent 
to rely on AC rather than CB to occlude porto-azygos shunts in the thoracic cavity. 
The authors acknowledge the limited number of patients treated by the transdiaphragmatic 
approach and the absence of a (historical) control group. The objective of the current study 
was to describe and document a novel surgical approach to attenuate porto-azygos shunts 
inserting in the thoracic part of the azygos vein. Due to the lack of current literature regarding 
outcome of porto-azygos shunts, comparison with other approaches was not attempted, but 
warrants further investigation. 
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6. Conclusion 
 
If a thoracic insertion of a porto-azygos shunt has been identified, a transdiaphragmatic 
approach exposes the insertion site for shunt attenuation. This approach is a relatively easy 
and fast surgical procedure, without unnecessary abdominal organ manipulation, while the 
risk of missing additional contributing branches is eliminated. 
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1. Abstract 
 
Objective: To compare ammonia levels in arterial blood, venous blood and cerebrospinal 
fluid (CSF) in dogs with and without extrahepatic portosystemic shunts (EHPSS). 
 
Study Design: Prospective clinical trial. 
 
Animals: 19 dogs with congenital EHPSS and 6 healthy control dogs. 
 
Procedures: Transsplenic portal scintigraphy was performed to confirm the diagnosis of 
EHPSS. In both groups, simultaneous samples were collected during general anesthesia from 
the femoral artery (arterial blood), the jugular vein (venous blood) and the cerebellomedullary 
cistern (CSF) for ammonia measurement by two different devices, the PocketChem BA 
(PocBA) and the Catalyst Dx (CatDx). 
 
Results: Ammonia concentration (arterial, venous, and CSF) were significantly higher in 
EHPSS dogs than in the control dogs and were comparable for both devices. Arterial 
ammonia levels were higher than venous levels, but this difference was only statistically 
significant when blood ammonia was measured by PocBA. A strong positive correlation up to 
96% was observed between arterial and venous ammonia. A significant positive correlation 
up to 89% was demonstrated between blood (arterial or venous) and CSF ammonia levels. 
 
Conclusion and Clinical Relevance: In this cohort of patients, ammonia levels were 
significantly higher in arterial than venous samples and both were significantly higher in 
EHPSS dogs compared to control dogs. The ammonia levels in the CSF of EHPSS dogs were 
significantly higher than in control dogs and were positively correlated to the arterial and 
venous blood ammonia levels, suggesting increased passage of ammonia across the blood-
brain barrier (BBB) in EHPSS patients. 
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2. Introduction 
 
Ammonia is a normal constituent of body fluids and is mainly produced in the gastrointestinal 
tract by bacterial metabolism of urea and glutamine.1 Ammonia is lipid soluble and 
consequently easily crosses cell membranes.1,2 In the gut, it diffuses via the intestinal mucosa 
into the portal venous circulation where it is converted to ammonium NH4+; the blood is then 
detoxified in the liver by the urea cycle.1,2 An increased plasma ammonia level occurs in cases 
of portosystemic shunting, liver failure and urea cycle disorders.3-5  
It is widely accepted that ammonia is a key factor in the pathogenesis of HE.6 Ammonia is 
widely considered to initiate HE through altered astrocyte function; astrocytes are the main 
cells in the brain that can metabolize ammonia. The conversion of glutamate and ammonia to 
glutamine results in osmotic stress leading to astrocyte swelling, cerebral edema and 
intracranial hypertension.7  
Ammonia in the brain is formed in situ from the metabolism of endogenous nitrogen-
containing substances.8-10 Additionally, it crosses the BBB by diffusion from the blood.8 
Ammonia is shown to diffuse into the brain more freely in humans with severe liver disease 
than in normal control subjects.11,12 Transport of ammonia from the blood to the brain 
increases with increasing arterial ammonia levels.11 Interestingly, increased BBB permeability 
results in increased diffusion of ammonia into the brain11,12 and can result in toxic levels even 
in the face of near normal arterial ammonia levels.11 
Dogs with PSSs are often presented with clinical signs of HE,13 but limited research is 
available on the association of PSS and HE. Two veterinary studies assessing several amino 
acids levels in the CSF of dogs with PSS suggested that ammonia levels in the CSF are 
elevated, but ammonia levels were not checked as such.14,15 Interestingly, in an animal model 
investigating different drugs to control chronic HE in human patients, a portocaval shunt was 
created in addition to a partial hepatectomy in experimental dogs. Ammonia levels in the CSF 
and blood were significantly higher in the operated group than in the sham-operated group.16 
The dogs in the former group developed HE signs.16  
Human patients with HE showed significantly higher arterial than venous blood ammonia 
levels.11,12 Arterial ammonia levels around 150 ?mol/L have a statistically significant 
association with the development of intracranial hypertension and cerebral edema.17,18 To our 
knowledge, there is only one study on the comparison of arterial and venous blood ammonia 
levels in canine HE.19 In that study, significantly higher ammonia levels were found in arterial 
blood than in venous blood in dogs with liver disease compared to control dogs, and there was 
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a strong correlation between the existence of HE and the presence of portosystemic collateral 
circulation. However, differences in ammonia levels in PSS dogs were not presented 
separately.19  
The objective of this study was to compare ammonia levels in arterial blood, venous blood 
and CSF in healthy control dogs and in dogs with a congenital EHPSS in an attempt to 
elucidate the pathogenesis of HE in dogs with EHPSS. We hypothesized that in a given 
patient with hyperammonaemia due to the presence of an EHPSS the arterial ammonia level 
would exceed the venous level. We also hypothesized that a positive correlation exists 
between ammonia levels in the blood and the CSF. 
 
 
3. Materials and Methods 
 
Animal and study design 
Client-owned dogs with congenital EHPSS were prospectively evaluated between July 2012 
and October 2015 and their data were compared to control dogs. The study was approved by 
the Ethical Committee of the Faculty of Veterinary Medicine of Ghent University 
(EC2012/164 and EC2013/33) and by the Belgian Deontological Committee. 
 
Control dogs 
Adult healthy Beagle dogs were used as controls. The dogs were fasted for 12 hours before 
testing with free access to water. A full physical examination, complete blood count, serum 
biochemical profile, paired serum bile acid concentration analysis, and urinalysis were 
performed to rule out preexisting disease. In addition, an abdominal ultrasound was obtained 
for health screening. The dogs were anesthetized (see below, anesthetic protocols) and a 
TSPS was performed to confirm the absence of portosystemic shunting. Intrasplenic injection 
of the tracer (sodium pertechnetate (Na99mTcO4-), Drytec technetium 99mTc generator, GE 
Healthcare, UK) was done with ultrasound guidance and the dynamic scan was started 
simultaneously on a gamma camera equipped with low-energy, high-resolution collimator 
(Toshiba GCA7200A DI, Toshiba, Japan). Prior to the TSPS, an arterial, venous, and CSF 
sample was obtained for the measurement of ammonia levels (see below). 
 
Dogs with an extrahepatic portosystemic shunt 
Enrollment of dogs in the study was subject to a written owner informed consent. Before 
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sampling, patients were fasted for a minimum of 12 hours unless they were younger than 6 
months of age (maximum of 4 hours). Patient data including age, sex, breed, body weight, and 
body condition were recorded. A full physical examination, complete blood count and serum 
biochemical profile, pre- and postprandial serum bile acid concentration analysis and arterial, 
venous and CSF ammonia level analysis were performed (see below). The clinical signs of 
HE were graded on a four-point scale (grade 0: normal; 1: reduced mobility and/or mild 
apathy; 2: severe apathy and/or mild ataxia; 3: salivation, severe ataxia, head pressing, 
apparent blindness, and/or circling; 4: seizures and/or coma) as previously described.20 An 
abdominal ultrasound was obtained to assess the abdominal organs and to screen for potential 
vascular abnormalities. Transsplenic portal scintigraphy was performed in each dog to 
confirm the diagnosis of PSS.21  
 
Collection of samples 
Blood samples for paired serum bile acid concentration analysis were collected from the 
jugular vein. Following the collection of the preprandial blood samples, dogs were fed 2 
teaspoons of a commercial highly digestible protein and fat diet (Hills a/d, Hillls Pet Nutrition 
NV, Brussels, Belgium) and the postprandial samples collected two hours thereafter.  
Samples for determining the ammonia levels were collected while the dogs were shortly 
anesthetized (see below) for the TSPS procedure. Arterial blood was collected from a femoral 
artery using a 25-gauge needle connected to a 1 mL syringe. Arterial blood (700 ?L) was 
transferred to a special heparinized whole blood separator (Idexx Laboratories Europe, 
Hoofddorp, The Netherlands) and immediately placed on melting ice. The sample was 
instantly analyzed in the in-house laboratory (described below). Immediately after collection 
and processing of the arterial sample, a venous sample (700 ?L) was collected from a jugular 
vein (using a 21-gauge needle connected to a 2.5mL syringe). The processing of the venous 
samples was identical to that described for the arterial samples. For the CSF sample, a small 
area of skin (3 x 3 cm) at the atlanto-occipital region was clipped and surgically prepared to 
allow aseptic collection of CSF via a cisternal puncture with a 21-gauge needle. The CSF 
sample was collected in a tube without additives. If blood contamination occurred, a new 
sample was taken. The tube was immediately placed on melting ice for prompt in-house 
analysis.  
 
Processing of samples 
Both pre- and postprandial serum samples for bile acid analysis were centrifuged and the 
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serum was sent to an external laboratory for analysis. 
Ammonia levels in the arterial and venous samples were measured in-house using both a 
portable blood ammonia analyzer (PocketChem BA, A. Menarini Diagnostics Benelux, 
Zaventem, Belgium; PockBA) and a non-portable chemistry analyzer (Catalyst Dx, Idexx 
Laboratories, Westbrook, USA; CatDx) immediately after sampling. Both devices measure 
the amount of gaseous ammonia (NH3) after the ammonium ions (NH4+) in the sample have 
been converted. The samples for the PockBA were taken from the whole blood separators 
with a capillary tube just before its insertion into the CatDx. 
Ammonia levels in the CSF samples were also measured in-house immediately after 
sampling. A small CSF sample (200 ?L) was transferred to a sample cup (Idexx Laboratories 
Europe, Hoofddorp, The Netherlands) for analysis in the CatDx and the sample for analysis in 
the PockBA was taken from the sample cup with a capillary tube just before processing. A 
white blood cell count was performed on the sample remaining in the tube without additives.  
 
Anesthetic protocols 
The same anesthetic protocol was used in the EHPSS dogs and in the control dogs. First, a 22-
gauge IV catheter was placed in one of the cephalic veins. Dogs were premedicated with 0.2 
mg/kg butorphanol (Dolorex, Intervet NV, Oostkamp, Belgium) given IV. After 10 minutes, 
anesthesia was induced by administering 2-4 mg/kg propofol (Propovet Multidose, Abbott 
Laboratories Ltd, Maidenhead, UK) IV to effect. Following endotracheal intubation, 
anesthesia was maintained by a total intravenous anesthesia of propofol at a rate of 0.2-0.4 
mg/kg/min. Oxygen (100%) was supplied throughout anesthesia at 1 L/min. 
 
Statistical analyses  
Statistical analysis was performed using a commercial software package (SPSS Statistics, 
IBM, Brussels, Belgium). Data were checked for normality by the Kolmogorov-Smirnov test 
with Lilliefors significance correction. For descriptive purposes, parametric data were 
summarized as mean +/- standard deviation (SD) whereas non-parametric data were described 
as median and range. To compare the continuous variables, an unpaired t-test (for normally 
distributed data) or the Mann-Whitney U-test (for non-normally distributed data) was used if 
the samples were independent whereas a paired sample t-test or a Wilcoxon signed rank test 
was used for paired data. Correlations were assessed by the Pearson’s product-moment 
correlation or Spearman’s rank correlation, depending on the respective normal or non-normal 
distribution of data. The significance level was set at 0.05.  
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4. Results 
 
Study population 
Six healthy dogs and 19 dogs with congenital EHPSS were studied.  
The age of the dogs in the control group ranged from 36 to 54 months and their body 
weight from 9.1 to 16.0 kg. Three dogs were spayed females and 3 were neutered males. No 
abnormalities were detected on physical examination or blood analysis. Abdominal 
ultrasound was unremarkable and TSPS confirmed the absence of portosystemic shunting in 
all dogs. 
The age of the EHPSS dogs at the time of diagnosis ranged from 3 to 65 months and their 
body weight ranged from 1.5 to 13.4 kg. Ten dogs were female (5 intact, 5 spayed) and 9 
were male (7 intact, 2 castrated). Breeds represented in the study population were Yorkshire 
terrier (n=4), Bichon frisé, Dachshund, and Chihuahua (n=2), and Beagle, Bolonka zwetna, 
Cross breed, Maltese, Jack Russell Terrier, Norwich Terrier, Miniature Pincher, Miniature 
Schnauzer, and Scottish Collie (n=1).  
 
Hepatic encephalopathy  
None of the control dogs showed signs of HE. Hepatic encephalopathy grades in the control 
and EHPSS patients are represented in Table 1. The median HE grade for EHPSS dogs was 3; 
15 out of the 19 dogs were presented with apathy and some degree of head pressing, ataxia, 
and/or circling. Seven dogs suffered from seizures (grade 4 HE), but none of them were 
comatose. 
 
Serum bile acids 
Bile acid concentrations are represented in Table 1. For the control dogs, all values were well 
within reference interval (<19 μmol/L). In EHPSS dogs, median pre-prandial bile acid levels 
and postprandial bile acids levels were 166 μmol/L (range, 27-381 μmol/L) and 218 μmol/L 
(range, 49-656 μmol/L), respectively. Pre- and postprandial bile acids levels were consistently 
and significantly elevated in EHPSS dogs compared to the control dogs (P<0.001).  
 
Ammonia levels 
Ammonia levels in the control dogs and EHPSS dogs are represented in Table 1. The mean 
arterial ammonia levels in the control dogs were 18.2 ± 8.0 μmol/L (PocBA) and 16.8 ± 8.1 
μmol/L (CatDx), whereas the mean venous ammonia levels were 19.3 ±7.7 μmol/L (PocBA) 
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and 23.0 ±9.5 μmol/L (CatDx). The mean arterial ammonia levels for the EHPSS dogs were 
173.1 ± 57.5 μmol/L (PocBA) and 119.7 ± 69.4 μmol/L (CatDx) and the mean venous 
ammonia levels were 158.0 ± 53.8 μmol/L (PocBA) and 103.8 ± 58.3 μmol/L (CatDx). 
The blood ammonia levels were significantly higher in the EHPSS dogs than in the control 
dogs (arterial and venous, P<0.0001). Ammonia levels in artery and vein measured by the 
PocBA were significantly higher than ammonia levels measured by the CatDx (arterial and 
venous, P<0.0001). The two devices had a positive correlation of 88.4% and 81.9% for 
measurements taken from the artery and vein, respectively. 
The arterial ammonia levels were higher than the venous levels, but statistical significance 
was only reached for the PocBA (P<0.05). Strong positive correlations of 96.0% (PocBA) and 
90.0% (CatDx) were found between the arterial and venous ammonia levels. 
Correlations between preprandial bile acids and venous ammonia measurements were weak 
for both methods (PocBA, 46.1%, P<0.05; CatDx, 48,6%, P<0.05). The correlations between 
postprandial bile acids and venous ammonia were also weak (PocBA, 41.4%, P<0.05; CatDx, 
39,4%). Likewise, only weak positive correlations of 44.5% (PocBA, P<0.05) and 46.1% 
(CatDx, P<0.05) were reached between arterial measurements and the HE grade. 
Macroscopically CSF samples were normal in both the control and the EHPSS dogs. 
White blood cell count was similar and within reference interval in both the control dogs and 
in EHPSS dogs (< 8 cells/μl). 
The mean CSF ammonia levels for the control dogs were 6.0 ± 5.3 μmol/L (PocBA) and 
3.7 ± 2.0 μmol/L (CatDx) (Table 1). The mean CSF ammonia levels for EHPSS dogs were 
106.6 ± 55.6 μmol/L (PocBA) and 60.1 ± 42.9 μmol/L (CatDx). The CSF ammonia levels 
were significantly higher in the EHPSS dogs than in the control dogs (PocPA, P<0.0001; 
CatDx, P<0.001). The mean ammonia levels in the CSF measured by the PocBA were 
significantly higher than measurements with the CatDx (P<0.0001). Strong positive 
correlations were demonstrated between arterial ammonia levels and the CSF ammonia levels 
(PocBA, 88.4%, P<0.001; CatDx 87.0%, P<0.001). Also between venous ammonia levels and 
CSF ammonia levels strong positive correlations were present (PocBA, 89.2%, P<0.001; 
CatDx 72.5%, P<0.001). 
No significant correlation was found between CSF ammonia measurements by PocBA and 
HE grade (P=0.09) whereas a weak positive correlation (39.6%) between CSF ammonia 
levels and HE grade was obtained with borderline significance (P=0.05) when the CSF 
ammonia level was measured by CatDx.   
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5. Discussion 
 
Measurements of ammonia levels in arterial and venous blood and CSF of dogs demonstrated 
remarkably higher ammonia levels in the blood (arterial, venous) and CSF of EHPSS dogs 
with HE signs compared to clinically normal dogs. A strong positive correlation was 
documented between ammonia levels in the CSF and ammonia levels in the blood (arterial, 
venous).  
The pathogenesis of HE is complex and although ammonia is not the sole agent involved, 
it has been until now the only measurable neurotoxin.22 Intra- and extracellular pH has an 
important influence on the distribution and the presence of ammonia or ammonium.1,11,12,23 At 
physiological pH, most ammonia is in the form of the positively charged ammonium ion 
(NH4+) and not the ammonia in gas form (NH3).1,2,11,12 Ammonia passively diffuses into the 
brain and is captured in the brain parenchyma due to a difference between systemic and brain 
pH values. Normal systemic pH in humans is 7.4, but the pH of the human brain is reported to 
be somewhat lower.23 Ammonia will diffuse toward a lower concentration gradient, and 
because the pH in the brain is lower, the ammonia will be converted to the ammonium ion. 
Entrapment of ammonia within the CNS occurs because the ammonium ion does not readily 
diffuse across cell membranes.11 In addition, ammonia is shown to diffuse into the brain more 
freely in humans with severe liver disease than in normal control subjects.11,12 Ammonia 
toxicity results from an increase in both plasma concentration and intra- and extracellular 
pH.23 The toxic effect of ammonia on the brain results from direct interaction with both 
excitatory and inhibitory neurotransmission.23 The consequences of hyperammonemia in the 
central nervous system include amino acid disturbances, alterations in neurotransmission, 
cerebral energy disturbances, alterations of nitric oxide synthesis and oxidative stress, 
impairments of axonal and dendritic growth, and alterations in signal transduction and 
channel transporter activities,25-29 subsequently leading to the swelling and death of 
astrocytes.25,30,31  
In human HE patients, a significant correlation between an increase in blood ammonia 
levels and the severity of HE was documented.32 Arterial ammonia levels ? 150 ?mol/L serve 
as a negative prognostic indicator in people.17,18 The previous canine study on HE also 
claimed a strong positive correlation between blood ammonia level and the degree of HE.19 In 
the current study, dogs with HE (irrespective of the grade) had significantly higher blood 
ammonia levels compared to dogs without HE. High plasma ammonia was predictive of HE. 
However, the observed correlations between the blood ammonia levels and the degree of HE 
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in dogs with EHPSS were rather weak.  
Traditionally, in humans, arterial rather than venous blood is utilized when measuring 
blood ammonia.11 In dogs, venous ammonia measurement is part of the work-up in dogs 
suspected of PSS.1,2 To the authors’ knowledge, there is only one previous study comparing 
ammonia levels in arterial and venous samples in canines with HE of various etiologies.19 
Unfortunately, no detailed data on the blood ammonia levels of the PSS dogs, which were a 
subgroup of the HE cases, were provided. In the same report, significantly higher ammonia 
levels were detected in the arterial compared to the venous samples. In the present study, we 
also observed higher arterial than venous levels; however, statistical significance was only 
reached when using PocBA.  
Of particular interest in the present study were the high levels of ammonia in the CSF of 
the EHPSS dogs, which had a strong positive correlation to blood ammonia levels. Several 
studies have previously assumptively stated that ammonia is elevated in the CSF of congenital 
EHPSS dogs; however, ammonia measurements in the CSF were not performed.7,14 A 
potential reason for these lacking data is the paucity of validated techniques to perform 
measurements on CSF. In the present study, two different commercial devices (PocketChem 
BA and Catalyst Dx chemistry analyzer) were used to measure ammonia levels in the blood 
as well as in the CSF. Both devices have the same mode of action. Their respective slides 
contain a buffer in the top layer that converts the ammonium ions in the sample into gaseous 
ammonia. The ammonia gas passes through a selectively permeable membrane and then 
reacts with a pH indicator (PocBA: Bromocresol Green; CatDx: Bromophenol Blue). In both 
cases, the color development is measured that is proportional to the amount of ammonia. 
There are no previous reports validating the devices to measure the ammonia level in CSF. 
The values obtained by PocBA were higher than by Cat Dx. Nevertheless, the measurement 
results of both devices showed a high correlation, suggesting that both devices can be used in 
clinical practice to get an idea of ammonia levels in CSF. The authors would like to stress, 
however, that the CSF values obtained in this study should not be considered as absolute 
values but rather in a comparative way, until the devices are validated for the measurement of 
ammonia in CSF.  
It has been previously suggested that in humans the amount of ammonia that enters the 
brain is not optimally reflected by its concentration in the blood.11 In humans, it has also been 
documented that ammonia uptake in the brain increases with a rise in the arterial ammonia 
level, but the relative increase in the brain exceeds by far the arterial one.11 The permeability 
of the BBB to ammonia was found to be a critical element in this non-linear increase of 
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ammonia levels in the brain. This implies that the impact of ammonia on the brain may be 
greater than that predicted on the basis of the blood ammonia levels.11,12,33 Similar studies 
have not yet been performed in dogs and there are no data on the permeability of the BBB to 
ammonia in PSS dogs. In the current study, the metabolic uptake of ammonia in the brain was 
not measured. The assumption that there is an increased permeability of the BBB to ammonia 
in EHPSS dogs needs further investigation. In human HE patients (including subclinical HE 
patients), it has been shown that the BBB was much more permeable to the gaseous form, but 
measurable amounts of the ionic form also crossed the BBB.11,34 Plasma ammonia level and 
CSF ammonia level in the current study were high in EHPSS dogs compared to the clinically 
normal control dogs, suggesting that the greater amount of ammonia in the brain potentially 
caused toxicity and led to severe HE signs. On the other hand, the authors could not 
definitively rule out the possibility that seizures and HE signs in some of the dogs were 
caused or triggered by another disease entity or neurodegenerative disease. Interestingly, if 
HE signs are indeed provoked by increases in cerebral ammonia levels, it can be suggested 
that a medical treatment regimen before EHPSS surgery might alter the ratio between the 
ionic and gaseous forms of ammonia, leading to less influx of ammonia to the CSF and brain. 
However, this warrants further investigation.  
Currently, measurement of pre- and postprandial serum bile acid concentrations is the 
most commonly used liver function test in the diagnosis of PSS in dogs. The reported 
specificity and sensitivity of serum pre-prandial bile acids are 68-87% and 88-93%, 
respectively.2,35 In the current study, and in agreement with previous EHPSS studies,2,35 both 
pre- and postprandial serum bile acid concentrations were markedly elevated above the 
reference interval. Only weak positive correlations were found between pre- and postprandial 
bile acids and the venous ammonia levels. 
The present study had a few limitations. The authors acknowledge the relatively limited 
number of patients with various degree of HE signs in the current study. Furthermore, 
ammonia is known to be unstable ex vivo and samples need to be processed with special care 
not to influence the test results. Precautions such as the use of melting ice and the nearly 
immediate processing of the samples (time to analysis for an individual sample was <120 sec, 
data not reported) and discarding CSF samples that were contaminated with blood should 
have minimized the risk for pre-analytical errors although they can never be completely 
excluded.  
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6. Conclusions 
 
In conclusion, the remarkably higher levels of ammonia level in CSF of EHPSS dogs 
compared to clinically normal dogs and the strong positive correlation between ammonia 
level in the CSF and the level in the blood (arterial and venous) of EHPSS dogs might suggest 
increased permeability of the BBB to ammonia in EHPSS dogs. The results also demonstrated 
that, at least in dogs with EHPSS, venous samples can substitute for arterial samples, which 
are more difficult to take and require anesthesia. In addition, because of the non-linear 
passage of ammonia through the BBB into the brain, caution is needed not to underestimate 
the severity of HE or the presence of HE when interpreting ammonia levels in the blood.  
The results of the current study encourage future investigation of the correlation of 
ammonia levels in the blood and CSF in EHPSS dogs with respect to HE signs and surgical 
outcome. 
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1. Abstract 
 
Objective: To describe the evolution in ammonia levels in blood and cerebrospinal fluid 
(CSF) in dogs with congenital extrahepatic portosystemic shunts (EHPSS) in dogs with 
and without successful surgical outcome 
 
Study Design: Prospective clinical trial 
 
Animals: 19 dogs with congenital EHPSS 
 
Methods: A thin film band or an ameroid ring constrictor was used for shunt attenuation. 
Three months postoperatively, transsplenic portal scintigraphy (TSPS) was performed to 
assess the surgical outcome. Dogs with patent shunts underwent a revision surgery, 
followed by TSPS 3 months later. Ammonia levels were assessed at the time of diagnosis 
(T0; arterial, venous, and CSF), at the day of surgery (T1; arterial and venous) and at 1 
(T2; venous), and 3 (T3; arterial, venous, and CSF) months after surgery. Paired SBA were 
measured at T0, T2 and T3. Dogs that had a revision surgery were assessed 1 (T2’) and 3 
(T3’) months after the revision surgery according to the same protocol. In the dogs with 
complete shunt closure, paired SBA and ammonia were measured 6 months after the 
surgery (T4; venous). Dogs were grouped based on their surgical outcome (closed, 
acquired, or patent group). For statistical analysis, parametric and non-parametric tests 
were used at a significance level of P<.05. 
 
Results: Complete shunt closure was confirmed in 12 dogs (9 after first and 3 after 
second surgery). In total, 7 dogs developed acquired shunts (5 after first and 2 after 
second surgery). At T0, the SBA and ammonia levels were elevated in all dogs. Despite 
medical management and clinical improvement, ammonia levels were not lower at T1. At 
T2 and T2’, only 2 dogs had normalized SBA (closed group), whereas venous ammonia 
levels were normal in all dogs. At T3 and T3’, SBA was normal in 5/12 dogs (closed 
group) and in 1/7 dogs (acquired group). Venous ammonia levels were within normal 
limits in 11/12 (closed group),  4/7 (acquired group) and in 2/5 (patent group). At T4, 
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SBA were still elevated in 5/12 dogs; venous ammonia was within reference interval in 
all dogs. Arterial ammonia levels and CSF ammonia levels demonstrated a strong 
positive correlation to the venous levels (95% and 89%, respectively; P<.001). CSF 
ammonia levels were above the reference value of venous ammonia in 14/19 dogs at T0. 
The decrease in CSF ammonia levels from T0 to T3 or T3’ was statistically significant in 
dogs with complete shunt closure. 
 
Discussion/Conclusion: Postoperative ammonia or SBA levels are no accurate indicators 
of the degree of postoperative shunting. Thus, although baseline venous ammonia levels 
and SBA might be a useful laboratory parameter in the primary diagnosis of EHPSS, they 
have little value to assess attenuation after a surgical intervention.   
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2. Introduction 
 
Ammonia is synthesised during amino acid metabolism and can be toxic in high 
concentrations. To prevent toxic build-up, the body converts ammonia to urea (via the 
urea cycle) or to glutamine (via glutamine synthetase) in the liver.1 In the presence of an 
extrahepatic portosystemic shunt (EHPSS), a vast proportion of the portal blood bypasses 
the liver. This results in accumulation of ammonia and other toxic by-products of 
metabolism in the blood2 and in reduced functional liver parenchyma due to inadequate 
nutrient supply.3,4 
In the diagnostic work-up of dogs suspected of EHPSS, measurement of paired serum 
bile acids (SBA) and venous ammonia level are commonly used screening tests.5-7 
Baseline venous ammonia levels are not considered to be as sensitive as SBA 
measurements for the diagnosis of portosystemic shunts (PSS) in dogs,3,8 although using 
optimal cut-off values can increase its sensitivity.6 A recent study confirmed abnormal 
pre-operative arterial and venous ammonia levels but also documented significantly 
increased ammonia levels in the CSF of dogs with congenital EHPSS when compared to 
normal dogs.9 Given the high correlation between blood and CSF values in EHPSS dogs, 
the blood-brain barrier (BBB) might be more permeable to ammonia in affected dogs.9 
To assess the outcome after shunt attenuation, paired SBA measurements are often 
performed but they do not seem reliable to evaluate PSS closure.3,10-13 Blood ammonia 
levels are not commonly reported in the postoperative evaluation. To the authors’ 
knowledge, only one retrospective study specifically dealt with postoperative venous 
ammonia levels in dogs.14 In that study, increased ammonia in postsurgical PSS dogs was 
conclusive for persistent shunting but, in case of normal levels, medical imaging was 
required to confirm or exclude persistent shunting.14 Currently, there are no studies 
describing arterial or CSF ammonia levels in EHPSS dogs in the postoperative period. 
 
The objectives of this study were to document the evolution of blood and CSF 
ammonia levels in dogs with congenital EHPSS before and after shunt attenuation, to 
compare pre-operative ammonia levels as a prognostic indicator for surgical success, and 
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to determine if blood and CSF ammonia levels could accurately indicate absence of 
persistent shunting. 
 
 
3. Materials and Methods 
 
Client-owned dogs with a congenital EHPSS were prospectively enrolled between July 
2012 and October 2015. Enrolment in the study was subject to informed owner consent. 
The study was approved by the Ghent University Ethical Committees (EC2013/33 and 
EC2014/188) and by the Belgian Deontological Committee. 
 
A dedicated owner questionnaire addressing topics like feeding, behaviour and 
clinical symptoms was completed. Dogs were suspected to have EHPSS based on clinical 
signs and SBA measurements. The presence of a PSS was confirmed by transsplenic 
portal scintigraphy (TSPS) after concurrent arterial, venous and CSF ammonia 
measurements and SBA were taken (T0). Medical stabilization consisting of a dietary, an 
antimicrobial, and a synthetic disaccharide regimen was initiated and continued for at 
least 4 weeks before surgical intervention. At the day of surgery (T1), a second owner 
questionnaire was completed. Arterial and venous samples for ammonia measurement 
were taken after anaesthetic induction. After surgical identification of the EHPSS, a thin 
film band or an ameroid ring constrictor was used for shunt attenuation. Patients were 
routinely hospitalized for 4-5 days postoperatively. The pre-operative medical 
management was continued for at least one month after surgery. The dogs were 
represented fasted for a follow-up appointment at 1 (T2), 3 (T3) and 6 (T4) months 
postoperatively at which point the owners were requested to complete additional 
questionnaires. At these follow-up appointments, a physical examination, paired SBA 
and ammonia measurements (T2: venous; T3: arterial, venous, and CSF; T4: venous) were 
performed. Three months postoperatively (T3), TSPS was repeated. In dogs with 
persistent shunting through the original shunt, a revision surgery was performed.  The 
follow-up after the second surgery was identical to the one described after the first 
surgery (T2’, T3’, and T4). 
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Details about the collection and processing of the samples have been described 
elsewhere9 and were identical at all occasions. Briefly, for paired SBA measurements, 
serum was sent to an external laboratory. The highest value obtained was used to make 
all calculations (reference, <19 ?mol/L). The ammonia tests were run in-house 
immediately after blood sampling. In the current study, only the ammonia levels obtained 
by the portable blood ammonia analyzer Pocket ChemBA are used (reference, ?70 
?mol/L). 
Statistical analyses were performed using a commercial software package SPSS 
Statistics (IBM, Brussels, Belgium). Normality was checked using the Kolmogorov-
Smirnov test with Lilliefors significance correction. Descriptive parametric data were 
described as mean +/- standard deviation (SD) whereas descriptive non-parametric data 
were summarized as median and range. The SBA and ammonia data were grouped 
according to the result of the TSPS (closed, acquired, or patent). For normally distributed 
continuous variables an unpaired t-test was used; for non-normally distributed data the 
Mann-Whitney U-test was used if the samples were independent. Similarly, a paired 
sample t-test or a Wilcoxon signed rank test was used for paired data. Correlations were 
assessed by the Pearson’s product-moment correlation (normally distributed data) or 
Spearman’s rank correlation (non-normally distributed data). The significance level was 
set at .05. 
 
 
4. Results 
 
Nineteen dogs with congenital EHPSS were enrolled in this study. Patient details are 
summarized in Table 1. One dog (dog 4) received anti-epileptic drugs (levetiracetam and 
imepitoine) since 2 months before enrolment; the anti-epileptic treatment was continued 
postoperatively in addition to the above-mentioned preoperative medical regimen.  
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 At the time of surgery (T1), all owners reported obvious clinically improvement since 
medical support was given to their dogs. Shunt classification was verified intra-
operatively. Sixteen of the 19 dogs had a portocaval and 3 had a porto-azygos shunt (dogs 
6, 8, and 12). At the time of the primary surgery, attenuation of the shunting vessel was 
undertaken using a thin film band in 14 dogs (12 portocaval, 2 porto-azygos) and ameroid 
ring constrictor in 5 dogs (4 portocaval, 1 porto-azygos). The only peri-operative 
complication was the development of focal seizures in one dog (dog 19) 4 days after 
surgery, successfully controlled by administration of levetiracetam. Only this dog and the 
dog that was on pre-operative anti-epileptic drugs (dog 4) were discharged on additional 
anti-epileptic drugs. Dietary change and the synthetic disaccharide regimen were 
continued until the time of repeated TSPS. At T2, all owners reported their dogs to have 
clinically improved to what they perceive to be normal for a dog. All but 2 dogs (dog 4 
and 13) were perceived to be clinically normal to the owner at T3. However, TSPS 
findings revealed normal shunt fraction in only 9 out of 19 dogs. The dogs with normal 
shunt fraction were gradually weaned of the hepatic diet by mixing increasing amounts of 
normal commercial diet with decreasing amounts of hepatic diet over 1-2 weeks, and the 
synthetic disaccharide was discontinued. In 5 dogs (3 portocaval, 2 porto-azygos) with an 
abnormal shunt fraction, a patent shunt was suspected. In the remaining 5 dogs (5 
portocaval), CT imaging confirmed that the abnormal shunt fraction was caused by 
acquired shunts, in the presence of a successfully closed congenital EHPSS. One of the 
dogs with acquired shunts (dog 13) was subsequently euthanized at the owners’ request 
because of repetitive obstructive urolithiasis. The owners of the other dogs with acquired 
shunts were advised to continue life-long medical management. 
 A revision surgery was performed in the 5 dogs with patent original EHPSS. In all of 
these dogs initially attenuation was attempted using a thin film band. An ameroid 
constrictor was placed in 4 of them (2 portocaval, 2 porto-azygos) and the remaining 
persistent portocaval shunt (dog 4) was ligated with a polypropylene suture. No peri-
operative complications occurred. In the 1-month follow-up after revision surgery (T2’), 4 
owners reported that their dog was normal; the remaining owner (dog 4) only reported 
clinical improvement. In the latter dog, epilepsy seemed well controlled after the revision 
surgery but there were episodes of dullness and intermittent anorexia; this was the dog 
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that was treated with anti-epileptic drugs since diagnosis. Repeated TSPS at T3’ revealed 
closure of all 5 congenital EHPSS. Unfortunately, in 2 dogs (2 portocaval), acquired 
shunts did develop. Life-long medical management was advised. 
 In total, 12 dogs had a successful surgical outcome although only 11 of them had a 
good clinical outcome. The dog that needed pre- and postoperative anti-epileptic drugs 
(dog 4) had recurrent seizures despite medication 5 months after the second surgery and 
was euthanized. The owners refused necropsy. 
 
 The correlation between SBA and venous ammonia levels was weak (48%; P<.001). 
Arterial and venous ammonia levels showed a very strong positive correlation of 95% 
(P<.001). Also between venous ammonia measurements and CSF ammonia 
measurements, a strong positive correlation was observed (89%; P<.001). 
 
 The data related to SBA measurements are presented in Table 2. At T0, elevated SBA 
levels were observed in all 19 dogs; the median SBA level was 218 ?mol/L (49-656 
?mol/L). There was no statistical difference between the T0 SBA levels in dogs that 
ultimately were closed after surgery and those that developed acquired shunts (P=.384). 
At T2, T2’, T3 and T3’, SBA levels were significantly higher in dogs with acquired shunts 
or patent shunts compared to those with successful closure (P<.01 at both time points) 
whereas dogs with patent shunts and acquired shunts had similar SBA levels (P=.876 and 
P=.639, respectively). Although the SBA lowered significantly in time after successful 
surgery, they only returned to normal in 2/12 dogs at T2, in 5/12 at T3, and in 7/11 at T4. 
In contrast, one dog with acquired shunts had normal SBA at T3. 
 
 The data related to ammonia measurements are presented in Table 3. Since venous 
samples were available at all time points and a strong positive correlation exists with the 
arterial ammonia measurements, only the venous data will be displayed in detail. High 
ammonia levels were observed in all 19 dogs; the median venous ammonia level was 154 
?mol/L (70-272 ?mol/L) at T0 and there was no statistical difference between the venous 
ammonia in dogs that would have a successful outcome and those that developed 
acquired shunts (P=.837). Despite medical management and apparent clinical 
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improvement, the ammonia levels were not lower after the pre-operative month of 
medical management (P=.587). However, one month after surgery (T2 and T2’), the 
venous ammonia levels were within the normal reference interval in all dogs and 
significantly lower than at T0 in all outcome groups (closed, P<.01; acquired, P<.05; 
patent, P<.05). The ammonia levels in the closed group were statistically lower than in 
the acquired (P<.01) as well as the patent (P<.05) group. At T3 and T3’, a significantly 
lower ammonia level was observed in the closed group compared to the patent group 
(P<.01) but not to the acquired group (P=.068). In the closed group, 11/12 dogs had 
normal venous ammonia levels, in the acquired group 4/7 dogs, and in the patent group 
2/5 dogs. The venous ammonia levels in the 11 dogs with closed shunts that were still 
alive at T4 were not statistically different from their respective values at T3 (P=.350). 
At T0, CSF ammonia levels were above the blood ammonia reference in 14 out of 19 
dogs (74%); the median CSF level was 94 ?mol/L (11-219 ?mol/L). There was no 
statistical difference between the T0 CSF ammonia levels in the dogs that ultimately had 
closed shunts and those that did develop acquired shunts (P=.398). At T3 and T3’, the 
only statistically significant difference was observed between CSF ammonia in the closed 
versus the patent group (P<.001). When the evolution of the CSF ammonia values from 
T0 to T3 and T3’was studied, statistically significant decreases in ammonia levels were 
observed in the closed group (P<.01) but not in the acquired (P=.310) nor the patent 
(P=.345) group, similar to the situation for the venous ammonia. Nevertheless, CSF 
ammonia levels were below the venous reference in 4 dogs with acquired shunts and in 4 
dogs with patent shunt. 
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5. Discussion 
 
The current study provided serial data on SBA and arterial, venous and CSF ammonia in 
dogs with EHPSS that underwent surgery. It was demonstrated that none of the 
laboratory parameters were accurate indicators of surgical success. In addition, outcome 
based on the owner questionnaires can be very misleading. 
 
At diagnosis, SBA were markedly elevated in all dogs. Statistically, there was no 
difference between dogs that would develop acquired shunts, and dogs with successful 
surgical outcome. Paired SBA were assessed in all dogs at all times for it is accepted that 
paired SBA have a higher sensitivity and specificity compared to preprandial samples 
alone.6,15,16 Since postprandial SBA were not consistently higher than preprandial 
samples in the individual dogs, the highest value of the both was used for all calculations 
and statistical comparison between outcome groups. After successful surgery, the SBA 
levels did not consistently normalize and, if they did, it was often only several months 
after the surgery. This slow amelioration in the bile acid enterohepatic cycle is somehow 
surprising. Liver volumes in dogs with congenital EHPSS normalize within a month after 
successful surgery.17 These findings point towards the fact that the liver function recovers 
slower with the redirection of the portal blood flow towards the liver irrespective of liver 
size. Furthermore, it remains to be elucidated to which extent the liver architecture and 
function are able to recover from the pathological changes that occurred during the period 
of portosystemic shunting. Another factor potentially attributing to the persistence of 
abnormalities in SBA levels is the presence of concomitant primary portal vein 
hypoplasia (PVH).18 In dogs with PVH without macroscopic portosystemic shunting, 
postprandial SBA are often only mildly to moderately increased. Since PVH often 
remains subclinical19,20 and no postoperative liver biopsies were taken, it cannot be 
excluded that some of the dogs in the current study had persistent microscopic shunting. 
The sensitivity of postoperative SBA measurements to determine successful surgery is far 
less than when used to support the diagnosis of PSS.3,14 Normal postprandial SBAs have 
been reported in dogs with persistent shunting or in the presence of multiple acquired 
PSS.18,21 On the other hand, it is not uncommon to observe persistent hepatic dysfunction 
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in clinically asymptomatic dogs after successful surgery.3,18,21-23 Both situations were also 
observed in the current case series. 
 
Besides SBA, measurement of the ammonia levels is considered a useful test in the 
work-up of patients suspected of PSS.3,6,8 Larger practices nowadays perform this 
laboratory test in-house, avoiding false positive results by incorrect sample handling.24 
Furthermore, the test requires only one small blood sample, is relatively cheap and the 
results are immediately available. In the current study, hyperammonaemia was present in 
all dogs at the time of diagnosis and levels did not differ between dogs that developed 
acquired shunts and dogs with successful attenuation. In the vast majority of dogs, the 
pre-operative medical management did not lead to venous ammonia levels within the 
reference interval at the time of surgery, although all owners noted noticeable clinical 
improvement. It was previously suggested that normal blood ammonia may be observed 
in dogs with EHPSS that are successfully controlled by medical management,3,25 but, 
based on the current findings, this seems exception rather than rule.  
An extensive retrospective study suggested that measurement of venous ammonia 
levels is the first test to assess the outcome after surgical attenuation of a congenital PSS 
1 month after surgery.14 In case of hyperammonaemia, it can be concluded that there is 
still portosystemic shunting; in case of normal ammonia levels, additional medical 
imaging is advised to visualize or exclude portosystemic shunting.14 In the current study, 
ammonia levels were within the normal range 1 month after surgery in all dogs, 
indicating that normalization occurred irrespective of the surgical outcome. In a study of 
14 dogs with EHPSS and 9 with intrahepatic PSS,26 ammonia was also re-evaluated 1 
month after surgery, which consisted of 5 complete or 18 partial ligations. These authors 
also found overall significantly decreased ammonia levels postoperatively despite the fact 
that most dogs still had some degree of shunting. There is no obvious explanation why 
ammonia levels would drop after unsuccessful surgery and not after clinically successful 
medical treatment. Although not checked routinely in the current study, there is some 
evidence in clinical reports describing dogs with postoperative seizures that the resolution 
of the hyperammonaemia after surgery occurred acutely. Excessive venous ammonia is 
often ruled out as aetiology of in dogs with postsurgical neurologic dysfunction.27,28 In 
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the dog that developed postoperative focal seizures, venous ammonia was low at the time 
of seizuring, whereas elevated ammonia levels were recorded 4 days earlier, at the time 
of surgery.  
 
To define hyperammonaemia, the cut-off level of 70 ?mol/L was used, as previously 
suggested.16,29,30 In an earlier study of our research group,9 venous ammonia levels were 
measured in a limited number of fasted healthy beagles under identical collection and 
processing conditions as those for the clinical patients; the highest value was 34 ?mol/L. 
Potentially, a more accurate cut-off level can be established. Using a cut-off as low as 45 
?mol/L as used in some other studies14,16,26 would not greatly influence the descriptive 
results of the current study, since the ammonia levels in the majority of dogs with an 
acquired or patent shunt would still have been considered normal at 1 month after 
surgery. 
 
In 2 veterinary studies, the level of several amino acids in CSF of dogs with 
congenital PSS were compared to those of control dogs without signs of hepatic or 
neurologic dysfunction.31,32 Both studies suggested that ammonia levels in CSF of PSS 
dogs will be elevated, given the observed glutamine elevation, but ammonia was not 
checked as such. To the authors’ knowledge, the reference interval of CSF ammonia in 
dogs has not been described. Ammonia is studied more extensively in human patients in 
studies dealing with HE. However, in contrast to PSS due to a congenital shunt, the 
underlying cause of HE in humans is in most instances not reversible. In human 
neurologic patients without liver disease, CSF ammonia levels up to 28 ?mol/L were 
measured using the indophenol direct method.33 The highest value measured by the 
Pocket ChemBA in healthy experimental dogs was 14 ?mol/L.9 However, prudence is 
called to use cut-off value in studies using other devices than the Pocket ChemBA to 
measure CSF ammonia. Recent validation of the device by a titration experiment 
demonstrated a very good correlation but a systematic underestimation of the true 
ammonia content in CSF samples (manuscript in preparation). For the descriptive 
representation of the CSF results in the current study, the same cut-off as for venous 
ammonia was used. Most likely, the optimal cut-off value for CSF measurement by 
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Pocket ChemBA is far lower than 70 or even 45 ?mol/L, but before a value can be 
proposed, CSF of a larger group of normal dogs should be assessed with this device.  
In the current study, CSF samples were obtained at the time of diagnosis and sampling 
was not repeated at the time of surgery; the reason being that ethical approval was 
obtained for one pre-operative and one postoperative sample only. This can be regretted; 
however, the strong correlation between CSF and venous ammonia levels leads to the 
assumption that venous ammonia levels are a good predictor of CSF ammonia levels.9  
 
 
6. Conclusion 
 
For the first time, selective changes of ammonia in the blood and CSF of dogs with 
congenital extrahepatic PSS, treated surgically, are demonstrated over time. Whereas 
SBA levels do not seem very useful in the postoperative follow-up because normalisation 
only occurs very slowly if at all, baseline venous ammonia is even less useful because it 
lowers irrespective of the surgical outcome. Presumably, a postprandial ammonia 
tolerance test or a rectal tolerance test would better differentiate between dogs with and 
without postoperative shunting. However, it might not always be safe to administer 
ammonia in dogs that still have portosystemic shunting since the ammonia challenge 
might provoke severe clinical signs of HE. Medical imaging seems preferable to correctly 
identify whether the reason of persistent shunting is a patent original shunt or acquired 
shunts. 
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1. Abstract 
 
Objective: To compare regional cerebral blood flow (rCBF) in dogs with congenital 
extrahepatic portosystemic shunt (EHPSS) and hepatic encephalopathy (HE) with rCBF in 
healthy control dogs. 
 
Study Design: Prospective clinical trial. 
 
Animals: 8 dogs with congenital EHPSS and 8 healthy control dogs. 
 
Procedures: Regional cerebral blood flow was determined using single photon emission 
computed tomography (SPECT) with a 99mtechnetium-hexamethylpropylene amine oxime 
(99mTc-HMPAO) tracer. 
 
Results: SPECT scans were abnormal in all PSS dogs. Compared to the control group, rCBF 
in PSS dogs was significantly decreased in the temporal lobes and increased in the subcortical 
(thalamic and striatal) area. 
 
Conclusion and Clinical Relevance: Brain perfusion imaging alterations observed in the 
dogs with EHPSS and HE are similar to those in human patients with HE. These findings 
suggest that dogs with EHPSS and HE have altered perfusion of mainly the subcortical and 
the temporal regions of the brain. 
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2. Introduction 
 
Dogs with a congenital portosystemic shunt (PSS) often have neurological abnormalities, 
referred to as hepatic encephalopathy (HE). There are several hypotheses regarding the 
pathogenesis of HE and many assumptions in dogs with HE are extrapolated from human 
findings. The most common neurological signs in PSS dogs with HE are behavioural 
abnormalities, reduced consciousness, visual deficits and ataxia.1 
Functional and structural brain imaging changes have been documented in human patients 
with HE; both modalities have identified alterations in specific brain regions.2-4 The 
correlation of functional brain abnormalities with cognitive impairments is believed to yield 
more consistent results than correlation of structural brain alterations with cognitive 
impairments.5 Cognitive deficits are challenging to assess in dogs, since neuropsychological 
tests are difficult to perform in animals. Functional brain imaging in PSS dogs with HE could 
improve the understanding of HE and yield knowledge for future comparison with rCBF data 
from dogs with PSS and subclinical HE, and after surgery for PSS. 
Single photon emission computed tomography (SPECT) is a functional nuclear imaging 
modality that uses a radiolabelled tracer. Different tracers permit the visualisation and 
quantification of neurotransmitter systems, as well as the regional cerebral blood flow (rCBF) 
in vivo in a non-invasive manner. Uptake of 99mtechnetium hexamethylpropylene amine 
oxime (99mTc-HMPAO) tracer has been used successfully to document functional alterations 
in specific brain regions in human patients with HE.5,6 
In human patients with subclinical and clinical HE, impairment of the subcortical, frontal 
and temporal lobes were most pronounced. 5,6 The temporal and frontal lobes are involved in 
detecting, processing and integrating sensory input. The subcortical structures receive massive 
different inputs from the cerebral cortex and peripheral sense organs; this information is 
integrated and shaped to provide output, which contributes to scaling, sequencing and timing 
of movement, as well as learning and behavioural control. 5,6 If the subcortical part of the 
brain is affected, more in particular the thalamus, sensory information will inadequately be 
processed and sensory confusion could result.  
 
We hypothesized that rCBF in dogs with PSS and clinical signs of HE might also be 
altered and that the most prominent changes would be observed in dogs with clinical signs of 
neurological dysfunction. The objectives of this study were to document alterations in rCBF 
in dogs with PSS and overt clinical signs of HE, and to determine which areas of the brain 
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have altered perfusion, based on SPECT analysis. The study was approved by the Ethical 
Committee of the Faculty of Veterinary Medicine of Ghent University (EC 2011/130 for 
healthy dogs, September 2011 and EC 2013/33 for EHPSS dogs, March 2013). 
 
 
3. Materials and Methods 
 
Eight dogs with a single congenital extrahepatic PSS, confirmed by trans-splenic portal 
scintigraphy (TSPS) or ultrasonography (US), exhibiting clinical signs of HE (HE group) and 
eight healthy beagles (control group) underwent a brain SPECT scan using 99mTc-HMPAO.7 
Emission data were fitted to an in-house template for use in dogs,8 permitting semi-
quantification using a predefined region map containing the following brain regions: right and 
left frontal, temporal, parietal and occipital lobes, the cerebellum and subcortical area. The 
latter includes both the thalamic and striatal structures; further subdivision was not feasible 
due to limited resolution of SPECT images. Regional brain perfusion indices (PI) were 
calculated by normalizing the regional counts per voxel to total brain counts per voxel. In 
addition, the clinical signs of HE were graded on a four-point scale (grade 0: normal; 1: 
reduced motility and/or mild apathy; 2: severe apathy and/or mild ataxia; 3: salivation, severe 
ataxia, head pressing, apparent blindness and/or circling; 4: seizures and/or coma).9 Ammonia 
levels in the blood and the cerebrospinal fluid (CSF) of PSS dogs and controls were 
determined by the portable blood ammonia analyzer PocketChem BA (A. Menarini 
Diagnostics). The PIs and the ammonia levels were statistically compared between the groups 
using the Mann-Whitney U test. Statistical significance was set at P<.05. 
 
 
4. Results 
 
Seven of the eight dogs with HE had a portocaval PSS, whereas one had a porto-azygos 
communication. The dogs with PSS had grade 3 (n = 3) or grade 4 (n = 5) HE signs. 
Ammonia levels in the blood and CSF of dogs in the HE group were significantly higher than 
in the control group (both P<.05) (Table 1). 
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Table 1 Age, sex, clinical signs, ammonia levels and perfusion indices in eight dogs with a single 
congenital extrahepatic portosystemic shunt (PSS) presenting with clinical signs of hepatic 
encephalopathy (HE) and in eight healthy control dogs 
?
PI, perfusion index; SD, standard deviation; * P<.05. 
 
  
 PSS dogs with 
HE 
(n=8) 
Control dogs 
(n=8) 
Mann-Whitney 
U (P-value) 
 
Age (months) as median (range) 
 
19 (5-122) 
 
60 (48-72) 
 
.05 
 
Gender  
   
Female:Male 5:3 6:2 NA 
    
Clinical signs    
Anorexia 6/8 0/8  
Apathy 8/8 0/8  
Ataxia 8/8 0/8  
Diarrhea 3/8 0/8  
Polyuria 6/8 0/8  
Salivation 3/8 0/8  
Seizures 5/8 0/8  
Vomiting 5/8 0/8  
    
Ammonia levels as median 
(range) 
   
Blood  (μmol/L)  153 (14-246) 27 (15-36) .012* 
CSF     (μmol/L) 87 (0-154) 13 (0-25) .045* 
    
Regional brain PI as mean±SD    
Left Temporal Cortex 0.80± 0.04 0.90±0.03 .002* 
Right Temporal Cortex 0.79±0.08 0.88±0.03 .02* 
Cerebellum 1.09±0.10 1.11±0.06 .916 
Subcortical Region 1.21±0.08 1.10±0.07 .005* 
Olfactory Bulb 0.70±0.35 0.52±0.13 .156 
Left Frontal Cortex 1.16±0.10 1.16±0.03 .598 
Right Frontal Cortex 1.14±0.07 1.11±0.07 .369 
Left Occipital Cortex 1.06±0.12 1.14±0.10 .082 
Right Occipital Cortex 1.05±0.11 1.14±0.08 .114 
Left Parietal Cortex 1.12±0.10 1.12±0.04 .526 
Right Parietal Cortex 1.11±0.09 1.07±0.03 .103 
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Regional brain perfusion indices were significantly higher in the subcortical region of the 
PSS group compared to the control group (P < 0.05), whereas significantly lower perfusion 
was demonstrated in both temporal lobes in the PSS group (P<.05) (Table 1; Fig. 1). These 
alterations in rCBF were present in 8/8 and 7/8 of the PSS dogs, respectively. 
 
 
 
Fig. 1. Region map and acquisitions obtained with 99mTc-HMPAO SPECT in dorsal (A) and transverse 
(B) slices. Brain of a normal dog (1A) with regions of interest over left (1) and right (2) frontal 
cortices, left (3) and right (4) temporal cortices, the subcortical area (5) and the cerebellum (6). Brain 
of a dog with HE (2A) demonstrating decreased activity in the temporal region compared to normal 
regional activity in this area in a normal dog (3A). Brain of a normal dog (1B) with regions of interest 
over the left (3) and right (4) temporal cortices, subcortical area (5), and left (7) and right (8) parietal 
cortices. Brain of a dog with HE (2B) demonstrating increased activity in the subcortical area 
compared to the regional activity in this area in a normal dog (3B). 
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5. Discussion 
 
The present study is the first brain perfusion imaging report in dogs with HE secondary to 
congenital PSS. Previous studies of HE in PSS dogs have mainly focused on measurement of 
serum and CSF chemistries. In accordance with previous data, higher ammonia levels in both 
blood and CSF were detected in dogs in the PSS group. 
Currently, there are two case series9, 10 and two case reports11,12 describing magnetic 
resonance imaging (MRI) findings in dogs with PSS. In the majority of dogs with PSS in the 
MRI study of Torisu et al.9, hyperintensity in the lentiform nuclei was observed on the T1W 
images. In the present study, the subcortical region (including the region of the lentiform 
nuclei) also showed a high regional uptake of 99mTc-HMPAO. The significant differences in 
rCBF by SPECT in the subcortical and temporal regions in PSS dogs with HE are compatible 
with previously published findings in human HE patients.4-6 
Conclusions about changes in functional brain activity in dogs with HE should be drawn 
cautiously, because the relationship between rCBF and functional anatomy is not completely 
understood in dogs. In contrast to human HE studies,4-6 which focus on cognitive dysfunction, 
there are no standardized neuropsychological tests to evaluate cognitive deficits in dogs 
showing HE signs. All PSS dogs in this study had overt clinical signs of HE (? grade 3). In 
humans, the neuropsychological impairment observed with subclinical HE is believed to be 
associated predominantly with the frontal and temporal lobes, and with the subcortical region, 
of the brain.6 There are indications to presume similarities in dogs with HE, but more canine 
cases should be recruited to support this. 
 
 
6. Conclusion 
 
In conclusion, we demonstrated hypoperfusion of the temporal cortex and hyperperfusion of 
the subcortical region in dogs with HE secondary to PSS. These data contribute to our 
understanding of the neuropsychological and pathophysiological mechanisms of HE in PSS 
dogs, suggesting predominant involvement and dysfunction of the temporal cortex and the 
subcortical area. Important similarities to the altered rCBF in humans with HE were found. 
Because of the small sample size and the lack of previous reports on SPECT studies in PSS 
dogs, the brain perfusion findings must be considered to be preliminary. Future studies should 
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examine rCBF changes in dogs with PSS with subclinical HE and should compare rCBF 
before and after successful PSS attenuation. 
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General Discussion 
 
Surgery is still the recommended treatment for the majority of dogs with congenital EHPSS 
since dogs undergoing vascular attenuation are reported to clinically recover to a greater 
extent and survive significantly longer than those controlled medically only.1,2 Many surgical 
patients do indeed enjoy a presumably normal life thereafter. However, some will be 
asymptomatic despite persistent shunting whereas others will fail to achieve significant 
clinical improvement. Literature on surgical outcome after EHPSS surgery is often 
inconsistent in how to categorize postoperative results as excellent, good, fair or poor. This is 
largely due to the fact that in many institutions and in various studies, only the clinical 
outcome is assessed. However, clinical success in dogs with EHPSS is not always 
overlapping with surgical success and thus the actual postoperative shunt status remains 
unknown. Yet it is very important to know whether the shunt is completely closed or shunting 
persists and whether acquired shunts did develop or not. Even in dogs that do clinically well, 
the knowledge of persistent shunting is important, as drugs with a hepatic first-pass 
metabolism should be avoided in these dogs.3 In our case series (Chapter 4), 2 out of the 19 
treated dogs were euthanatized, one because of recurrent neurological symptoms despite 
successful surgery and one because of obstructive urolithiasis in the presence of acquired 
shunts; all other dogs had an excellent clinical outcome regardless the postoperative shunt 
status (closed, persistent or acquired shunting). 
 
With regard to persisting shunting, different situations have to be considered; incomplete 
closure of the congenital EHPSS or of one of its late tributaries, the presence of a second PSS, 
shunting through acquired portosystemic shunts, or concurrent primary portal vein 
hypoplasia.4-7 
It has been recently reported that in 18% to 36% of dogs with EHPSS, treated with an 
ameroid ring constrictor or a thin band, respectively, the original EHPSS did not close 
completely.6,7 This is in agreement with the results in our patient group when surgery 
involved placement of a thin film band. However, when an ameroid constrictor was used, we 
did not experience persistent shunting (Chapter 4). In our patients, we always advised re-
operation in case of non-closure of the shunt 3 to 6 months after the first surgery. A second 
surgical intervention has been advised when blood flow is present in the primary EHPSS in 
the presence of clinical signs, or if an additional congenital EHPSS is identified that was 
missed during the first surgery.8 However, debate is ongoing regarding the most appropriate 
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approach for patients that are still not shunt-free after surgery despite absence of clinical 
signs. There are currently no studies that document whether or not it is justified to wait and 
see if the status of the patient remains stable or not. 
According to the literature, acquired shunts do occur in 10% to 29% of the dogs 
undergoing surgical attenuation of a single congenital EHPSS, regardless of the surgical 
approach.9-11 Acquired shunting vessels involve pre-existing portosystemic anastomoses that 
become functional due to the inability of the liver to tolerate the increased portal pressure 
induced by the corrective surgery.12-14 Placement of a device that induces gradual shunt 
attenuation is meant to reduce the risk of this postoperative complication.12 Similarly, 
reduction to less than 3 mm shunt diameter at the time of placement of the device should be 
avoided.11 Despite being at least as conservative as that advice, a high percentage (37%) of 
acquired shunts was also observed in our case series (Chapter 4). Interestingly, but not 
completely surprising, all acquired shunts occurred in dogs operated for a congenital 
portocaval EHPSS and none in dogs that had a porto-azygos shunt. Similar to portophrenic 
shunts, the diameter of a porto-azygos shunt is on and off reduced due to diaphragmatic 
movement leading to temporary increases of blood flow towards the liver through the portal 
system.8 Another explanation can be, based on Poiseuille’s law, that due to the smaller 
diameter of the azygos vein compared to the caudal vena cava, resistance to blood pressure is 
higher in this vessel.15 Furthermore, on CT images, we consistently observed a marked 
reduction in shunt diameter at the insertion site of porto-azygos shunts (Chapter 1), a finding 
that has not been documented in portocaval shunts so far. In dogs that develop acquired 
shunting, vena caval banding has been attempted, but turned out not to be superior to medical 
management,12 a strategy that is mainly focused on avoiding clinical signs of HE by feeding a 
high quality low-protein diet.8 The dogs in our patient group that developed acquired shunts 
were all fed a commercial liver or kidney diet and received life-long lactulose. One dog was 
euthanized at the time of obstructive urolithiasis 7 months after surgery. The other dogs with 
acquired shunts are still alive at the time of writing, with a follow-up varying from 16 till 42 
months. 
Dogs with a congenital EHPSS that have concomitant primary portal vein hypoplasia 
might not be clinically perfect after successful closure of the shunt because microscopic 
shunting persists, although the clinical signs will be milder as usually not all liver lobes are 
affected.16,17 As portal vein hypoplasia cannot be cured, continuation of the dietary 
management that was installed prior to the shunt surgery is recommended.18,19 The presence 
of portal vein hypoplasia cannot be accurately predicted pre-operatively since the diagnosis 
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can only be made by histopathology after the macroscopic shunt has been completely closed 
(Allen et al 1999).18 It has been suggested in the literature that 10% to 58% of dogs with 
congenital EHPSS have concomitant primary portal vein hypoplasia.20,21 However, in our 
institution, dogs with this combination are only exceptionally diagnosed22 and, in our patient 
group, we did not suspect any. Some of them might be overlooked since liver biopsies are not 
routinely taken in the follow-up of dogs after EHPSS surgery.  
To evaluate surgical outcome with objective measures, imaging or follow-up of laboratory 
tests may be used. Erroneously, many laboratory tests currently used for primary diagnosis of 
EHPSS are used for postoperative assessment, without knowledge on their sensitivity and 
specificity. Measurement of pre- and postprandial serum bile acid (SBA) and ammonia 
concentrations are currently the most commonly used liver function test in the follow-up of 
EHPSS in dogs.8 However, there is currently no biochemical test that provides accurate 
evidence of surgical success and normalization of SBA after surgery is not proven to be a 
reliable measure to evaluate shunt closure.6,23 We agree that normalized or reduced bile acids 
(<50% from initial measurements) indicate improvement in hepatic function and therefore are 
suggestive for (some degree of) shunt attenuation. One retrospective study concentrated on 
ammonia to evaluate the effect of surgical attenuation of the EHPSS.21 It was stated that 
increased basal ammonia concentration in postsurgical dogs was conclusive for persistent 
shunting; if fasting plasma ammonia concentration was normal, medical imaging was required 
to visualize or exclude persistent shunting.21 At one month after surgery, ammonia levels 
were normal in all dogs of our patient group. Three months after surgery, abnormal ammonia 
levels were only observed in the minority of situations with persistent shunting through the 
original shunt (2/5) and developed acquired shunts (3/7) (Chapter 4). In conclusion, 
measurements of ammonia concentrations (neither plasma nor CSF levels) did not adequately 
reflect the final outcome after surgery. As such, neither plasma nor CSF ammonia levels can 
be considered accurate to use in the follow-up of shunt patients. 
 
During the study years (January 2014 to July 2016), the surgical protocols and 
postoperative evaluation for EHPSS were gradually adjusted according to the accumulated 
experience. This included the switch to the transdiaphragmatic approach in cases of porto-
azygos shunts to avoid missing late tributaries to the shunt (Chapter 2) and renewed our 
preference for placing ameroid constrictors rather than thin film bands for shunt attenuation 
(Chapter 4). The studies that compared blood and CSF ammonia concentrations in the dogs 
with a congenital EHPSS (Chapters 3 and 4) were designed to be completed 6 months after 
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the EHPSS surgery in each individual case. However, the results of the TSPS at the 3-month 
follow-up were surprising and somehow disappointing. They indicated that in one fourth of 
the dogs that underwent shunt attenuation with a thin film band, the shunt was still patent 
(Chapter 4). It should be noted that “cellophane” only very recently became commercially 
available as Cellovet® and therefore the thin film we used might not have been true 
cellophane. None of the dogs in which an ameroid constrictor was placed had persistent 
shunting through the original shunt. 
It is a general belief that currently only imaging modalities such as scintigraphy,24,25 
CTA,6,7 or US using microbubbles26 can accurately evaluate complete shunt closure. To date, 
we therefore strongly advice a postoperative TSPS or other imaging modality at the 3- or 6-months 
postoperative follow-up in all our patients as none of the available biochemical tests provides 
accurate evidence of shunt closure and status and the incidence of persistent shunting seems higher 
than expected. 
 
Do porto-azygos shunts deserve the attention they received during this PhD 
research project? 
Although it cannot be completely excluded that there are porto-azygos shunts that may insert 
at different locations, our study on CTA (Chapter 1) confirmed intra-thoracic insertion in 36 
out of 36 dogs with porto-azygos shunts. In addition, all 9 dogs with porto-azygos shunt that 
were treated since the start of the PhD, described in Chapter 2, also had a thoracic terminus 
into the azygos vein. Our results demonstrated that the vast majority (if not all) of the porto-
azygos shunts in dogs insert in the thorax. This is in agreement with earlier suggestions that 
most porto-azygos shunts traverse the diaphragm.8,23,27 Moreover, in the recent reports of 
Hunt and colleagues6 and Nelson and Nelson7 the provided CT images depict porto-azygos 
shunts that insert in the thorax. Yet both studies did not clearly mention this finding in the 
text.  
To the best of our knowledge, no current reports address specifically the outcome of 
surgical attenuation of porto-azygos shunts. Two recent reports6,7 mention the outcome of 
porto-azygos shunts in dogs in tables and/or figures provided albeit without specific reference 
and discussion in the text. In the report of Hunt and colleagues, 2 out of 5 porto-azygos shunts 
attenuated at the abdominal side of the diaphragm, had postoperative persistent shunting 
whereas none of the 17 portocaval shunts attenuated near their insertion site were persistent.6 
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In the most recent study of Nelson and Nelson, 5 out of 6 porto-azygos shunts that were 
treated intra-abdominally had postoperative persistent shunting.7 In both studies, it was 
concluded that persistent shunting was due to misplacement of the attenuating device, which 
did not include cranial tributaries from the stomach. The dogs in our prospective study on 
porto-azygos shunts (Chapter 2) were operated via a transdiaphragmatic approach and all had 
a long-term follow-up including scintigraphic confirmation of shunt closure. Although some 
porto-azygos shunts were still patent 3 months after the first surgery due to inadequate 
reaction on the thin film band used for attenuation, none of the dogs did experience persistent 
shunting due to missed tributaries, because that was efficiently precluded by thoracic 
placement of the device.  
The accepted recommendation for attenuating EHPSSs in general is near their insertion 
site, but, for unknown reasons, this guideline was not implemented in case of porto-azygos 
shunts. To our best knowledge, there is no obvious reason why not to assume that the same 
principle applies to porto-azygos shunts. We therefore challenged these guidelines for 
attenuation of porto-azygos shunts that describe attenuation of the shunt at the abdominal side 
of the diaphragm.8 Our preliminary findings based on a limited number of patients does support 
our hypothesis that thoracic attenuation will avoid the risk of persistent shunting due to 
missed tributaries to the shunt.  
It has been reported that the abdominal dissection for attenuating porto-azygos shunt in the 
abdomen can be very challenging.8,27 In our experience, the transdiaphragmatic approach is a 
straightforward procedure. Although we did not perform a prospective study comparing the 
transdiaphragmatic approach with the classic abdominal approach, the surgical time for the 
former approach did not seem to be prolonged. In addition, the transdiaphragmatic approach 
seems to result in less morbidity because manipulation of the liver lobes and abdominal 
organs is minimized. Furthermore, a transdiaphragmatic approach provides a safe corridor to 
the thorax with excellent exposure of the most ideal site for shunt attenuation.  
Alternatively, a lateral approach to the thorax would also allow placement of a device on 
the thoracic portion of the porto-azygos shunt. However, in comparison to a lateral 
thoracotomy, the transdiaphragmatic approach has many advantages. It allows simultaneously 
evaluation of the gastro-intestinal tract and the pancreas before and after an attenuating device 
is placed. In addition, it does not exclude concomitant intra-abdominal procedures. 
Furthermore, a pre-operative CTA is not strictly necessary whereas in case of a lateral 
thoracotomy, a CTA is needed to determine the side and the most ideal intercostal space. 
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Finally, we argue that a transdiaphragmatic approach is less invasive, less painful and less 
time-consuming compared to a thoracotomy. 
 
In conclusion, in the majority of porto-azygos shunts, a thoracic terminus will be present. 
In those cases, a transdiaphragmatic approach exposes the insertion site for shunt attenuation. 
This approach is a relatively easy and fast surgical procedure, without unnecessary abdominal 
organ manipulation, while the risk of missing additional contributing branches is eliminated. 
 
 
The controversy is not about ammonia being involved in the HE syndrome in 
EHPSS dogs, but how to interpret its participation … 
It has long been established that ammonia is increased in most dogs with congenital EHPSS, 
because conversion of ammonia to urea by the underdeveloped liver is inefficient and because 
a major part of the intestinal blood does not even pass through the liver.28,29 Furthermore, all 
case series report a high incidence of HE in dogs with congenital EHPSS, although the 
clinical signs of HE can vary between very obvious to subtle.10,12,30,31 Yet the role of ammonia 
in the development of HE in dogs is controversial and ammonia received limited attention, 
particularly in the context of EHPSS.28 
In the current PhD research, it was shown that high plasma ammonia levels are predictive 
for the presence of HE in dogs (Chapters 3-5). Our observations are similar to those in 
humans with HE.32-34 Ammonia is widely considered to initiate HE for the greater part 
through altered astrocytes function as these are the main cells in the brain that can metabolize 
ammonia.35-41 However, it is important to acknowledge that several dogs with congenital 
EHPSS without overt HE signs (Chapter 4) still had high plasma ammonia levels after they 
had been on medical treatment for 4 weeks before surgery. This finding highlights that 
hyperammonemia is not limited to dogs with a congenital EHPSS that have overt clinical 
signs of HE. It suggests that there might be another explanation to link plasma ammonia 
levels with HE or, that other factors are involved in the pathogenesis of HE. This finding is 
also consistent with the observation that dogs with urea cycle enzyme deficiency have 
increased plasma ammonia concentrations but do not typically develop clinical signs of HE.42 
In humans with HE, similar observations have been reported. Ammonia is frequently raised in 
these patients; however, there is an imperfect correlation between ammonia plasma levels and 
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severity of HE signs.40 Human clinicians also tried to address the challenge to identify cases 
with subclinical HE. In this respect, arterial ammonia levels were found to be more sensitive 
and predictive for HE than venous ammonia levels.32,34 Functional brain imaging techniques 
were also used to evaluate HE.32,34,43 
The novel findings of this PhD dissertation concerning HE in dogs with portosystemic 
shunts were the documentation of high arterial and CSF ammonia levels in EHPSS dogs with 
HE (Chapters 3-5), and the documentation of alterations in regional cerebral blood flow in 
these patients (Chapter 5). Our findings are consistent with the results of studies in humans 
with liver disease and HE. 32,34,43-45 In human HE patients, arterial ammonia levels over 150 
?mol/L were prognostic indicators to predict future development of intracranial hypertension 
and cerebral edema.45,46 It still needs to be established whether the same cut-off values do 
apply to dogs with EHPSS and HE. None of our dogs that had arterial ammonia level above 
150 ?mol/L at the day of diagnosis had a history of seizures (Chapter 4). However, neither 
intracranial hypertension nor cerebral edema was objectively assessed in any of the dogs at 
the time of diagnosis. The only dog that did have a history of pre-operative seizures had 
relatively low blood ammonia at diagnosis. 
There might be little rationale behind measuring blood ammonia in the detection of HE as 
ammonia exerts its impact on cerebral function only after entering the brain. The rate of 
ammonia entry into the brain is therefore important, not the blood levels. Brain imaging 
techniques have provided substantial insight into the pathophysiology of HE in humans. 
Neuropsychological impairment observed with subclinical and clinical HE is believed to be 
predominantly associated with the frontal and temporal lobes, and with the subcortical region 
of the brain.47-49 Also brain functional imaging studies found that the subcortical area is 
predominantly exposed to increased ammonia levels, resulting in astrocytic alterations and 
impairment of subcortical function.43,49 The significant alterations in regional cerebral blood 
flow in the subcortical and temporal regions in dogs with EHPSS and HE (Chapter 5) also 
suggest predominant involvement and dysfunction of these regions. Therefore, in dogs with 
hyperammonaemia and high CSF ammonia levels, those areas in the brain might have been 
more exposed to the increased ammonia levels and/or are the target regions for ammonia in 
the brain, as in humans. Furthermore, PET studies in human HE patients, using ammonia as a 
tracer, showed that the cerebral metabolism of ammonia and the permeability of the BBB for 
ammonia was increased in cirrhotic patients compared to healthy controls.32,49 The regional 
ammonia supply was in accordance with the regional blood flow.32,34,49 In our study, we did 
not directly assess the permeability of the BBB, but we studied the selective changes of 
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ammonia in the blood and CSF of dogs with EHPSS over time pre- and postoperatively 
(Chapter 4). The positively correlated CSF to blood ammonia levels (Chapters 3 and 4) 
suggest passage of ammonia across the BBB and potentially increased permeability of the 
BBB to ammonia in dogs with EHPSS. It explains and supports the former findings of 
significantly higher CSF concentrations of metabolites of ammonia such as glutamine and 
glutamate and other factors in the CSF of PSS dogs with HE.36,50 
Blood and CSF ammonia concentration in the current study (Chapters 3 and 4) were high 
in EHPSS dogs. Of particular interest was that the 4-week medical management before 
surgery resulted in decreased HE signs in all dogs while ammonia levels in the blood 
remained high (Chapter 4). This may suggest that medical treatment alters the proportion of 
blood ammonia that reaches the CNS more than the amount of blood ammonia itself. To our 
knowledge, this finding has not been described earlier. It is of great importance, however, 
since it might influence future therapeutic strategies to control HE. It has been suggested 
earlier that management of HE should not only be aim to reduce ammonia formation and 
absorption but also to reduce formation of ammonia metabolites such as glutamine and 
glutamate.50 Research should therefore focus on defining the major factors that can prevent 
ammonia from reaching the CNS. In this respect, it is important to acknowledge that factors 
such as concentration gradient, pH, and BBB permeability have an important influence on the 
distribution and the form of ammonia.34,51,52 Ammonia will diffuse toward a lower 
concentration gradient, that is, toward the brain. In addition, the pH in the brain is reported to 
be lower than the blood pH;34 therefore ammonia (NH3) will be converted to ammonium 
(NH4+).29,34,51,52 Entrapment within the CNS occurs because the ammonium ion is not readily 
diffusible across cell membranes.34 Furthermore, the BBB will not adequately prevent 
ammonia to pass in case of hyperammonaemia. It has been observed in humans HE patients 
that the BBB is much more permeable to the gas form but that measurable amounts of the 
positively charged ammonium ion (NH4+) also cross the BBB.34 
Our findings of high CSF ammonia concentrations and the previous findings of high CSF 
glutamate and glutamine concentrations in dogs with PSS36,50 raise the possibility that 
overstimulation of the N-methyl-D-aspartate class receptors by glutamate is involved in the 
disease mechanisms of HE development in dogs with PSS. Potentially, ammonia excess might 
also deregulate the delicate balance between glutamatergic and GABAergic systems in dogs 
with congenital EHPSS. 
Ammonia levels in blood and CSF of dogs with pre-operative signs of HE dropped to the 
low normal range and HE signs were no longer observed one month after surgery (Chapter 4). 
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Although the results of this PhD research do not establish that ammonia initiates HE in dogs 
with EHPSS, ammonia definitively does play a role in the HE pathogenesis (Chapter 3-5).  
Postoperative seizures are reported in 5–18% of dogs and typically occur within 72 hours 
of surgery.24,54-56 The cause of postoperative neurologic dysfunction, seizures, and other 
pathologic changes of the CNS in dogs with PSS are not clear. The seizures are often 
refractory to standard anticonvulsant drug treatment, and frequently progress to status 
epilepticus.53,54,57 Two case series on EHPSS dogs euthanatized because of uncontrollable 
seizures report CNS lesions that were more severe than those in dogs with PSS that did not 
seizure.53,58 Yet it is not clear whether those CNS lesions represented the cause or the 
pathologic consequence of the seizures. In our case series, none of the dogs developed 
seizures in the immediate postoperative phase. However, one dog developed partial epilepsy 
80 hours after an AC had been placed around its portocaval shunt. Levetiracetam successfully 
controlled the problem. The dog was diagnosed with acquired shunting 3 months 
postoperatively. The other dog with postoperative epilepsy was the only dog that also 
experienced pre-operative seizures. Despite successful surgery and despite medical 
management with imepitoin and levetiracetam, the dog’s seizures could not be controlled and 
was finally euthanized. Since the dog had a normal postoperative scintigraphic scan as well as 
normalization of both ammonia and SBA values, the neurological problems might not have 
been directly related to portosystemic shunting. This assumption could not be assessed, since 
the owners declined postmortem analysis. 
Histologic lesions are sometimes found in the CNS of PSS dogs at postmortem 
evaluation.28,53,58 Findings in a histologic study revealed polymicrocavitation of the brainstem, 
cerebellar nuclei, and sometimes polymicrocavitation at the border of the white and gray 
matter in the cerebral cortex, in addition to an increase in numbers of protoplasmic 
astrocytes.28 
 
Portosystemic shunt disease is one of those disease entities of which a lot still has to be 
discovered. With this PhD research, we attempted to fill in some of the gaps on EHPSS in 
dogs. The hypotheses that were initially proposed were all tested and novel findings already 
have initiated further research and will certainly continue to do so in the near future.  
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Limitations of the current PhD research 
It should be clear to the readership that portosystemic shunt disease in dogs comprises much 
more than EHPSS alone. Other conditions involving portosystemic shunting in dogs are 
intrahepatic PSS, acquired PSS and primary portal vein hypoplasia. The relative 
predominance of dogs with EHPSS in our clinic population as well as the wide range and 
nature of portosystemic shunt disease dictated to limit the PhD research to the study of dogs 
with EHPSS. 
Using a greater sample size in the experimental studies may have increased the reliability 
of the results, shedding more light on the etiopathogenesis of HE in EHPSS dogs, the role of 
ammonia, and the outcome of porto-azygos shunts. Choice of sample size was based on 
practical and ethical considerations. 
Ammonia is known to be unstable ex vivo, and, although samples were processed with 
special care, pre-analytical errors cannot be completely excluded. Furthermore, ammonia is 
only one out of more than 20 different compounds that are known to accumulate in the 
systemic circulation when liver function is impaired. Several of them might also contribute to 
the etiopathogenesis of HE in dogs with congenital EHPSS. 
 
 
Future Perspectives 
Firstly, this PhD research (Chapters 1 and 2) presented a new scientific approach towards 
porto-azygos shunts, recommending attenuating these shunts in the thorax, at the insertion 
point of the shunting vessel, as opposed to former recommendations to attenuate these shunts 
in the abdomen. A transdiaphragmatic approach was successfully performed. However, we 
believe that minimal invasive approaches such as interventional radiology or thoracoscopy 
should also be explored for these shunt types, giving the anatomic location of the insertion 
point of these shunts. The feasibility, advantages and disadvantages should be studied to find 
out whether such approaches would be valuable alternatives. 
Secondly, the results of this PhD research (Chapters 3-5) “lifted a corner of the veil” in 
regards to the BBB permeability and brain changes in EHPSS dogs with neurological signs, 
encouraging further studies to better understand and treat HE related to PSS. To further 
investigate the role of ammonia in EHPSS dogs with HE and to better understand the mental 
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changes observed in PSS dogs, further studies of brain perfusion imaging based on specific 
ammonia markers as well as more advanced structural imaging are needed. 
There do remain some gaps in the management of portal shunt disease. A substantial 
bottleneck is the poor and inaccurate documentation of postoperative outcome in dogs that 
underwent surgical attenuation of a congenital EHPSS. Clinical outcome can be very 
misleading and also the currently available biochemical screening tests are not appropriate to 
judge postoperative shunt status. To date, clinicians should rely much more on advanced 
medical imaging techniques to objectively document the result of the attenuation process; 
complete closure of the congenital EHPSS without formation of acquired shunts, persistent 
shunting through the original EHPSS, or complete closure of the congenital EHPSS with 
formation of acquired shunts. Dogs with persistent shunting due to incomplete closure or 
acquired shunts will not always have obvious clinical issues, yet they are affected somehow 
by subclinical disease. It should be explored whether this group of patients could not benefit 
from some type of regenerative medicine. A recent experimental study in dogs found a high 
uptake of mesenchymal stem cells in the liver after transcutaneous ultrasound-guided splenic 
injection or jejunal vein catheterization.61 If stem cell delivery can be a key to enhanced liver 
regeneration, there is a potential to optimize the surgical outcome after gradual attenuation of 
congenital EHPSSs. In addition, the live expectancy in dogs with a congenital EHPSS that are 
not surgical candidates could be prolonged.  
Moreover, the findings in this PhD dissertation (Chapters 3-5) provide further evidence 
that dogs with EHPSS are a good spontaneous model of human HE.59,60 Further studies into 
the pathogenesis of HE in dogs with a EHPSS may offer additional insights into the biology 
of HE in humans as well as additional insights into the biology of HE in PSS dogs, and could 
potentially reduce the numbers of experimental animals with induced shunts that are currently 
used as a model.  
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In the first chapters (Chapter 1 and 2) of this PhD dissertation, the gap in knowledge 
concerning the morphology and the surgical approach to porto-azygos shunts was addressed. 
In the following chapters (Chapter 3-5), the focus was on ammonia levels in blood and 
cerebrospinal fluid (CSF) and hepatic encephalopathy (HE) in dogs with a congenital 
extrahepatic portosystemic shunt (EHPSS) before and after surgical attenuation and on 
changes in regional perfusion of cortical and subcortical brain regions in dogs with a 
congenital EHPSS and overt signs of HE. 
 
The goal of Chapter 1 was to describe the morphology of porto-azygos shunts in a large 
series of dogs using computed tomographic angiography (CTA), with special attention to the 
site of insertion of these shunts. Thirty-six dogs with porto-azygos shunt underwent CTA, and 
three-dimensional images were created to aid in understanding porto-azygos shunt 
morphology. CTA was found well suited to provide details on porto-azygos shunt anatomy in 
dogs. Two main conformations of porto-azygos shunts were documented, with the vast 
majority of dogs having a left gastro-azygos shunt whereas the other few having a right 
gastro-azygos communication. Anatomic variations in shunt types existed, but were minor. Of 
particular interest was that all porto-azygos shunts crossed the diaphragm through the 
esophageal hiatus and terminated in the thoracic part of the azygos vein, perpendicular to the 
aorta, in a characteristic “L” shape. Sticking to the general principles of shunt attenuation, it 
seems logical to attenuate also a porto-azygos shunt as close to its insertion site as possible, 
necessitating access to the thoracic cavity in cases were the shunting vessel terminates in the 
thorax. This led us to evaluate an alternative surgical approach toward porto-azygos shunts 
that insert in the thoracic part of the azygos vein (Chapter 2). In this chapter we described and 
documented the surgical technique and evaluated the feasibility of a transdiaphragmatic 
approach to attenuate porto-azygos shunts. The study comprised a cadaveric study including 6 
dogs and a prospective case series including 9 dogs with insertion of the porto-azygos shunt 
in the thoracic part of the azygos vein. Landmarks for creating a safe transdiaphragmatic 
approach to the caudal intra-thoracic portion of the azygos vein were first established in the 
cadaveric dogs and implemented in the clinical cases. Exposure of the shunt insertion site to 
the azygos vein was excellent in all clinical cases, and all shunts were successfully attenuated 
close to their insertion site at the level of the characteristic “L” shape via this novel approach. 
No peri-operative complications were encountered. Thus, if thoracic attenuation of a porto-
azygos shunt is considered, a transdiaphragmatic approach is safe and adequate to expose the 
insertion site for shunt attenuation. This approach is a straightforward surgical procedure, 
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without unnecessary abdominal organ manipulation, while the risk of missing additional 
contributing branches is eliminated. Furthermore, additional intra-abdominal procedures such 
as gonadectomy or cystotomy can be performed through the same approach. 
For the first time in the veterinary literature, selective changes of ammonia in the blood 
and CSF of dogs with congenital EHPSS, treated by thin film band (TFB) or ameroid 
constrictor (AC), are demonstrated over time (Chapters 3 and 4). The ammonia levels in 
arterial blood, venous blood, and CSF were assessed on the day of diagnosis by two different 
devices, the portable PocketChem BA and the Catalyst Dx (Chapter 3). Those measurements 
were made in 6 control dogs and in 19 dogs with a congenital EHPSS. Ammonia levels in 
blood (arterial and venous) and CSF of dogs were significantly higher in dogs with a 
congenital EHPSS than in clinically normal dogs. A strong positive correlation was 
documented between the different ammonia levels in the different body fluids tested within 
each patient. The results of this study also demonstrated that, at least in dogs with EHPSS, 
venous samples can substitute the more cumbersome arterial samples. Of particular interest 
were the high levels of ammonia in the CSF of the EHPSS dogs that were strongly and 
positively correlated to the blood ammonia levels, suggesting permeability of the blood-brain 
barrier (BBB) to ammonia in case of excessive blood ammonia levels. Since PocChem and 
CatDx were both recently validated to perform measurements of ammonia in the CSF, the 
CSF ammonia levels obtained in this study should not be considered as absolute values but 
rather as underestimated values. In addition, the absolute values should not be used as an 
indicator for the diagnostic or prognostic of HE or in a comparative way, until  cutoff values 
in a larger group of normal dogs will be evaluated.  
To circumstantiate the clinical interpretation of the ammonia levels in the different body 
fluids, and to relate them to the surgical outcome after TFB or AC placement, ammonia levels 
were re-measured (Chapter 4) on the day of surgery and several points thereafter (at 1, 3 and 6 
months after surgery) in 19 dogs. Transsplenic portal scintigraphy was repeated 3 months 
after surgery in all dogs to enable correlation of the ammonia levels to the surgical outcome. 
The correlations between the blood (arterial and venous) and CSF after successful surgical 
attenuation of the EHPSS were similar to those calculated before surgery. Ammonia levels in 
arterial blood, venous blood, and CSF of dogs with closed shunts were remarkably lower 
compared to the preoperative measurements. However, normalization of the blood ammonia 
levels after surgery did not necessarily indicate surgical success. In 3 of the 5 dogs that 
developed acquired shunts after the first surgery and in 3 out of 5 dogs that had persistent 
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shunting, the ammonia levels were within the normal range. Hence postoperative ammonia 
levels are not an accurate predictor of the shunt status (closed, patent, acquired) after surgery. 
In Chapter 5, 8 dogs with a congenital EHPSS showing overt clinical signs of HE and an 
equal number of healthy beagles underwent a brain SPECT scan to document the alterations 
in regional cerebral blood flow (rCBF). The clinical signs of HE were graded and the 
ammonia levels in the blood and the CSF were measured. The areas of the brain with an 
altered perfusion were determined. The brain SPECT scans were abnormal in all EHPSS 
dogs. Compared to the control group, rCBF was decreased significantly in the temporal lobes 
while increased in the subcortical (thalamic and striatal) area in all dogs with EHPSS, 
cautiously suggesting the predominant involvement and dysfunction of these areas in the 
pathogenesis of HE due to congenital EHPSS in dogs. 
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De eerste hoofdstukken (Hoofdstuk 1 en 2) van deze doctoraatsthesis beschrijven het gebrek 
aan morfologische kennis en chirurgische benadering van porto-azygos shunts. In de volgende 
hoofdstukken (Hoofdstukken 3 tot 5) wordt dieper ingegaan op het ammoniakgehalte in het 
bloed en cerebrospinaal vocht (CSV) alsook op hepatische encefalopathie (HE) bij honden 
met een congenitale extrahepatische portosystemische shunt (EHPSS) voor en na chirurgische 
behandeling. Ook de veranderingen in regionale perfusie van de corticale en subcorticale 
regio’s in de hersenen bij honden met een congenitale EHPSS en symptomen van HE worden 
beschreven. 
 
In het eerste hoofdstuk wordt de morfologie van porto-azygos shunts beschreven in een 
groot aantal honden. Hiervoor werd gebruik gemaakt van computer tomografische angiografie 
(CTA) waarbij speciale aandacht werd besteed aan de insertieplaats van de shunts. 
Zessendertig honden met een porto-azygos shunt kregen een CTA waarbij driedimensionale 
beelden werden gecreëerd om de morfologie van de porto-azygos shunts in beeld te brengen. 
CTA blijkt een goede beeldvormingsmodaliteit om gedetailleerde informatie te leveren over 
de morfologie van porto-azygos shunts bij honden. Twee conformaties van porto-azygos 
shunts werden vastgesteld, waarbij bij de grote meerderheid van de honden een linkse gastro-
azygos shunt werd vastgesteld en bij een kleiner aantal een rechtse gastro-azygos verbinding. 
Ook minimale anatomische variaties in deze shunt types werden beschreven. Opmerkelijk 
was dat alle shunt types het diafragma doorkruisten door de oesofagale hiatus en eindigden in 
het thoracale gedeelte van de azygos vene, loodrecht ten opzichte van de aorta en in een 
karakteristieke “L”-vorm.  
Volgens de chirurgische principes voor de behandeling van portosystemische shunts moet 
een shunt zo dicht mogelijk bij zijn insertieplaats onderbonden worden, waarbij het in het 
geval van porto-azygos shunts die eindigen in de thorax noodzakelijk zou zijn om de 
thoraxholte te openen. Dit gegeven resulteerde in een evaluatie van een alternatieve 
chirurgische benadering voor porto-azygos shunts die eindigen in het thoracale deel van de 
azygos vene (Hoofdstuk 2). In dit hoofdstuk beschreven en documenteerden we de 
chirurgische techniek en  evalueerden we de haalbaarheid van een transdiafragmatische 
benadering voor de behandeling van porto-azygos shunts. De studie omvatte een 
kadaverstudie met 6 honden en een prospectieve gevallenreeks met 9 honden met een porto-
azygos shunt die eindigde in het thoracale gedeelte van de azygos vene. Eerst werden 
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anatomische herkenningspunten voor een veilige transdiafragmatische benadering van het 
caudale intrathoracale deel van de azygos vene bepaald in de kadavers. Deze coördinaten 
werden vervolgens gebruikt in de klinische gevallen. Bij alle patiënten was de insertieplaats 
van de shunt in de azygos vene perfect toegankelijk en konden alle shunts dicht bij de 
insertieplaats op het niveau van de karakteristieke “L” vorm worden onderbonden. Er werden 
geen peroperatieve complicaties waargenomen.  
Indien een thoracale behandeling van een porto-azygos shunt overwogen wordt, is een 
transdiafragmatische benadering een veilige en adequate techniek om de insertieplaats 
toegankelijk te maken. Deze benadering is een rechttoe rechtaan procedure zonder onnodige 
manipulatie van abdominale organen die daarenboven het risico op het missen van additionele 
kleine shunttakken minimaliseert. Daarenboven kunnen bijkomende intra-abdominale 
ingrepen zoals een gonadectomie of een cystotomie tijdens eenzelfde chirurgie worden 
uitgevoerd. 
 
Voor het eerst in de diergeneeskundige literatuur werden de selectieve veranderingen van 
het ammoniakgehalte in het bloed en CSV bij honden met een congenitale EHPSS die 
behandeld werden met een thin film band (TFB) of een ameroid constrictor (AC) over de tijd 
beschreven (Hoofdstukken 3 en 4). 
De ammoniak gehaltes in arterieel bloed, veneus bloed en CSV werden gemeten op de dag 
van de diagnose met behulp van twee verschillende toestellen: de draagbare PocketChem BA 
en de Catalyst Dx (Hoofdstuk 3). Deze metingen werden uitgevoerd bij 6 controle honden en 
bij 19 honden met een congenitale EHPSS. De ammoniakgehaltes in het bloed (arterieel en 
veneus) en CSV waren significant hoger bij honden met een congenitale EHPSS dan bij 
klinisch gezonde honden. Binnen eenzelfde hond werd een duidelijk positieve correlatie 
aangetoond tussen de gehaltes aan ammoniak in de verschillende lichaamsvochten. De 
resultaten van deze studie toonden ook aan dat, bij de honden met een EHPSS, de veneuze 
bloedstalen een gelijkaardig gehalte opleverden dan de arteriële bloedstalen, die veel minder 
makkelijk te preleveren zijn.  
Van bijzonder belang was de positieve correlatie tussen de hoge ammoniakgehaltes in het 
CSV en de gestegen ammoniak gehaltes in het bloed bij honden met een EHPSS wat doet 
vermoeden dat, eens er sterk gestegen ammoniakgehaltes in het bloed aanwezig zijn, de 
bloed-hersenbarriere permeabel wordt voor ammoniak. Aangezien zowel de PocChem als de 
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CatDx niet gevalideerd zijn voor de metingen van ammoniak in het CSV mogen de ammoniak 
gehaltes van het CSV die in deze studie bekomen werden niet als absolute waardes gezien 
worden maar eerder als vergelijkende waardes en dit tot dat de toestellen gevalideerd worden 
voor het meten van ammoniak in het CSV. 
Bij de 19 honden werden de ammoniakgehaltes opnieuw bepaald (Hoofdstuk 4) op de dag 
van de chirurgie en op verschillende tijdstippen nadien (1, 3 en 6 maanden na chirurgie). Het 
was de bedoeling om de evolutie van de ammoniakgehaltes in de verschillende 
lichaamsvochten te evalueren alsook om de correlatie na chirurgische plaatsing van een TFB 
of AC te bestuderen. Om de correlatie tussen de ammoniakgehaltes en het chirurgisch 
resultaat aan te geven, werd bij alle honden de transsplenische portale scintigrafie herhaald 3 
maanden na de operatie. De correlatie tussen de ammoniakgehaltes in het bloed (arterieel en 
veneus) en het CSV bleek zowel voor als na de chirurgische correctie van de shunt 
gelijkaardig. De ammoniakgehaltes in het arterieel bloed, veneus bloed en CSV waren echter 
na de chirurgische correctie opmerkelijk lager dan voor de ingreep. Nochtans bleek 
normalisatie van het ammoniakgehalte na chirurgie niet noodzakelijk te duiden op chirurgisch 
succes gezien bij 3 van 4 honden die een verworven shunt ontwikkelden na chirurgie en bij 5 
van 6 honden die een persisterende shunt hadden na chirurgie, de ammoniakgehaltes ook 
genormaliseerd waren. Hieruit kan geconcludeerd worden dat postoperatieve 
ammoniakgehaltes geen accurate indicator zijn voor de status van de shunt (gesloten, 
persistent of verworven) na chirurgie. 
 
In Hoofdstuk 5 worden de resultaten weergegeven van 8 honden met een congenitale EHPSS 
en duidelijke klinische tekenen van HE en 8 gezonde beagles die een SPECT scan van de 
hersenen ondergingen met als doel veranderingen in de regionale cerebrale bloedvloei (rCBV) 
te detecteren. De klinische tekenen van de HE werden gegradeerd en ammoniakgehaltes in 
bloed en CSV werden gemeten. De regio’s in de hersenen waar perfusieveranderingen werden 
vastgesteld, werden gedefinieerd. De SPECT scans van de hersenen waren afwijkend bij alle 
honden met een EHPSS en HE. De perfusie was significant gedaald in de temporale lobben en 
gestegen in de subcorticale (thalamus en striatale) regio’s bij alle EHPPS honden in 
vergelijking met de controle groep. Uit deze resultaten kan afgeleid worden dat disfunctie van 
deze regio’s een dominante rol speelt bij de pathogenese van HE ten gevolge van EHPSS bij 
honden. 
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